Investigation of an unusual GABA-A receptor: studies on the promiscuous ε [epsilon] subunit by Schwabe, T
Investigation of an unusual GABAA receptor -
Studies on the promiscuous ε subunit
Tina Schwabe
A thesis submitted in partial fulfilment of the requirements of
Nottingham Trent University for the degree of Doctor of Philosophy.
December 2010
Copyright statement
This work is the intellectual property of the author, and may also be owned by Nottingham
Trent University. You may copy up to 5 % of this work for private study, or personal, non-
commercial research. Any re-use of the information contained within this document should
be fully referenced, quoting the author, title, university, degree level and pagination. Queries
or requests for any other use, or if a more substantial copy is required, should be directed in
the first instance to the author.
i
Abstract
γ-aminobutyric acid (GABA) type A (GABAA) receptors are pentameric, chloride-selective
ion channels. Nineteen different GABAA receptor subunits are known to exist in man and va-
rious subunit combinations are able to form receptor subtypes with different, subunit-specific
pharmacological properties. GABAA receptors are targeted by many clinically-important
drugs, for example, benzodiazepines. Unwanted side effects, such as tolerance and depen-
dence, often occur due to non-selective receptor targeting. There is, therefore, a need for
subtype-selective drugs. Comparatively little is known about the role of the ε subunit or
ε-subunit-containing receptors in vivo. Recently, it has been recognised that a GABAA re-
ceptor subtype, that contains the α3 and ε subunits, is present in neurons within the forebrain
that synthesise acetylcholine, and this may regulate neurotransmitter release. In Alzheimer’s
disease, cholinergic neurotransmission is reduced; therefore, this subtype might be a target
for the development of anti-Alzheimer’s disease drugs that would function by increasing
acetylcholine release in forebrain regions where cholinergic neurons are dying. The phar-
macological properties of a GABAA receptor that comprises the α3, β2 and ε subunits were
examined in Xenopus laevis oocytes using the two-electrode voltage-clamp technique. The
results obtained confirm that the ε subunit confers unusual properties on the GABAA recep-
tor. α3β2ε receptors were spontaneously active and displayed high agonist sensitivity. Next,
a screening assay was established in human embryonic kidney 293 cells, which were tran-
siently transfected with complementary DNAs for GABAA receptor subunits and a yellow
fluorescence protein variant (YFP-H148Q/I152L). The latter is quenched by anion influx into
cells upon receptor activation. Using this assay, receptor activity and GABA-concentration
relationships could be demonstrated. It was, therefore, used to screen for compounds that
modulate the activity of ε-subunit-containing receptors. Several interesting compounds were
identified, and they were further examined using the two-electrode voltage-clamp technique.
These compounds are potential candidates for drug development, and may help to identify
the physiological role(s) of GABAA receptors that contain the ε polypeptide in vivo.
I would like to dedicate my thesis to my grandma Ursula Pöller.
Acknowledgements
I would like to thank my supervisor Professor Mark Darlison for giving me the opportunity
to do my PhD in his laboratory, for the help and guidance I received from him and for
introducing me to the exciting field of ion channel research. I would also like to thank my
other supervisors Professor John Wallis and Dr Chris Garner for their support.
I am grateful to my co-supervisor Dr Ian Mellor for all his help throughout my PhD and,
especially, for giving me the opportunity to work in his laboratory at the University of Not-
tingham on a regular basis. It has been a great experience and I very much enjoyed working
with you. I would also like to thank Ian for proof-reading most parts of my thesis.
Next, I would like to thank all friends and colleagues at Nottingham Trent University, Uni-
versity of Nottingham and Edinburgh Napier University for the help they have given me
during the various stages of my PhD. I very much appreciated the warm welcome, friendli-
ness and support I received in Ians laboratory as well as in Edinburgh after I first arrived. I
am thankful to Amy Poole who has been a great help for me, especially during the last two
years. It was nice to getting to know you better.
Most importantly, I would like to thank my family, especially my parents and grandparents
for their constant support and encouragement. I very much missed seeing you more often.
Finally, I would like to thank my fiancï£¡e Shiva Marthandan who has been there for me
throughout these past few years, helping, encouraging and comforting me. Thanks for having
faith in me and my work; this has greatly helped me to get to the end and finish my thesis.
Finally, I am thankful to Prof. Erwin Sigel (Institute of Biochemistry and Molecular Medi-
cine, University of Bern, Switzerland) for supplying the GABAA receptor α3-, β2- and γ2L-
subunit cDNAs, to Dr Maurice Garret (Laboratoire de Neurophysiologie, Bordeaux, France)
for providing the ε-subunit cDNA, to Dr Thomas Kuner (Institute of Anatomy and Cell Bio-
logy, Heidelberg University, Germany) for the pRK5-Clomeleon plasmid and to Prof. Alan
Verkman (Department of Medicine, University of California, San Francisco, USA) for sup-
plying the pEYFP H148Q/I152L mutant vector. I am also grateful to Prof. Anne Stephenson
(The School of Pharmacy, University of London, UK) for providing HEK293 cells.
iv
Table of Contents
List of Figures viii
List of Tables xi
Abbreviations xiii
1 General Introduction 1
1.1 Alzheimer’s disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 1
1.2 GABA and GABAA receptors . . . . . . . . . . . . . . . . . . . . . . . . 2
1.2.1 Molecular structure of GABAA receptors . . . . . . . . . . . . . . 3
1.2.2 GABAA receptor subunit diversity . . . . . . . . . . . . . . . . . . 4
1.2.3 GABAA receptor stoichiometry and distribution in the brain . . . . 6
1.2.4 Pharmacology of GABAA receptors . . . . . . . . . . . . . . . . . 8
1.2.5 Minor GABAA receptors . . . . . . . . . . . . . . . . . . . . . . . 13
1.2.5.1 The GABAA receptor ε subunit . . . . . . . . . . . . . . 14
1.3 Investigating ion channel properties . . . . . . . . . . . . . . . . . . . . . 19
1.3.1 Mammalian expression systems . . . . . . . . . . . . . . . . . . . 21
1.3.2 Xenopus laevis oocytes . . . . . . . . . . . . . . . . . . . . . . . . 23
1.3.3 Electrophysiological techniques . . . . . . . . . . . . . . . . . . . 25
1.3.4 Flux assays . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
1.3.5 Fluorescence-based assays . . . . . . . . . . . . . . . . . . . . . . 28
1.4 Aims and objectives of the study . . . . . . . . . . . . . . . . . . . . . . . 29
2 Materials and Methods 32
2.1 General molecular biology techniques . . . . . . . . . . . . . . . . . . . . 32
2.1.1 Preparation of competent Escherichia coli (E. coli) cells . . . . . . 32
2.1.2 Transformation of plasmid DNA into competent E. coli cells . . . . 33
2.1.3 Plasmid preparation . . . . . . . . . . . . . . . . . . . . . . . . . 33
2.1.3.1 Minipreparation . . . . . . . . . . . . . . . . . . . . . . 33
2.1.3.2 Maxipreparation . . . . . . . . . . . . . . . . . . . . . . 33
2.1.4 Restriction endonuclease digestion . . . . . . . . . . . . . . . . . . 34
2.1.5 Measuring nucleic acid concentrations . . . . . . . . . . . . . . . . 34
2.1.6 Ethanol precipitation . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.1.7 Sequencing . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
2.1.8 Side-directed mutagenesis - Generating a truncated ε subunit . . . . 35
2.1.8.1 Primer design . . . . . . . . . . . . . . . . . . . . . . . 35
2.1.8.2 Polymerase chain reaction . . . . . . . . . . . . . . . . . 37
2.1.8.3 Ligation of the εT subunit cDNA into the pcDNA3+ vector 39
2.2 GABAA receptor subunits & fluorescence proteins . . . . . . . . . . . . . . 40
v
TABLE OF CONTENTS
2.2.1 Recovery of vectors harbouring GABAA receptor subunits . . . . . 40
2.2.2 Recovery of pRK5-Clomeleon and pEYFP H148Q/I152L vectors . 40
2.2.3 Examination of received vectors . . . . . . . . . . . . . . . . . . . 41
2.2.4 Subcloning . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 41
2.3 Electrophysiological recordings in Xenopus oocytes . . . . . . . . . . . . . 42
2.3.1 Making cRNA from cDNA . . . . . . . . . . . . . . . . . . . . . . 42
2.3.2 Selection of Xenopus laevis oocytes . . . . . . . . . . . . . . . . . 44
2.3.3 Injection of cRNA into Xenopus laevis oocytes . . . . . . . . . . . 45
2.3.4 Two-electrode voltage-clamp . . . . . . . . . . . . . . . . . . . . . 45
2.3.5 Data analysis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
2.4 Patch clamping mammalian cells . . . . . . . . . . . . . . . . . . . . . . . 47
2.5 Cell culture . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 48
2.5.1 Culturing HEK293 cells . . . . . . . . . . . . . . . . . . . . . . . 48
2.5.2 Long term storage of HEK293 cells in liquid nitrogen . . . . . . . . 49
2.5.3 Thawing cells stored in liquid nitrogen . . . . . . . . . . . . . . . 50
2.5.4 Transient transfection of HEK293 cells . . . . . . . . . . . . . . . 50
2.5.4.1 Evaluation of transient transfection efficiency . . . . . . 51
2.5.5 Reseeding cells into appropriate tissue culture plasticware . . . . . 51
2.6 Assay development to screen compound libraries . . . . . . . . . . . . . . 52
2.6.1 A cell-based assay using the chloride-ion indicator Clomeleon . . . 52
2.6.1.1 Excitation and emission spectra of Clomeleon . . . . . . 52
2.6.1.2 Evaluating a screening assay using Clomeleon . . . . . . 52
2.6.2 Setting up an iodide-flux assay . . . . . . . . . . . . . . . . . . . . 53
2.6.3 Setup and optimisation of a mutant YFP-based assay . . . . . . . . 55
2.6.3.1 Data analysis . . . . . . . . . . . . . . . . . . . . . . . . 57
2.7 Compound screening using mutant YFP-H148Q/I152L . . . . . . . . . . . 58
2.7.1 Chemical compound library . . . . . . . . . . . . . . . . . . . . . 58
2.7.2 Screening assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . 58
2.7.2.1 Data analysis . . . . . . . . . . . . . . . . . . . . . . . . 59
2.7.3 Further testing of ’hit’ compounds . . . . . . . . . . . . . . . . . . 59
3 Pharmacological characterisation of the α3β2ε GABAA receptor subtype 61
3.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 61
3.1.1 The GABAA receptor ε subunit . . . . . . . . . . . . . . . . . . . 61
3.1.2 ε subunit splice variants . . . . . . . . . . . . . . . . . . . . . . . 62
3.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 66
3.2.1 Agonist sensitivity . . . . . . . . . . . . . . . . . . . . . . . . . . 66
3.2.2 Current-voltage relationships . . . . . . . . . . . . . . . . . . . . . 68
3.2.3 Effect of zinc . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 68
3.2.4 Application of the benzodiazepine flunitrazepam . . . . . . . . . . 69
3.2.5 Constitutive activity of the α3β2ε GABAA receptor subtype . . . . 70
3.2.6 Effect of etomidate on α3β2ε GABAA receptors . . . . . . . . . . 71
3.2.7 Expression of a truncated ε splice variant . . . . . . . . . . . . . . 74
3.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 75
3.3.1 Pharmacological characteristics of the ε subunit . . . . . . . . . . . 75
3.3.2 Investigation of a truncated ε subunit variant . . . . . . . . . . . . 79
3.3.3 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 80
vi
TABLE OF CONTENTS
4 Development of an assay to screen compound libraries 81
4.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 81
4.1.1 Clomeleon . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
4.1.2 Iodide-flux method . . . . . . . . . . . . . . . . . . . . . . . . . . 84
4.1.3 YFP-based assays . . . . . . . . . . . . . . . . . . . . . . . . . . . 87
4.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 89
4.2.1 Evaluating a screening assay using Clomeleon . . . . . . . . . . . 89
4.2.2 Iodide-flux assay . . . . . . . . . . . . . . . . . . . . . . . . . . . 93
4.2.3 Optimisation of a YFP-based screening assay . . . . . . . . . . . . 103
4.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 108
4.3.1 Clomeleon-based screening assay . . . . . . . . . . . . . . . . . . 108
4.3.2 Colorimetric iodide-flux assay . . . . . . . . . . . . . . . . . . . . 110
4.3.3 YFP-based screening assay . . . . . . . . . . . . . . . . . . . . . . 115
4.3.4 Summary . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 118
5 Screening a chemical compound library 119
5.1 Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
5.2 Results . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 121
5.2.1 Preliminary screening . . . . . . . . . . . . . . . . . . . . . . . . 121
5.2.2 Investigation of ’hit’ compounds on α1β2ε receptors . . . . . . . . 128
5.2.3 Investigation of ’hit’ compounds on α3β2γ2 receptors . . . . . . . 149
5.2.4 Investigation of ’hit’ compounds in Xenopus laevis oocytes . . . . . 158
5.3 Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 162
6 General Discussion 167
6.1 Pharmacological characterisation of the α3β2ε GABAA receptor . . . . . . 167
6.2 Search for and setup of a cell-based screening assay . . . . . . . . . . . . . 169
6.3 Screening of α1β2ε and α3β2γ2 GABAA receptors . . . . . . . . . . . . . 171
6.4 Future Work . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 172
6.5 Conclusions . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 173
Bibliography 175
Appendices 191
A Vector maps 192
B Additional Graphs 195
vii
List of Figures
1.1 GABAA receptor structure . . . . . . . . . . . . . . . . . . . . . . . . . . 4
1.2 Schematic illustration of the GABAA receptor with some drug binding sites 8
1.3 Genetic engineering studies revealed GABAA receptor subunit functions . . 10
1.4 Possible subunit arrangements in ε-containing GABAA receptors . . . . . . 16
1.5 Interrelations between different attributes of ion channel assays . . . . . . . 20
1.6 Xenopus laevis oocytes . . . . . . . . . . . . . . . . . . . . . . . . . . . . 23
1.7 Schematic diagram of the functional expression of genetic information in
Xenopus oocytes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 24
1.8 Schematic representation of the two-electrode voltage-clamp technique . . 26
1.9 Schematic representation of the patch-clamp whole-cell configuration . . . 27
2.1 Side-directed mutagenesis using overlap PCR to create εT . . . . . . . . . . 36
2.2 Healthy and impaired Xenopus laevis oocytes . . . . . . . . . . . . . . . . 44
3.1 Alignment of the partial rat GABAA receptor ε subunit amino acid sequence 64
3.2 Structure of the ε subunit . . . . . . . . . . . . . . . . . . . . . . . . . . . 65
3.3 Sample current traces evoked by ascending GABA concentrations in oocytes
expressing different receptor subtypes . . . . . . . . . . . . . . . . . . . . 66
3.4 Effect of GABA on receptors expressed in Xenopus oocytes . . . . . . . . . 67
3.5 Muscimol activation of GABAA receptors expressed in oocytes . . . . . . . 67
3.6 Current-voltage relationships of GABA-evoked currents in Xenopus oocytes 68
3.7 Effect of zinc on GABAA receptors expressed in Xenopus oocytes . . . . . 69
3.8 Effect of flunitrazepam on GABAA receptors expressed in oocytes . . . . . 70
3.9 Current traces evoked by GABA and picrotoxin in oocytes expressing α3β2
or α3β2ε receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 71
3.10 Effect of etomidate on oocytes expressing α3β2 and α3β2ε receptors . . . 73
3.11 Effect of GABA and zinc on oocytes expressing α3β2εT receptors . . . . . 74
4.1 Principle of Clomeleon, a FRET-based chloride-indicator protein . . . . . . 83
4.2 Assay principle of the colorimetric iodide-flux assay . . . . . . . . . . . . 86
4.3 Schematic diagram showing the principle of the YFP screening assay . . . 88
4.4 Emission scan of the chloride-indicator protein Clomeleon . . . . . . . . . 90
4.5 Excitation scan of the chloride-indicator protein Clomeleon . . . . . . . . . 91
4.6 Fluorescence signal of Clomeleon in HEK293 cells expressing GABAA re-
ceptors after addition of the agonist GABA . . . . . . . . . . . . . . . . . 92
4.7 NaI flux assay standard curve . . . . . . . . . . . . . . . . . . . . . . . . . 94
4.8 OD405 readings obtained from HEK293 cells expressing GABAA receptors 95
4.9 Iodide efflux from HEK293 cells using SK assay . . . . . . . . . . . . . . 97
4.10 OD405 values of cells exposed to GABA with different incubation times . . 98
viii
LIST OF FIGURES
4.11 Iodide-flux assay results after applying GABA over different time periods . 99
4.12 SK assay results obtained from different HEK293 cell densities . . . . . . . 101
4.13 SK assay applying GABA, bicuculline and picrotoxin to the cells . . . . . . 102
4.14 Current traces evoked by GABA and picrotoxin in HEK293 cells expressing
α3β2γ2 receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 103
4.15 Net fluorescence signal of mutant YFP-H148Q/I152L in HEK293 cells ex-
pressing α3-subunit-containing GABAA receptors . . . . . . . . . . . . . . 105
4.16 Net fluorescence signal of mutant YFP-H148Q/I152L in HEK293 cells ex-
pressing α1-subunit-containing GABAA receptors . . . . . . . . . . . . . . 106
4.17 GABA concentration-response relations in a YFP-based screening assay . . 107
4.18 Fluorescence signal change after addition of flunitrazepam to cells expres-
sing α3β2γ2 GABAA receptors . . . . . . . . . . . . . . . . . . . . . . . 108
5.1 Sample negative results from preliminary screen of α1β2ε receptors . . . . 122
5.2 Sample negative results from preliminary screen of α3β2γ2 receptors . . . 123
5.3 Representative positive screening results for α1β2ε GABAA receptors . . . 124
5.4 Representative positive screening results for α3β2γ2 GABAA receptors . . 125
5.5 Results obtained for different concentrations of a test compound in cells ex-
pressing α1β2ε receptors . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
5.6 Results obtained for different concentrations of a test compound in cells ex-
pressing α3β2γ2 receptors . . . . . . . . . . . . . . . . . . . . . . . . . . 127
5.7 Effect of compound TS-1 on α1β2ε-receptor-containing cells . . . . . . . . 129
5.8 Effect of compound TS-2 on cells expressing α1β2ε GABAA receptors . . 130
5.9 Effect of compound TS-3 on cells expressing α1β2ε GABAA receptors . . 131
5.10 Effect of compound TS-4 on cells expressing α1β2ε GABAA receptors . . 132
5.11 Effect of compound TS-5 on cells expressing α1β2ε GABAA receptors . . 133
5.12 Effect of compound TS-6 on cells expressing α1β2ε GABAA receptors . . 134
5.13 Effect of compound TS-7 on α1β2ε-receptor-containing cells . . . . . . . . 135
5.14 Effect of compound TS-8 on α1β2ε-receptor-containing cells . . . . . . . . 136
5.15 Effect of compound TS-9 on cells expressing α1β2ε GABAA receptors . . 137
5.16 Effect of compound TS-10 on cells expressing α1β2ε GABAA receptors . . 138
5.17 Effect of compound TS-11 on cells expressing α1β2ε GABAA receptors . . 139
5.18 Effect of compound TS-12 on cells expressing α1β2ε GABAA receptors . . 140
5.19 Effect of compound TS-13 on cells expressing α1β2ε GABAA receptors . . 141
5.20 Effect of compound TS-14 on cells expressing α1β2ε GABAA receptors . . 142
5.21 Effect of compound TS-15 on cells expressing α1β2ε GABAA receptors . . 143
5.22 Effect of compound TS-16 on cells expressing α1β2ε GABAA receptors . . 145
5.23 Effect of compound TS-17 on cells expressing α1β2ε GABAA receptors . . 146
5.24 Effect of compound TS-18 on cells expressing α1β2ε GABAA receptors . . 147
5.25 Effect of compound TS-19 on α1β2ε-receptor-expressing cells . . . . . . . 148
5.26 Effect of compound TS-10 on cells expressing α3β2γ2 GABAA receptors . 150
5.27 Effect of compound TS-20 on cells expressing α3β2γ2 GABAA receptors . 151
5.28 Effect of compound TS-21 on cells expressing α3β2γ2 GABAA receptors . 152
5.29 Effect of compound TS-22 on cells expressing α3β2γ2 GABAA receptors . 153
5.30 Effect of compound TS-23 on cells expressing α3β2γ2 GABAA receptors . 155
5.31 Effect of compound TS-16 on cells expressing α3β2γ2 GABAA receptors . 156
5.32 Effect of compound TS-24 on cells expressing α3β2γ2 GABAA receptors . 157
5.33 Effect of compound TS-3 on oocytes expressing α1β2ε GABAA receptors . 159
ix
LIST OF FIGURES
5.34 Effect of compound TS-16 on oocytes expressing α1β2ε or α3β2γ2 receptors 160
5.35 Effect of compound TS-23 on oocytes expressing α3β2γ2 GABAA receptors 161
A.1 pcDNA3.1 vector map . . . . . . . . . . . . . . . . . . . . . . . . . . . . 192
A.2 pcDNA3 vector map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
A.3 pCMV vector map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 193
A.4 pBS vector map . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 194
A.5 pRK5-Clomeleon vector map . . . . . . . . . . . . . . . . . . . . . . . . . 194
B.1 Effect of DMSO on oocytes expressing different GABAA receptor subtypes 195
B.2 Fluorescence signal of mutant YFP-H148Q/I152L in response to different
concentrations of DMSO . . . . . . . . . . . . . . . . . . . . . . . . . . . 196
B.3 OD405 values of cells exposed to GABA or DPBS with different incubation
times . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 197
B.4 OD405 values of cells exposed to GABA or DPBS with different incubation
times . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 198
B.5 Effect of GABA on α1β2ε receptors expressed in Xenopus oocytes . . . . . 199
B.6 Effect of GABA on α3β2γ2 receptors expressed in HEK293 cells . . . . . 199
x
List of Tables
1.1 GABAA receptor subunit clusters in the human genome . . . . . . . . . . . 6
1.2 Native GABAA receptors in the brain . . . . . . . . . . . . . . . . . . . . . 7
2.1 Oligonucleotide design to generate a GABAA receptor εT subunit . . . . . . 35
2.2 Restriction enzymes used to digest different GABAA receptor cDNAs . . . 41
2.3 Transient transfection using TransPassTM D2 in different culture vessels . . 50
3.1 Effects of GABA and muscimol on different GABAA receptors . . . . . . . 67
4.1 Analysis of OD405 readings obtained from SK assay using HEK293 cells . 95
xi
Abbreviations
5-HT3Rs Serotonin 5-hydroxytryptamine3 receptors
A Absorbance
ACh Acetylcholine
AD Alzheimer’s disease
AE1 Anion exchanger 1
BF Baseline fluorescence
BLAST Basic local alignment search tool
bp Base pairs
cDNA Complementary DNA
CFP Cyan fluorescence protein
CFTR Cystic fibrosis transmembrane conductance regulator protein
CNS Central nervous system
cRNA Complementary RNA
DEPC Diethylpyrocarbonate
DMCM methyl-6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate
DMEM Dulbecco’s modified Eagle’s medium
DMSO Dimethyl sulfoxide
DPBS Dulbecco’s phosphate buffered saline
E.coli Escherichia coli
εT Truncated ε subunit
EC50 Effective concentration for 50 % receptor activity
EDTA Ethylenediaminetetraacetic acid
FBS Fetal bovine serum
FLIPR Fluorometric Imaging Plate Reader
FRET Förster (or Fluorescence) Resonance Energy Transfer
GABA γ-Aminobutyric acid
GABAA GABA type A
GABAB GABA type B
GAD Glutamate decarboxylase
GFP Green fluorescence protein
GlyRs Glycine receptors
HEK Human embryonic kidney
HTS High throughput screening
IC50 Effective concentration for 50 % receptor inhibition
KApp Apparent dissociation constant
Kd Dissociation constant
kb Kilo bases
LB Lysogeny broth
LC Locus coeruleus
xii
ABBREVIATIONS
LGICs Ligand-gated ion channels
MQAE N-(ethoxycarbonylmethyl)-6-methoxyquinolinium bromide
MRK-016 3-tert-butyl-7-(5-methylisoxazol-3-yl)-2-(1-methyl-1H-1,2,4-triazol-5-
ylmethoxy)-pyrazolo[1,5-d]-[1,2,4]triazine
mRNA Messenger RNA
nAChRs Nicotinic ACh receptors
NKCC Na+-K+-Cl- co-transporters
OD Optical density
PCR Polymerase chain reaction
PKC Protein kinase C
rpm Revolutions per minute
rTEV Recombinant Tobacco Etch Virus
SD Standard deviation
SEM Standard error of the mean
SK Sandell-Kolthoff
Tm Melting temperature
TAE Tris-acetate
TM Transmembrane domain
UV Ultraviolet
v/v Volume per volume
w/v Weight per volume
YFP Yellow fluorescence protein
YFP-H148Q/I152L YFP with mutation at positions 148 (histidine to glutamine) and 152
(isoleucine to leucine)
xiii
Chapter 1
General Introduction
1.1 Alzheimer’s disease
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder and the most frequent
form of dementia in elderly people. More than 25 million people worldwide are suffering
from dementia, a number that is expected to double every 20 years as the general age of
the human population increases (Ferri et al., 2005; Citron, 2010). Clinical features of AD
include loss of memory, cognitive dysfunction as well as behavioural disturbances, such as
mood disorders, agitation and psychosis, leading to death on average nine years after AD
was first diagnosed. AD is the sixth leading cause of death in the USA. The illness not
only has a dramatic effect on the patient, but there is also a considerable burden on close
relatives and caregivers, and ultimately national economies due to the frequent requirement
for institutionalisation. Total costs caused by AD worldwide are thought to be more than 200
billion dollars per annum (Citron, 2010).
The pathological hallmarks of AD are the presence of extracellular plaques containing β-
amyloid peptides, which derive from the amyloid precursor protein, and neurofibrillary
tangles, which contain abnormally phosphorylated forms of the cytoskeleton-associated pro-
tein tau, as well as the degeneration of synapses and neurons (Kar et al., 2004; Citron, 2010).
It is also well established that there is a loss of cholinergic neurotransmission in the hippo-
campus and neocortex of the brain. This is the result of reduced choline uptake, acetylcholine
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(ACh) release and choline acetyltransferase activity and, ultimately, the loss of basal fore-
brain cholinergic neurons. ACh is essential for cell-to-cell communication in the forebrain,
and neuronal pathways regulated by this transmitter are important for cognition. The fin-
dings outlined above have led to the ’cholinergic hypothesis’ of AD, in which the loss of
basal forebrain cholinergic neurons and the interruption of cholinergic neurotransmission
in the cerebral cortex and other areas is proposed to cause the observed cognitive impair-
ments (Kar et al., 2004; Yuede et al., 2007). Currently, there is no cure for this debilitating
illness. However, therapeutic approaches have been developed, for example ACh-esterase
inhibitors, which increase ACh levels in the brain resulting in improved cognitive functions.
There are currently four approved ACh-esterase inhibitors to treat mild to moderate AD: ta-
crine (Cognex®), donepezil (Aricept®), rivastigmine (Exelon®) and galantamine (Reminyl®;
Yuede et al., 2007). The latter also potentiates the activity of neuronal nicotinic ACh re-
ceptors (nAChRs), which is believed to further improve neurotransmission (Seltzer, 2010).
However, these drugs merely delay the progression of disease symptoms for one to two years.
Moreover, the ACh-esterase inhibitor tacrine has been shown to trigger hepatotoxic effects
and its use has been diminished (Watkins et al., 1994). Hence, to treat AD more efficiently,
new drug targets and more effective treatments are urgently needed.
1.2 GABA and GABAA receptors
γ-Aminobutyric acid (GABA) is a four-carbon nonprotein amino acid. It is synthesised from
L-glutamic acid catalysed by glutamate decarboxylase (GAD); GAD requires the cofactor
pyridoxal phosphate (Martin & Rimvall, 1993). It exists in two isoforms, GAD65 (65 kDa
isoform) and GAD67 (67 kDa isoform). The two forms are regulated separately and localised
in different subcellular compartments. GAD67 is present throughout the cytoplasm of neu-
rons, generating GABA for metabolic purposes rather than neurotransmission, for example
protection after neuronal injury or regulation of redox potential in response to oxidative stress
(Kaufman et al., 1991; Waagepetersen et al., 1999; Lamigeon et al., 2001; Buddhala et al.,
2009). GAD65 is present in nerve terminal endings generating GABA for neurotransmission
purposes. GABA is removed from the synaptic cleft by high-affinity transporters and bro-
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ken down by GABA transaminase into succinic semialdehyde and glutamic acid (D’Hulst &
Kooy, 2007).
GABA is the main inhibitory neurotransmitter in the mammalian central nervous system
(CNS) and found in 30 % of neuronal synapses. Its effects are mediated via ionotropic GABA
type A (GABAA) receptors or via metabotropic GABA type B (GABAB) receptors. The latter
are coupled to G proteins, which mediate signal transduction via secondary messengers,
whereas the former are directly gating Cl- ions (Bormann, 2000). GABAA receptors are
widespread throughout the mammalian CNS where they control the majority of physiological
actions of GABA, including learning and memory processes, cognition, feeding and drinking
behaviour and the modulation of anxiety (Bormann, 2000; Sieghart & Sperk, 2002; D’Hulst
et al., 2009). Mutations or functional deficits of GABAA receptors have been implicated with
a variety of neuropsychiatric diseases, such as anxiety, schizophrenia, fragile X syndrome
and several genetic forms of epilepsy (D’Hulst & Kooy, 2007; Moult, 2009; Macdonald
et al., 2010). The receptors importance is further reflected by the fact that it is targeted by
a plethora of pharmacologically and clinically important drugs, including benzodiazepines
and anaesthetics.
1.2.1 Molecular structure of GABAA receptors
GABAA receptors belong to the superfamily of Cys-loop ligand-gated ion channels (LGICs)
that also includes nAChRs, serotonin 5-hydroxytryptamine3 receptors (5-HT3Rs), glycine
receptors (GlyRs) and zinc-activated ion channels (Schofield et al., 1987; Olsen & Sie-
ghart, 2008). Cys-loop LGICs mediate fast synaptic neurotransmission by conducting ca-
tions (nAChRs, 5-HT3Rs and zinc-activated ion channels) or anions (GABAA receptors and
GlyRs), mediating excitatory or inhibitory neurotransmission, respectively (Pless & Lynch,
2008). GABAA receptors consist of five subunits, each of which comprises a large extracel-
lular amino terminal domain of about 220 amino acids, four hydrophobic, α-helical trans-
membrane domains (TM1-4) each of about 20 amino acids in length, a large intracellular
loop between TM3 and TM4 and a short extracellular carboxyl-terminal domain (Figure 1.1
A). The extracellular amino terminal domain includes a 13 amino acid sequence flanked by
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two cystein residues that form a disulphide bond. This characteristic structural feature, com-
mon to all Cys-loop LGICs, determined the superfamily’s name (Simon et al., 2004). The
receptor subunits are arranged in a circle to form a central ion-conducting channel, with the
second TM of each subunit forming the channel pore (Figure 1.1 B; Hevers & Lüddens,
1998). Residues within the amino terminal domain of two adjacent subunits form the ligand
binding sites. Binding of two GABA molecules to a GABAA receptor triggers a conformatio-
nal change in the receptor, resulting in the opening of the intrinsic channel pore, the influx of
extracellular ions (primarily Cl- ions) via diffusion and subsequent hyperpolarisation of the
post-synaptic membrane, which leads to an increase in the inhibitory tone (Darlison et al.,
2005).
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Figure 1.1: GABAA receptor structure. (A) Schematic representation of a receptor subunit
and (B) the pentameric receptor structure.
1.2.2 GABAA receptor subunit diversity
Nineteen different GABAA receptor subunits are known to exist in man; analysis of the
human genome database revealed that there are no further GABAA receptor subunit genes
(Simon et al., 2004). The subunit genes are subdivided into classes according to their amino
acid sequence homology. Sequence similarities between members of the same family are
around 70 % and between different families around 20 to 40 % (Darlison et al., 2005). There
are six alpha (α1-α6), three beta (β1-β3), three gamma (γ1-γ3), one delta (δ), one epsilon
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(ε), one theta (θ) and one pi (pi) subunit as well as three rho (ρ1-ρ3) subunits. The latter
were formerly classified as GABA type C receptors due to their distinct pharmacological
characteristics and the fact that they are highly expressed in the vertebrate retina and do
not co-localise with other GABAA receptor subtypes (Bormann, 2000; Olsen & Sieghart,
2008). A number of receptor subunits exhibit splice variants, among others the α6, γ2 and ε
subunits, generating further structural diversity of GABAA receptors (see also Section 3.1.2,
Chapter 3; Whiting et al., 1990, 1997; Korpi et al., 1994; Simon et al., 2004). Furthermore,
two other subunits, β4 and γ4, have been identified in lower vertebrates which lack the ε
and θ subunits (Bateson et al., 1991; Harvey et al., 1993). Based on sequence similarities
between the ε and γ4 subunits (49 % identity) as well as between the θ and β4 subunits
(56 % identity) and gene mapping studies, it has been concluded that the ε and θ subunits
are orthologues of the γ4 and β4 subunits, respectively (Simon et al., 2004; Darlison et al.,
2005).
Each receptor subunit is encoded by a distinct gene; most of which are clustered on dif-
ferent chromosomes in the human genome (see Table 1.1; Simon et al., 2004; Darlison et al.,
2005). The subunit genes are expressed independently from other genes of the same clus-
ter and associate together in different combinations to form a variety of receptor subtypes.
This explains the large number of different GABAA receptor subtypes present in the verte-
brate brain (see below). However, co-regulation of clustered genes may play a role in some
receptor subtypes, for example in α1β2γ2 receptors. All three subunits are clustered on
chromosome 5; the β2 and α1 genes are separated by the α6 subunit gene (β2-α6-α1-γ2).
It was shown in α6 ’knockout’ mice that α1 and β2 subunits are most likely regulated to-
gether by a common regulatory element, since expression of both subunits was reduced in
mice lacking the α6 subunit (Uusi-Oukari et al., 2000). Furthermore, α1 and β2 subunits are
widely expressed and exhibit a nearly identical expression pattern in the mammalian brain.
Expression of the γ2 subunit was not affected in α6 ’knockout’ mice compared to wild-type
mice. Nevertheless, these results suggest that subunit gene-clustering may partly contribute
to α1β2γ2 receptor assembling and may also play a role in subunit assembling of certain
other receptor subtypes.
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Table 1.1: GABAA receptor subunit clusters in the human genome
GABAA receptor subunits Chromosome
α2, α4, β1, γ1 4p12-p13
α1, α6, β2, γ2 5q31-q35
α5, β3, γ3 15q11-q12
α3, θ, ε Xq28
ρ1, ρ2 6q14-q21
The pi subunit gene is located on chromosome 5 (5q34-q35), but apart from the β2-α6-α1-γ2 subunit
gene cluster. The δ subunit is present separately from all other GABAA receptor genes on chromo-
some 1 (1p36.3; Simon et al., 2004; Darlison et al., 2005).
1.2.3 GABAA receptor stoichiometry and distribution in the brain
Hypothetically, if all existing GABAA receptor subunits could co-assemble at random, the
number of potential receptor subtypes would be huge. However, cell type-specific regulation
mechanisms control subcellular localisation, trafficking and subunit assembly (Fritschy &
Brünig, 2003; Lüscher & Keller, 2004), resulting in the existence of only a fraction of those
potential GABAA receptors in vivo. Sieghart (2000) estimated that there could be more than
500 different receptor subtypes expressed in the brain. Although, the presence of α and β
subunits is sufficient to form functional GABA-gated channels, most of the native receptors
are composed of three different types of subunits, usually two α subunits, two β subunits and
one γ subunit with a common stoichiometry of α-β-α-β-γ (Baumann et al., 2002; Sieghart
& Sperk, 2002). The γ subunit is in certain receptor subtypes replaced by a δ or ε subunit.
The distribution of the different GABAA receptor subtypes is brain area and cell type specific;
distinct neurons can express more than one receptor subtype. Subunit co-localisation in
different brain areas is important for receptor subunit composition. In situ hybridisation
and immunohistochemistry experiments revealed that α1, β1, β2, β3 and γ2 subunits are
widely expressed throughout the brain, albeit with different distribution patterns (Sieghart
& Sperk, 2002; Olsen & Sieghart, 2009). Expression of α2, α3, α4, α5, α6, γ1 and δ
subunits is less abundant and restricted to specific brain areas. The α2 subunit, for example,
is predominately expressed in the forebrain, whereas the α6 subunit is located only in granule
cells of the cerebellum and the cochlear nucleus (Pirker et al., 2000). Furthermore, the
majority of serotonergic neurons located in the raphne nuclei contain α3 subunits, but lack
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α1 subunits (Gao et al., 1993). In contrast, GABAergic neurons in this area express both α
subunits and, hence, contain different receptor types.
The most common receptor subtype is the α1β2γ2 receptor, which is present in most areas
of the brain and makes up for 60 % of all GABAA receptors (Möhler, 2006, 2007). Other
common receptor subtypes are α2β3γ2 and α3βγ2 receptors, which count for 15 to 20 %
and 10 to 15 % of all receptors, respectively. Despite extensive research in the area, only
ten different native receptor subtypes have been identified indubitably by taking into account
specific criteria for receptor identification, including localisation, subunit composition, stoi-
chiometry and receptor pharmacology (see Olsen & Sieghart, 2008, 2009). Further receptor
subtypes have been proposed to exist with high probability or tentatively (see Table 1.2).
Table 1.2: Native GABAA receptors in the brain
Identified Existing with high probability Tentative
α1β2γ2 α1β3γ2 ρ1
α2βγ2 α1βδ ρ2
α3βγ2 α5β3γ2 ρ3
α4βγ2 αβ1γ/αβ1δ αβγ1
α4β2δ αβ αβγ3
α4β3δ α1α6βγ/α1α6βδ αβθ
α5βγ2 αβε
α6βγ2 αβpi
α6βδ αxαyβγ2
ρ
By investigating different aspects of GABAA receptors, including localisation, subunit composition
and receptor pharmacology, ten native receptor subtypes have been unequivocally identified, further
receptor subtypes exist with high probability and others tentatively (adapted from Olsen & Sieghart,
2009).
Although most receptors contain only one type of α or β subunits several studies have sug-
gested that there may be receptor subtypes co-expressing two different α or β subunits in
the brain (Sieghart & Sperk, 2002; Benke et al., 2004; Olsen & Sieghart, 2009). Immuno-
precipitation and -purification experiments and expression of α1, α6, β2 and γ2 subunits in
Xenopus laevis oocytes suggested that α1 and α6 subunits can co-exist in α1α6β2γ2 recep-
tor subtypes (Jechlinger et al., 1998; Sigel & Baur, 2000). Similarly, Fisher & Macdonald
(1997) showed that two different β subunits can co-exist in recombinant GABAA receptors
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expressed in L929 fibroblasts conferring different properties to the receptor compared to
receptors containing only one of the two β subunits.
Different receptor subtypes exhibit distinct functional, physiological and pharmacological
characteristics. The specific subunit composition as well as the subunits position in the
pentameric receptor structure determine the receptors affinity for GABA, its pharmacological
profile as well as the receptors assembling patterns and targeting to different subcellular
domains (Ebert et al., 1994; Connolly et al., 1996; Whiting et al., 1999).
1.2.4 Pharmacology of GABAA receptors
As mentioned above, GABAA receptors have two GABA binding sites. They are located at
the interface between the α and β subunits and amino acid residues on both subunits form
the agonist binding pocket (Figure 1.2; Sigel & Buhr, 1997). Additionally, GABAA recep-
tors possess multiple other binding sites for a variety of pharmacologically and clinically
important drugs, such as benzodiazepines, general anaesthetics, neurosteroids, barbiturates
and convulsants (Figure 1.2 A; Bateson, 2004).
βα αγ
Cl-
β
Benzodiazepine
GABA
GABA
PTX
ZincEthanol
α
α
β
β
γ Cl-
A B
Loreclezole/ 
etomidate
Figure 1.2: (A) Schematic illustration of the GABAA receptor and some of the several drug
binding sites. (B) Cross section of the pentameric receptor structure. Yellow circles represent
the agonist GABA, which binds to the receptor between the α and β subunits. The binding
site for benzodiazepines (red circles) is located at the interface of α and γ subunits.
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The benzodiazepine binding site has received notable interest due to the clinical impor-
tance of benzodiazepines. Full agonists, such as diazepam, antagonists, such as methyl-
6,7-dimethoxy-4-ethyl-beta-carboline-3-carboxylate (DMCM), or inverse agonists, such as
flumazenil, but no endogenous ligands have been identified to bind to the site (van Niel et al.,
2005). Full benzodiazepine agonists have been used since the 1960s in a wide range of cli-
nical applications, such as treatment of anxiety disorders and insomnia and as anti-epileptic
and muscle relaxing agents (Bateson, 2004; Rudolph & Möhler, 2006). Inverse agonists
have been used as research tools only, due to their proconvulsant effects (van Niel et al.,
2005). The allosteric binding site is located at the interface between the α and γ subunits
(Pritchett et al., 1989b; Stephenson et al., 1990) and benzodiazepine ligand pharmacology
is determined by both the α and γ subunits of a receptor subtype (Pritchett et al., 1989a;
Hadingham et al., 1993; Wafford et al., 1993). Amino acid residues of the benzodiazepine
binding pocket are homologues to those in the GABA binding site (Olsen et al., 2004). It has
been shown that the γ2 subunit confers high sensitivity to classical benzodiazepines, such
as diazepam and triazolam, whereas receptors containing γ1 or γ3 subunits show decreased
affinity (Knoflach et al., 1991; Wafford et al., 1993). The α1, α2, α3 and α5 subunits also
confer sensitivity to classical benzodiazepines (Pritchett et al., 1989a; Smith & Olsen, 1995;
Sigel & Buhr, 1997), whereas receptors containing the α4 and α6 subunits are insensitive
to most clinically used benzodiazepines (Wisden et al., 1991; Möhler et al., 2002). Recep-
tor subtypes containing the δ and ε subunits are also benzodiazepine insensitive (Saxena &
Macdonald, 1994; Whiting et al., 1997).
Work with genetically engineered mice and studies using subunit specific ligands revealed
that the various effects of benzodiazepines (sedative/hypnotic, anxiolytic, anticonvulsant,
muscle relaxing and amnesic) are mediated by different GABAA receptor subtypes (McKer-
nan & Whiting, 1996; Rudolph et al., 1999; Rudolph & Möhler, 2006). In these mice, point-
mutations were introduced in α1, α2, α3 or α5 subunits, which caused insensitivity of the
specific subunit to diazepam (Rudolph & Möhler, 2004). Deficits in the behaviour of the
mutant mice were then examined and revealed the actions mediated by the mutated subunit
(Figure 1.3). By this means, it was demonstrated that receptors containing the α1 subu-
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nit mediate the sedative, amnesic as well as partly the anticonvulsant effects of diazepam
(Rudolph et al., 1999). In contrast, the anxiolytic and myorelaxing effects of diazepam are
mediated by receptors containing the α2 subunit (Löw et al., 2000; Rudolph et al., 2001). It
was further revealed that α3 subunits mediate myorelaxation as well as an anxyolytic effect
at high receptor occupation. Several studies investigating α5 subunit functions revealed a
role in learning and memory, for example, mice lacking the α5 subunit performed better in a
spatial learning exercise than wild type mice (Rudolph & Möhler, 2006).
β3β2
α5α3α2α1
Diazepam
Sedation
Anterograde 
amnesia
Anticonvulsion
(partly) Anxiolysis Myorelaxation
Learning, 
memory
Etomidate
Hypnosis Immobility
α1/2/3/5 mutant mice
β2/3 mutant mice
Figure 1.3: Genetic engineering studies in mice revealed distinct actions of diazepam and
etomidate on different GABAA receptor subtypes.
Point-mutations in specific α or β subunits rendered them insensitive to diazepam or etomidate,
respectively. Behavioural deficits in these genetically engineered mice gave information about the
actions mediated by these specific receptor subtypes. For example, α1-containing receptors are me-
diating the sedative action of benzodiazepines (adapted from Agid et al., 2007).
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Subunit specific ligands have been shown to also demonstrate GABAA receptor subunit func-
tions and could confirm results obtained from genetically engineered mice (Chambers et al.,
2004; Sternfeld et al., 2004; Atack et al., 2006; Rudolph & Möhler, 2006). For example,
compound MRK-016 is an inverse agonist on the benzodiazepine binding site and acts pri-
marily on α5-subunit-containing receptors mediating enhanced cognition (Chambers et al.,
2004; Atack et al., 2009). Another example is the hypnotic, non-benzodiazepine zolpidem.
It binds preferentially to receptors containing the α1 subunit and with less or no affinity to re-
ceptors containing α2, α3 or α5 subunits (Pritchett & Seeburg, 1990). Crestani et al. (2000)
have demonstrated that the anticonvulsant and sedative effects mediated by zolpidem are
solely conferred by the α1 subunit. The described compounds are subunit selective, howe-
ver, they cannot discriminate between different receptor subtypes. Therefore, native GABAA
receptor subtypes cannot be identified using these compounds.
The application of classical benzodiazepines is often accompanied by adverse side effects,
such as dependence, withdrawal or tolerance limiting their clinical suitability (Buffett-Jerrott
& Stewart, 2002; Möhler et al., 2002; Bateson, 2004; Agid et al., 2007). It was suggested
that this was due to the lack of selectivity for a given receptor subtype. Ligands acting
on smaller subpopulations of GABAA receptors, such as zolpidem, are thought to produce
specific actions and show fewer side effects compared with the classical benzodiazepine
drugs. Currently there are a number of subtype specific ligands under investigation, which
may substitute the use of classical benzodiazepines in the future to contain the occurrence
of side effects (see Möhler et al., 2002; Rudolph & Möhler, 2006; Whiting, 2006). These
are, for example, zaleplone, a compound with high affinity for α1 subunits, but decreased
sensitivity to α2, α3, or α5 subunits or dihydroquinoline that has shown to exhibit agonist
efficacy at α2 subunits, but lacks affinity for α1-containing receptors (Johnstone et al., 2004;
Rudolph & Möhler, 2006). L-655,708 is a memory enhancing drug preferentially binding to
the α5 subunit (Navarro et al., 2002; Rudolph & Möhler, 2006; Whiting, 2006).
GABAA receptors are also targeted by volatile and intravenous anaesthetics, which exhibit
three different modes of action on the receptors: (1) allosteric receptor activation at low
concentrations, (2) at higher concentrations they directly activate receptors in the absence of
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GABA and (3) at very high concentrations they block the chloride channel (Thompson et al.,
1996). A number of studies have demonstrated the importance of β subunit isoforms for
the action of certain anaesthetics, such as etomidate (Harris et al., 1995; Sanna et al., 1995,
1997). Etomidate produces modulatory actions on recombinant receptors containing any of
the β subunits, but has been shown to be less potent on β1-containing receptors compared to
β2- and β3-containing receptors (Hill-Venning et al., 1997; Sanna et al., 1997). The direct
action of etomidate, in contrast, is dependent on the presence of β2 and/or β3 subunits, since
receptors containing the β1 subunit did not show GABA-mimetic actions (Belelli et al., 1996;
Hill-Venning et al., 1997; Pistis et al., 1997; Sanna et al., 1997). These findings have led to
the suggestion that the modulatory and GABA-mimetic actions of etomidate are mediated
via distinct binding sites on the GABAA receptor.
Similar studies as described above using genetically engineered mice have shown that the
different actions of anaesthetics are also mediated by different GABAA receptor subtypes.
Point mutations of residue N265 in β2 (N265S) and β3 (N265M) subunits were introduced
in mice. The effects of etomidate in these mice were compared to the effects seen in wild
type mice (Jurd et al., 2003; Reynolds et al., 2003). Missing or reduced behavioural pattern
in mutant mice was suggested to be mediated by the mutated subunit. Via this means it was
demonstrated that the β3 subunit mediates the immobilising as well as in part the hypno-
tic effect of etomidate. The β2 subunit was found to also mediate the hypnotic action of
etomidate (Figure 1.3).
Neurosteroids are the only endogenously synthesised GABAA receptor modulators. They
interact with many different receptor subtypes and lack specificity, although several reports
suggested a more potent action on extrasynaptic δ-containing receptors (Belelli et al., 2002;
Wohlfarth et al., 2002; Mitchell et al., 2008). It was proposed that neurosteroids mediate
their action via two different binding pockets (Belelli & Lambert, 2005; D’Hulst et al., 2009;
Olsen & Sieghart, 2009), since they enhance GABA-mediated effects at low concentrations
whereas at higher concentrations they directly activate GABAA receptors. The binding site
for the former action has recently been shown to consist of highly conserved amino acid
residues in the TM domains of α subunits, whereas the site for direct receptor activation is
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located in the interface between α and β subunits (Hosie et al., 2007, 2009).
As described before, there are various further drug binding sites located at the GABAA re-
ceptor (for a detailed review see Korpi et al., 2002) and the examples described illustrate the
complexity of allosteric ligand binding on GABAA receptor subtypes. They also indicate
the great potential of GABAA receptors for future drug development, especially in terms of
subtype selective compounds. Currently, most drugs in use are not subtype selective, but act
on multiple subunits/receptor subtypes. Consequences are frequent appearance of adverse
side effects. Hence, new subtype-selective compounds are needed.
1.2.5 Minor GABAA receptors
As mentioned above, most GABAA receptors comprise of α, β and γ subunits. However, in
certain areas of the brain receptors containing minor subunits are expressed and may play
important roles. ε, θ and pi subunits were the last identified GABAA receptor subunits. They
were discovered by searching DNA databases (Davies et al., 1997; Hedblom & Kirkness,
1997; Whiting et al., 1997; Bonnert et al., 1999). All three have been assigned into their
own subunit classes, due to the relative low sequence similarities with members of other
subunit classes. ε and θ subunits are closest to γ and β subunits (Section 1.2.1), whereas
the pi subunit shows closest homology to β (37 % identity), δ (35 % identity) and ρ (33 %
identity) subunits (Hedblom & Kirkness, 1997).
Little is known about properties and functions of these subunits and their roles in vivo are
still not known. It seems as if there has been a lack of interest in investigating these su-
bunits, since only a relatively small number of studies have been performed, compared to
other GABAA receptor subtypes. This may be partly, due to the fact that receptor subtypes
containing ε, θ or pi subunits are insensitive to benzodiazepine-type drugs and no subunit-
specific pharmacologies could yet be established. Furthermore, their expression patterns are
restricted to few brain areas or, in case of the pi subunit, are mainly expressed in peripheral
tissues and barely in the brain (Hedblom & Kirkness, 1997). However, these subunits may
have important functions in some areas of the brain.
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1.2.5.1 The GABAA receptor ε subunit
The ε subunit was first described in 1997 by Davies et al., Garret et al. and Whiting et al.. It
was detected in several peripheral tissues, such as heart, liver, testis and placenta, as well as
in the mammalian brain, where its expression pattern is restricted to specific areas (Whiting
et al., 1997; Erlitzki et al., 2000; Davies et al., 2002). In situ hybridisation and Northern
blot analyses in primates and rodents have revealed distinct ε subunit expression in several
areas of the forebrain, such as basal ganglia, thalamus, hypothalamus and amygdala as well
as in the locus coeruleus (LC; Whiting et al., 1997; Moragues et al., 2000; Sinkkonen et al.,
2000; Sieghart & Sperk, 2002). ε subunit gene expression has also been demonstrated in
all forebrain and a few hindbrain cholinergic cell groups; many of these also contain the α3
subunit (Moragues et al., 2002). Furthermore, the expression pattern of the ε subunit widely
overlaps with that of the θ subunit in the brain, for example in hypothalamus, amygdala and
LC (Bonnert et al., 1999; Sieghart & Sperk, 2002). The θ subunit also exhibits a restricted
expression pattern in the brain. It is noteworthy that both subunit genes as well as the one
encoding the α3 subunit are clustered together on chromosome Xq28 in the human genome
(see Section 1.2.2; Wilke et al., 1997). Therefore, it is likely that the three subunits alone or
containing a further subunit form functional receptor channels in some areas of the brain, for
example in the LC or other areas in the forebrain, where all three subunits are co-expressed
(Moragues et al., 2000; Sieghart & Sperk, 2002).
Kasparov et al. (2001) proposed that neurons of the caudal nucleus of the solitary tract ex-
press ε-containing receptors. The authors investigated rat brain slices electrophysiologi-
cally as well as performed immunocytochemistry analyses, and concluded that the obser-
ved benzodiazepine insensitivity of these neurons could be due to expression of ε-subunit-
containing receptors. Another area where ε-subunit-containing receptors are expressed is the
LC. GABAA receptors expressed in the LC have interesting properties. It was assumed that
they comprise of α3, θ, ε and probably β1/3 subunits, but do not contain γ subunits (Chen
et al., 1999; Belujon et al., 2009). Indeed, in situ hybridisation experiments in brains from
21-day old rats did not detect γ subunit expression in LC neurons. However, conflicting
data were obtained when investigating benzodiazepine sensitivity in these neurons. Chen
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et al. (1999) reported diazepam did not effect the GABA-induced firing rate of LC neurons
using LC slice preparations. Belujon et al. (2009) performed in vivo extracellular and in vitro
patch-clamp recordings in adult rats and slice preparations from juvenile rats, respectively,
to investigate the effects of flunitrazepam and diazepam on LC neurons. The former had
no effect, but surprisingly, diazepam at micromolar concentrations was able to potentiate
GABA-induced currents in vitro. Functions of ε-subunit-containing receptors in these brain
regions are not known yet.
The ε subunit exhibits a great level of sequence divergence across species. Furthermore,
several ε subunit splice variants have been found (see also Section 3.1.2, Chapter 3; Whi-
ting et al., 1997). Northern blot analysis revealed an incomplete ε subunit splice variant of
5.5 kilobases (kb) in several peripheral tissues, such as placenta and pancreas, and a correctly
spliced messenger RNA (mRNA) of 3.5 kb in several brain areas, and, to a lesser extent, in
the heart. Davies et al. (2002) showed that only the 3.5 kb version of the ε subunit mRNA
results in a full length protein. Exclusively in rodents, a splice variant containing a large
Pro/Glx domain that consists of 483 amino acid residues (mostly proline/glutamic acid and
proline/glutamine tandem repeats) has also been recognised as well as a splice variant la-
cking this insertion (Moragues et al., 2000; Sinkkonen et al., 2000). Even without this large
insertion at the amino-terminus, the amino acid sequence homology between the human and
rodent ε subunits is only 68 %, whereas it is between 88 % and 99 % for other orthologous
GABAA receptor subunits from different species.
In recombinant expression systems, the ε subunit forms functional receptor channels when
co-expressed with α and β subunits (Davies et al., 1997; Whiting et al., 1997). It may, the-
refore, substitute for the γ or δ subunit in native receptors. However, two recent studies
have examined alternative stoichiometry in ε-subunit-containing receptors (Jones & Hender-
son, 2007; Bollan et al., 2008). Most studies expressing recombinant ε-containing GABAA
receptors used subunit ratios of 1:1:1 for α, β and ε subunits. Jones & Henderson (2007)
investigated the influence of a range of transfection ratios of ε versus α and β subunits and
discovered that spontaneous current density, receptor deactivation time and a shift in rectifi-
cation from outward to inward changed with increased ε subunit expression. It was suggested
15
Chapter 1. General Introduction
that, unlike in recombinant αβγ receptors, which exhibit a fixed stoichiometry of two α, two
β and one γ subunit (Baumann et al., 2002), receptor stoichiometry may vary, depending on
the amount of ε subunit expression. It was proposed that higher ε subunit abundance may
create receptors containing two ε subunits, where one subunit substitutes for the γ subunit
and the second for a β subunit (Figure 1.4 C).
A different attempt to solve ε-containing receptor stoichiometry was approached by Bollan
et al. (2008), who used concatenated subunits. These subunit constructs, consisting of two
or three different subunits, enable investigation of receptor stoichiometry and characteristics
of receptors with different subunit isoforms in specific locations (Minier & Sigel, 2004).
Bollan et al. (2008) proposed, upon functional expression of different concatenated subunits
in Xenopus laevis oocytes, that the ε subunit can assemble at different positions in receptor
pentamers. However, most likely it is located at position four in α1β2ε receptors (α1-β2-
α1-ε-β2), substituting for the β2 subunit, or at position one in α1β2γ2ε receptors (ε-β2-α1-
β2-γ2), substituting for the α1 subunit (Figure 1.4 A, B).
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Figure 1.4: Schematic representation of possible subunit arrangement in ε-containing
GABAA receptors. Subunit positions in (A) α1β2ε receptors, (B) α1β2γ2ε receptors (both
suggested by Bollan et al., 2008) and (C) α1β2ε receptors (proposed by Jones & Henderson,
2007). Yellow circles represent the agonist GABA.
As mentioned above, subunit position in the receptor pentamer contributes to different re-
ceptor properties, for example agonist binding. The proposed ε subunit positions in αβε
or αβγε receptors as well as in receptors containing two ε subunits would all result in re-
ceptors with no benzodiazepine binding site and only one GABA binding site (Figure 1.4).
The latter could explain the low Hill coefficient seen in ε-containing receptors exposed to
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GABA (Whiting et al., 1997; Neelands et al., 1999; Jones et al., 2006). However, the subunit
combination and stoichiometry of ε-containing GABAA receptors in vivo is still unknown.
The ε subunit has often been described as γ-like, due to its highest sequence similarity with γ
subunits and the fact that it forms functional channels with α and β subunits in recombinant
expression systems (Whiting et al., 1997; Bollan et al., 2008). Jones & Henderson (2007)
demonstrated that the ε subunit exhibits β-subunit-like characteristics too, in particular β3-
subunit-like. A series of experiments showed that the ε subunit is able to access the cell
surface on its own as well as in conjunction with the α1 subunit, but not together with the
β2 or γ2 subunit. This is also the case for β subunits. Moreover, the ε subunit possesses
similar assembly domains as the β3 subunit (Jones & Henderson, 2007). This could enable
the ε subunit to also assemble at a different position in the receptor complex and to replace
a β subunit. However, unlike the β3 subunit, the ε subunit expressed alone or together with
the α1 subunit was unable to form functional, GABA-sensitive channels at the cell surface
(Jones & Henderson, 2007; Bollan et al., 2008).
ε-containing GABAA receptors possess unique pharmacological properties, for instance in-
sensitivity to benzodiazepines (mentioned above; Davies et al., 1997; Whiting et al., 1997).
This is not surprising, because benzodiazepine binding requires amino acid residues from
α and γ subunits (Section 1.2.4). Several studies have been conducted to acquire the phar-
macological profile of ε-containing GABAA receptors (Davies et al., 1997; Whiting et al.,
1997; Thompson et al., 1998; Neelands et al., 1999; Maksay et al., 2003; Ranna et al., 2006).
Results obtained examining the effect of general anaesthetic agents, such as propofol, pen-
tobarbital or etomidate on ε-containing receptors were conflicting. Investigations in na-
tive neurons expressing ε subunits have shown reduced sensitivity to anaesthetics (Irnaten
et al., 2002; Sergeeva et al., 2005). Davies et al. (1997, 2001) also reported that ε-subunit-
containing receptors are insensitive to pentobarbital and propofol in heterologous expression
systems. In contrast, several other studies showed that general anaesthetics potentiate the
effect of submaximal GABA concentrations (Whiting et al., 1997; Thompson et al., 1998;
Neelands et al., 1999). Since the level of enhancement was similar in αβε and αβγ receptors,
but lower compared to αβ receptors, it was suggested that the inclusion of a third subunit
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into the receptor complex lowers the potency of anaesthetic agents, such as pentobarbital.
Thompson et al. (2002) investigated the discrepancies in sensitivity to general anaesthetics
between the different in vitro studies described above. It was concluded that they were cau-
sed by the use of different expression vectors, which resulted in an overexpression of the ε
subunit versus α and β subunits in the studies by Davies et al. (1997, 2001). Thompson et al.
(2002) presumed that receptor stoichiometry varied in the different studies, which was corro-
borated by a study mentioned earlier by Jones & Henderson (2007). Nevertheless, all studies
demonstrated direct receptor activation after applying high concentrations of the anaesthetic
agents.
Recombinant ε-containing receptors are highly sensitive to GABA, but they also exhibit
agonist-independent channel activity (Neelands et al., 1999; Davies et al., 2001; Maksay
et al., 2003; Wagner et al., 2005). Spontaneous currents have also been seen in homomeric
β1 receptors or heteromeric receptors containing the β1 and α2 or γ2 subunits, but not in
receptors containing all three subunits (Miko et al., 2004). Thus, αβε receptors are the first
receptors comprising of three different subunits that exhibit constitutive receptor activity in
vitro. Davies et al. (2001) reported that receptors containing α, β, ε and γ subunits also exhi-
bited spontaneous receptor activity. A possible reason for this may be that the open state of
ε-containing receptors is energetically more favourable than the closed receptor form (Nee-
lands et al., 1999; Maksay et al., 2003). Whether or not ε-containing receptors in vivo exhibit
spontaneous activity remains unclear. In vitro studies by Belujon et al. (2009), Irnaten et al.
(2002) and Sergeeva et al. (2005) in LC neurons, native parasympathetic cardiac neurons and
hypothalamic neurons, respectively, could not detect significant spontaneous receptor acti-
vity, whereas Jones et al. (2006) described the occurrence of constitutive receptor activity in
cultured ganodotrophin-releasing hormone neurons, which was comparable to that described
in human embryonic kidney (HEK) 293 cells expressing α2β3ε receptors.
From numerous studies investigating the pharmacological profile of ε-subunit-containing
receptors, it can be summarised that the receptors exhibit different pharmacological charac-
teristics compared to receptors expressing α and β subunits only or αβγ receptors (Davies
et al., 1997; Whiting et al., 1997; Thompson et al., 1998; Neelands et al., 1999; Maksay et al.,
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2003; Ranna et al., 2006). However, to this date no ε-subunit-specific pharmacology could
be identified. Moreover, it is not known whether ε-subunit-containing receptors are located
at the synapse or extrasynaptic and subunit composition in ε-containing receptors in vivo as
well as the function of the ε subunit remain still elusive.
1.3 Investigating ion channel properties
Ion channels are involved in a wide range of different diseases, for example epilepsy. Over
recent years, pharmaceutical industries developed an enhanced interest in ion channel drug
targets, due to an increased availability of chemical compounds and the advancement in the
field of genomic research, providing a large amount of previously unknown drug targets.
Among the 100 top selling drugs worldwide are, at present, 15 % ion channel modulators
generating more than six billion dollars yearly (Gill et al., 2003). As mentioned above,
GABAA receptors exhibit a wide range of structural diversity and possess a number of dif-
ferent modulatory binding sites that are targeted by a plethora of different drugs. In order to
lessen the appearence of adverse side effects commonly implicated with current drugs on the
market, new subtype-selective drugs are needed. Many methods are available to study ion
channel/GABAA receptor properties, including expression studies, assays to gain structural
or pharmacological insights, gene targeting, for instance knockout mice, as well as electro-
physiological studies to directly assess ionic current flow (for a review see Smith & Simpson,
2003).
Although it is technically challenging to screen chloride channels for modulatory com-
pounds, over recent years, a number of assay formats have been developed to screen for
compounds that target ion channels/GABAA receptors. Important assay characteristics are
sensitivity, specificity, throughput and information content, among others (Xu et al., 2001).
Many of these thwart each other, as pictured in Figure 1.5. For instance, highly informa-
tive assays, such as electrophysiological methods, usually have a low throughput, whereas
high throughput techniques, for example fluorescence-based techniques, lack informational
content. Thus, it is important to select the right assay type for a specific project.
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Figure 1.5: Interrelations between different attributes of ion channel assays. Solid lines mark
antagonising features; dashed lines display other relationships between them (from Xu et al.,
2001).
There are biochemical as well as cell-based assays to examine ion channel properties or
screen for compounds. However, the latter are often the preferred method since they provide
a physiologically relevant environment (An & Tolliday, 2009). Several possibilities exist to
express functional channels for ion channel screening, such as primary cell culture or engi-
neered cell lines. Relevant and frequently applied biological systems for GABAA receptor
expression are, for example, mammalian cells or Xenopus laevis oocytes (Sections 1.3.1 and
1.3.2). As mentioned before, the choice of a suitable assay approach is a further important
factor when investigating ion channels. Electrophysiological methods, like the two-electrode
voltage-clamp and the patch-clamp technique (Section 1.3.3), measure ionic conductance ac-
cross the cell membrane and provide high quality and informational content when assessing
ion channel function and drug-channel interactions (Xu et al., 2001). However, only a limited
number of cells can be examined per experiment, because the method is technically challen-
ging and labour intensive yielding only 10-20 data points per day. It is, therefore, used in
basic research as well as for secondary or safety screenings applying a smaller number of
compounds (Gonzalez & Maher, 2002). However, since the method provides high quality
data, systems for automated electrophysiological recordings have been developed to improve
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throughput. Nevertheless, further miniaturisation and, thus, improving throughput remains
difficult, due to the complexity of the assay setup (Xu et al., 2001). Miniaturisation plays an
important role in high throughput screening (HTS), since a smaller assay scale requires less
reagents, hence, reducing the overall costs. Automated recording methods are implicated
with high costs that limit their use in HTS.
Several alternative assay technologies with high throughput have been developed to identify
ion channel modulators from large chemical compound libraries. In most cases, ion flux
assays or fluorescence-based methods, such as chloride-sensitive indicator dyes, membrane
potential fluorescence probes or the use of halide-sensing mutant green fluorescent proteins
(GFP), are applied in preliminary, large-scale screening assays (Xu et al., 2001). Both can
be set up in microtiter plate format with the possibility of measuring multiple samples at the
same time (see Sections 1.3.4 and 1.3.5 and Sections 4.1.2 and 4.1.3, Chapter 4).
Many factors influence the choice of the assay system to investigate ion channel function and
to screen for compounds that modulate them, which include the level of sensitivity required,
assay resolution, safety issues, costs, the ability to handle low volumes and the availability
of a suitable measuring device.
1.3.1 Mammalian expression systems
Heterologous expression systems, such as mammalian cell lines or Xenopus laevis oocytes
(Section 1.3.2) are commonly used to investigate structure-function relationships of recom-
binant proteins (Sigel & Minier, 2005). Studying a protein in a foreign host cell rather than
in its genuine environment is advantageous because of the relative ’pure’ environment and
the possibility of choosing the cell type for expression according to the type of experiment
planned as well as practical and cost reasons.
Mammalian cell lines are a popular expression system for recombinant proteins. Plasmid
vectors carrying genetic information of the gene of interest can be introduced stably or tran-
siently into the cells which in turn translate, modify and express the desired protein (Witchel
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et al., 2002). Producing stably transfected cell lines requires great initial effort and time. Ho-
wever, once produced they are easier and more convenient to use than transiently transfected
cells. Advantages of a stable cell line are the homogeneous cell population as well as the
fact that errors in protein assembly are reduced. However, if several different proteins are
being investigated, it would be necessary to prepare stable cell lines for each protein of inter-
est. In this case, it is often more practical to transiently transfect the different proteins into
the cell line of choice. Mammalian expression systems benefit from the fact that numerous
cells can be transfected at the same time. Also advantageous is that mammalian cell lines
may resemble the physiological system in humans more than alternative expression systems
and experiments can be carried out at physiological temperature (37°C; Witchel et al., 2002;
Hogg et al., 2008). However, experiments using transiently transfected cells often suffer
from a change in receptor expression over time as well as relatively low transfection effi-
ciencies. For certain applications, such as electrophysiological measurements, this problem
can be overcome by using a detection system for successfully transfected cells. For instance,
a plasmid that expresses GFP can be simultaneously transfected with the protein of interest,
highlighting transfected cells.
The HEK293 cell line is a frequently used expression system for recombinant proteins, such
as ligand-gated ion channels (Thomas & Smart, 2005). HEK293 cells exhibit similarities
with early differentiating neurons by expressing many mRNAs which are present in neurons,
such as neurofilament proteins. The cells also contain several signalling pathways found in
native neurons. Therefore, the expression of foreign neuronal proteins in HEK293 cells re-
sembles expression in their native cell environment (Thomas & Smart, 2005). Furthermore,
HEK293 cells are relatively easy and cheap to maintain, they are robust, have a quick cell di-
vision rate (between 24 to 36 hours) and a good size for electrophysiological measurements.
Several different transfection techniques have been applied successfully, resulting in suffi-
cient protein expression for many different applications, ranging from electrophysiological
recordings to biochemical assays. HEK293 cells express a number of endogenous receptors
(for details see Thomas & Smart, 2005), and experiments should be carefully monitored for
interference of these proteins using adequate controls. Nevertheless, the expression levels
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of recombinant proteins are usually high enough that endogenous proteins are outnumbered
and the risk of interference is minimal.
1.3.2 Xenopus laevis oocytes
The oocytes of the South African clawed frog Xenopus laevis have been commonly used as
a heterologous expression system for over 30 years (Sigel & Minier, 2005), for example for
comparing the functions of wild-type and mutated ion channels or to investigate drug actions
on expressed proteins. Oocytes undergo six developmental stages (I-VI), which take place
asynchronous, i.e. the ovary contains oocytes of all stages (Dumont, 1972). Most electro-
physiological studies are performed using oocytes from stages V and VI. Characteristic for
Xenopus oocytes is the ’two-toned colour scheme’: the animal pole containing the nucleus
is dark brown whereas the vegetal pole exhibits a yellowish colouration (Figure 1.6).
Figure 1.6: Xenopus laevis oocytes (from Sigel & Minier, 2005).
Oocytes are able to express foreign genetic material precisely and at high levels (Sigel, 1990;
Sigel & Minier, 2005). Complementary DNA (cDNA) can be microinjected into the nucleus
of an oocyte or, alternatively, RNA can be introduced into the cytoplasm (Figure 1.7). After-
wards, the nucleic acid is efficiently transcribed (in the case of cDNA injection) and transla-
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Figure 1.7: Schematic representation of the functional expression of genetic information in
Xenopus oocytes (after Sigel, 1990).
ted by the oocyte. The resulting protein is then assembled, post-translationally modified and
finally targeted to the surface membrane or an appropriate subcellular compartment.
Proteins are usually expressed within 24 hours after RNA or cDNA microinjection and oo-
cytes can then be used for up to 14 days (Wagner et al., 2000; Sigel & Minier, 2005). RNA
injection usually results in protein expression in > 98 % of the injected cells, whereas mi-
croinjection of cDNA is often successful in only a small percentage of the injected oocytes
(Sigel & Minier, 2005). There are several advantages of using oocytes over mammalian cells.
Oocytes are available at low cost and easy to handle in the laboratory due to their large size
(1-1.2 mm in diameter) and robustness (Wagner et al., 2000; Sigel & Minier, 2005). Further-
more, the number of endogenously expressed (surface) proteins is relatively low (Dascal,
1987). The quantity of electrophysiological data which can be obtained from a single oocyte
is relatively high; the robust setup permits recording for more than an hour (Witchel et al.,
2002). However, there are a number of limitations to the use of oocytes: (1) each oocyte
needs to be injected separately, (2) oocytes are less suitable for studying very fast cellular
events, due to their large size and associated slow fluid exchange rate and slow changes in
membrane potential, (3) the intracellular ionic composition cannot be influenced, (4) com-
pounds can be absorbed by the egg yolk, which may result in lower sensitivity, (5) oocytes
show seasonal differences in expression and quality and (6) frogs are poikilothermic ani-
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mals. For that reason, experiments need to be carried out at room temperature rather than
at physiological temperature of 37°C (Wagner et al., 2000; Xu et al., 2001; Sigel & Minier,
2005; Hogg et al., 2008). This may hamper certain applications, for instance kinetic studies.
Moreover, findings should be evaluated carefully, since there may be variations between the
expression in oocytes and the native tissue, as a result of different signalling pathways.
1.3.3 Electrophysiological techniques
Electrophysiological techniques measure differences in current carried by ions accross a cell
membrane of a whole cell or a membrane patch (Xu et al., 2001). The two-electrode voltage-
clamp technique is often used to study ion channel properties in large cells, such as Xenopus
laevis oocytes. The technique measures whole-cell currents by impaling two glass microelec-
trodes into an oocyte; one electrode acts as a current-delivering electrode (i), which clamps
the membrane potential to a desired voltage, and the other measures the membrane poten-
tial (V; see Figure 1.8). The measured membrane potential is compared with the command
voltage (delivered by the current delivering electrode) and the difference is set to zero by the
amplifier. Thus, it is possible to measure ionic current flow across the membrane (deviation
from the baseline current) mediated by either ion channels or transporters (see also Section
1.3.2; Baumgartner et al., 1999; Wagner et al., 2000).
The patch-clamp method is the ’gold standard’ for measuring ion channel functions, pro-
viding high quality and physiologically relevant data. It is a highly flexible technique with
different configurations, such as whole-cell recording, inside-out and outside-out patches
(Hamill et al., 1981). The first configuration allows the recording of ionic currents from
ion channels expressed in the whole cell membrane (Figure 1.9), whereas the latter two are
single channel configurations. They enable the study of individual ion channels in isolation
in a small membrane patch to obtain, for example, data on channel gating and kinetics. The
main difference to the two-electrode voltage-clamp technique is that a single micropipette
is pressed against the membrane of a cell forming an electrical "giga-seal" (high resistance
seal in the gigaohm range) between the membrane and the micropipette. Giga-seals enable
most of the ionic currents to go into the pipette, reducing the ’leak current’; they are me-
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Figure 1.8: Schematic representation of the two-electrode voltage-clamp technique.
The membrane potential is measured by an electrode (V) that is linked to a voltage follower (triangle)
and it is then compared with the command voltage (E; given by a generator) via the feedback amplifier
(FBA). The amplified difference between the signals is delivered as a current through the current-
delivering electrode (i), which clamps the membrane potential to a desired voltage and further over
the cell membrane to the grounding electrode in the bath. Changes in the ion flux across the membrane
can then be monitored as variation from the baseline current (adapted from Wagner et al., 2000).
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chanically stable and offer a low background noise (Hamill et al., 1981). The advantages
of this technique are that the intracellular environment can be controlled, due to the mixing
of pipette solution and cytosol (whole-cell recording), it can be performed at physiological
temperatures and fast cellular events can be studied, due to a rapid solution exchange rate
and a high temporal resolution.
Cell
Patch pipette
Pipette 
solution
Figure 1.9: Schematic representation of the patch-clamp whole-cell configuration.
This method enables the recording of ionic currents from ion channels expressed in the whole mem-
brane of the cell. To acquire the whole-cell configuration, a glass microelectrode is lowered onto
the cell surface (cell-attached mode), slight suction is then applied to obtain a high-resistance seal
between cell membrane and glass pipette. Subsequently, the membrane is ruptured and the amplifier
can control and measure voltage accross the entire cell membrane (adapted from Wood et al., 2004).
1.3.4 Flux assays
Commonly used ion flux assays apply radioactive tracer ions, such as 36Cl- or 125I- which can
be used to measure ion influx or efflux through ion channels, thereby measuring ion channel
activity directly (Smith & Simpson, 2003; Terstappen, 2005; Verkman & Galietta, 2009).
The throughput of these assays is considerably higher than with electrophysiological recor-
dings, since assays are usually performed in 96- or 384-well plates, however, it is lower com-
pared to fluorescence-based methods. Radioactive flux assays are easy to perform, reliable
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and robust and exhibit high sensitivity. Nevertheless, slow temporal resolution, reduced re-
producibility, difficulties of further assay miniaturisation and low informational content as
well as high costs and safety issues are major drawbacks (Gill et al., 2003). Tang & Wil-
dey (2004) recently presented a non-radioactive flux assay using iodide as an indicator of
chloride channel activity (Section 4.1.2, Chapter 4). The advantages of this assay setup are
lower costs and increased safety. However, sample mixtures and buffers of the assay are re-
latively unstable and fast reading is required, which may limit its use in HTS. Furthermore,
flux assays suffer from long incubation times needed to load the cells with tracer molecules
and require high levels of ion channel expression to lower the signal-to-noise ratio (Xu et al.,
2001).
1.3.5 Fluorescence-based assays
Fluorescence-based methods are ideally suited for assay miniaturisation, because they are
volume-independent. There are several different fluorescence-based methods to screen for
ion channel modulators, for instance chloride indicator dyes or membrane potential-sensing
dyes (Gill et al., 2003; Molokanova & Savchenko, 2008; Verkman & Galietta, 2009). Assays
applying membrane permeable, quinoline-derived chloride indicator dyes, such as MQAE,
are easy to set up and exhibit relatively high chloride sensitivity (Marandi et al., 2002).
However, they suffer from high background noise, leakage from the cells and the low half-
life of the fluorescence dye (Gill et al., 2003; Verkman & Galietta, 2009). Another method
is to measure changes in intracellular pH, using proton-sensitive dyes and a fluorometric
imaging plate reader (FLIPR; Gill et al., 2003; Verkman & Galietta, 2009). Voltage-sensing
Förster (or Fluorescence) Resonance Energy Transfer (FRET)-based, ratiometric dyes are
also commonly used for ion channel screening. FRET is the transfer of energy from an
excited fluorophore (donor) to another fluorescent molecule (acceptor), which is dependent
on the distance between them (Piston & Kremers, 2007). These dyes are lipophilic molecules
and can be easily introduced into the cell membrane. Changes in membrane potential can
then be measured with fast resolution using a voltage/ion probe reader; it is also possible to
quantify membrane potential changes. A wide range of different dyes is available to measure
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changes in membrane potential. They differ in chloride sensitivity, response kinetics and
sensing mechanisms (Verkman & Galietta, 2009). The main drawback of these dyes is that
the membrane potential can be influenced by many different factors, such as cytoplasmic
composition or activity of other ion channels or transporters in the membrane rather than
only the channel of interest. The latter leads to a high rate of false positive readings which is
further increased by test compounds exhibiting autofluorescence. Furthermore, such systems
are more suitable for stably transfected cell lines, since the dye molecules are present in every
cell’s membrane. False negative results can also be obtained due to the high background
noise masking weaker signals.
There are also assay technologies using halide-sensing mutant GFPs, such as Clomeleon.
Clomeleon is a ratiometric, FRET-based and genetically-encoded chloride-ion indicator pro-
tein. It was developed by Kuner & Augustine (2000) and consists of a chloride-sensitive
yellow fluorescence protein (YFP) linked to a chloride-insensitive cyan fluorescence protein
(CFP) and can be targeted to specific cellular compartments (see Section 4.1.1, Chapter 4).
Compared to chloride-sensitive indicator dyes, such as MQAE, Clomeleon exhibits slower
kinetics and its chloride sensitivity is relatively low. YFP mutants with higher chloride sen-
sitivity have, therefore, been developed, such as YFP-H148Q/I152L (Section 4.1.3, Chapter
4; Galietta et al., 2001a; Verkman & Galietta, 2009). Although fluorescence membrane
potential-sensing dyes and YFP mutant proteins both have similar signal-to-noise ratios and
dynamic ranges, there are several advantages of YFP-based assays: they are faster, less ex-
pensive, YFP is genetically encoded and cannot leak out of the cells and the assay does
not require ion channel expression in a stable cell line, but can also be used in transiently
transfected cells, which is advantageous when investigating several of the various GABAA
receptor subtypes (Kruger et al., 2005).
1.4 Aims and objectives of the study
As mentioned in Section 1.2.5.1, expression of the GABAA receptor ε subunit is relatively
restricted in the mammalian brain; it is mainly expressed in the forebrain as well as in all
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major neuronal groups, including cholinergic cells (Moragues et al., 2000, 2002). 84-95 % of
cholinergic neurons also express the α3 subunit (Gao et al., 1995). Due to the co-expression
of α3 and ε subunits in cholinergic neurons, it was hypothesised that the subunits form
functional channels in these neurons, which may regulate ACh release (McGehee & Role,
1996; Cervetto & Taccola, 2008). The α3- and ε-subunit-containing receptor subtype is,
therefore, a potential target for the development of anti-AD drugs that would function by
increasing ACh release in forebrain regions where cholinergic neurons are dying.
The initial aim of this project was to functionally express and pharmacologically characterise
the GABAA receptor subtype that contains the α3 and ε subunits applying an electrophysiolo-
gical approach. It was shown in several studies, that the β subunit has no significant effect on
the benzodiazepine modulation of the GABAA receptor (Pritchett et al., 1989b; Hadingham
et al., 1993). Therefore, the α3 and ε subunits were co-expressed with the rat β2 subunit, a
subunit combination that has not been pharmacologically characterised before. However, it
is likely that receptor subtypes of this combination exist in the brain, since the β2 subunit
is the most widely expressed β subunit in the brain. At first, it was planned to establish the
patch-clamp method at Nottingham Trent University using HEK293 cells transiently trans-
fected with rat cDNAs encoding the respective GABAA receptor subunits. This would have
also provided information about correct assembly of the subunits in HEK293 cells, impor-
tant for the subsequent cell-based screening assay setup (see below). However, problems
with the setup of the electrophysiological rig at Nottingham Trent University caused a slight
change in the project and electrophysiological recordings were performed in Xenopus laevis
oocytes microinjected with complementary RNA (cRNA) in the laboratory of Dr Ian Mellor
at the University of Nottingham instead.
After the pharmacological characterisation of the α3β2ε receptor, the aim was to establish
a cell-based screening system using HEK293 cells and search for compounds that modulate
the activity of this GABAA receptor subtype. It is generally accepted that modulation of the
agonist binding site of ligand-gated ion channels is not a productive avenue for drug disco-
very. Therefore, as part of the project, search was narrowed down to compounds that bind
elsewhere on this multi-subunit receptor complex. Whiting (1999) suggested the existence
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of a new modulatory site on ε-containing receptors, since steroids, barbiturates and anaes-
thetics have no significant influence on these receptors. Since GABAA receptor subunits
exhibit strong sequence similarity to one another (Section 1.2.2), it was hoped to identify
a site between the α3 and ε subunits that is analogous to the benzodiazepine binding site
that is found at the interface between α and γ subunits. For this purpose, a search for lead
compounds from a chemical compound library that, in the presence of GABA, modulate
receptor activity was conducted. Such compounds could not only serve as potential future
drugs on ε-containing receptor subtypes, but may also help providing important information
to uncover the role of the ε subunit in future studies.
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Materials and Methods
2.1 General molecular biology techniques
2.1.1 Preparation of competent Escherichia coli (E. coli) cells
100 µl already competent E. coli XL1 blue cells were added to 5 ml lysogeny broth (LB) me-
dium (10 g/l peptone from casein, 5 g/l yeast extract, 10 g/l sodium chloride, Miller), supple-
mented with tetracycline (25 µg/ml) and incubated overnight in an orbital shaking incubator
(S150, Stuart) at 37°C and 200 rpm. On the next day, 2 ml of the overnight culture was ad-
ded to 100 ml LB medium supplemented with tetracycline (25 µg/ml) and incubated further
at 37°C and 200 rpm for several hours, measuring the optical density (OD) of the culture
at regular intervals at a wavelength of 660 nm until an OD660 of 0.4 to 0.5 was reached.
The inoculated LB medium was then split and transferred to two 50 ml tubes (Sartstedt) and
centrifuged 3,000 rpm for 15 minutes (Beckman Coulter) at room temperature (18-25°C).
Supernatants were discarded subsequently and the bacterial cell pellets resuspended in 20 ml
cold, sterile-filtered TFB1 buffer (30 mM KAc, 50 mM MnCl2, 100 mM KCl, 10 mM CaCl2
and 15 % (v/v) glycerol; pH 5.8) each by briefly vortexing the tubes. Next, the bacteria were
incubated on ice for 30 minutes, followed by centrifugation at 1,750 rpm for 20 minutes at
4°C. Supernatants were discarded and bacterial cell pellets carefully resuspended in 2 ml
ice-cold TFB2 buffer (10 mM MOPS buffer, 76 mM CaCl2, 10 mM KCl and 15 % (v/v)
glycerol). Finally, the competent E. coli Xl1 blue cells were aliquotted into microfuge tubes
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and stored at -80°C until usage.
2.1.2 Transformation of plasmid DNA into competent E. coli cells
1 to 5 µg plasmid DNA was added to 50 µl competent E. coli Xl1 blue cells and incubated
on ice for 30 minutes. The cells were then heat-shocked by incubating them at 42°C for
50 seconds and subsequently cooled on ice for another two minutes. 100 µl SOC medium
(20 g/l 2 % (w/v) Bacto tryptone, 0.5 % (w/v) Bacto yeast extract, 10 mM NaCl, 10 mM KCl,
20 mM MgCl2, 20 mM glucose) was added followed by incubation at 37°C, 200 rpm for 45
minutes. Transformed bacteria were cultured on LB agar plates (10 g/l peptone from casein,
5 g/l yeast extract, 10 g/l NaCl, 12 g/l agar-agar, Miller) containing 0.1 % (w/v) ampicillin
overnight at 37°C.
2.1.3 Plasmid preparation
2.1.3.1 Minipreparation
Plasmid DNA transformed into E. coli cells was isolated by selecting single colonies from
a LB agar plate using a sterile pipette tip. 2 ml LB medium supplemented with 0.1 % (w/v)
ampicillin were inoculated with a single bacterial colony and incubated overnight at 37°C,
200 rpm. On the following day, the plasmid DNA was purified from the overnight cultures
using a GenEluteTM Plasmid Miniprep Kit (Sigma) or QIAprep Spin Miniprep Kit (Qiagen)
following the manufacturer’s protocols. Isolated plasmid DNA was finally eluted in 50 µl
0.1 % (v/v) diethylpyrocarbonate (DEPC)-treated water and stored at -20°C.
2.1.3.2 Maxipreparation
In order to generate multiple copies of plasmid DNA, single bacterial colonies containing
the desired plasmid were transferred into 5 ml LB medium supplemented with 0.1 % (w/v)
ampicillin and incubated for 8 hours at 37°C, 200 rpm. Next, 2 to 3 ml of the bacterial culture
was transferred to 100 ml LB medium (containing 0.1 % (w/v) ampicillin) and incubated
overnight at 37°C, 200 rpm. On the following day the plasmid DNA was isolated using a
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Plasmid Maxi Kit (Qiagen) following the manufacturer’s instructions. The purified DNA
was resuspended in 200 µl 0.1 % (v/v) DEPC-treated water and stored at -20°C for further
use.
2.1.4 Restriction endonuclease digestion
Purified plasmid DNAs and polymerase chain reaction (PCR) products were digested using
one or two (depending on further applications) restriction enzymes (Promega). First, enough
0.1 % (v/v) DEPC-treated water was added into 0.5 ml microcentrifuge tubes to make up a
final volume of 10 or 20 µl. Reactions were then further assembled by adding the respective
10 x buffer, 0.2 to 1.5 µg DNA and respective restriction endonuclease, using a tenfold ex-
cess of enzyme over DNA (see Section 2.2.3 for details). After incubating the mixtures for
1 to 2 hours at 37°C, the digested as well as corresponding undigested plasmid DNAs were
analysed by gel electrophoresis on a 1 % (w/v) agarose gel, containing ethidium bromide
(10 mg/ml), in 1× tris-acetate (TAE)-buffer (40 mM Trizma Base, 1.14 % (v/v) Glacial ace-
tic acid, 1 mM disodium EDTA (pH 8)) and visualised by UV trans illumination (InGenius
or G:Box, Syngene).
2.1.5 Measuring nucleic acid concentrations
Nucleic acids were diluted and concentrations were measured using a UV spectrophotometer
(DU530 or DU800, Beckman). Based on the absorbance (A) at 260 nm the concentrations
were calculated as shown below:
concentration [ng/µl] = A260 × dilution factor× conversion factor (2.1)
The conversion factors for nucleic acids are as follows (Maniatis et al., 1982):
Double-stranded DNA : 50 ng/µl
Single-stranded DNA & RNA : 40 ng/µl
Single-stranded oligonucleotides : 20 ng/µl
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2.1.6 Ethanol precipitation
Nucleic acids were precipitated using 2.5 × volume 100 % (v/v) ethanol and 1/10 volume
3 M NaAc (pH 5.2), incubated at -20°C for at least 30 minutes and subsequently centrifuged
at 13,000 rpm, 4°C for 30 minutes. Supernatants were discarded and pellets were washed
with 75 % (v/v) ethanol and centrifuged again at 13,000 rpm, 4°C for five minutes. Nucleic
acid pellets were briefly air-dried before resuspension in DEPC-treated water.
2.1.7 Sequencing
15-20 µl DNA at a concentration of 60-100 ng/µl were added into a 1.5 ml microfuge tube.
Tubes containing DNA samples were sent to Eurofins MWG Operon (London) for sequen-
cing. Sequencing results were aligned and compared with corresponding GABAA receptor
subunit or other respective sequences in the nucleotide sequence database using a basic lo-
cal alignment search tool (BLAST; URL: http://www.ncbi.nlm.nih.gov/BLAST/) and a se-
quence alignment tool (ClustalW; URL: http://www.justbio.com/aligner/index.php), respec-
tively, to confirm their identity.
2.1.8 Side-directed mutagenesis - Generating a truncated ε subunit
2.1.8.1 Primer design
A truncated ε (εT) subunit version, lacking 26 amino acids ranging from within TM2 until
TM3 compared to the full length ε subunit version (Figure 3.1, Chapter 3), was construc-
ted using overlap PCR and cDNA encoding the rat ε subunit (in pcDNA3 vector). Two
sets of sequence specific primers were designed according to the ε subunit cDNA sequence
(Table 2.1).
Table 2.1: Oligonucleotide design to generate a GABAA receptor εT subunit
Oligonucleotide Sequence Tm
rGABRE-T_F1 5’-GCC AGT GTG CTG GAA TTC TG-3’ 56.6°C
rGABRE-T_R1 5’-AGA AGT CCA AAG CTA CAG AGG CCC T-3’ 61.6°C
rGABRE-T_F2 5’-AGG GCC TCT GTA GCT TTG GAC TTC T-3’ 61.6°C
rGABRE-T_R2 5’-CTA GAT GCA TGC TCG AGC GG-3’ 58.1°C
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Forward and reverse primers (rGABRE-T_F1 and rGABRE-T_R2), flanking the entire ε
subunit sequence, overlapped with the multiple cloning site of the ε-subunit-containing vec-
tor and contained an EcoRI or XhoI endonuclease restriction site (underlined), respectively.
The introduction of restriction sites facilitated the insertion of the εT subunit cDNA into the
pcDNA3.1+ vector after generating the correct sequence. The oligonucleotides positioned
within the ε subunit sequence, rGABRE-T_R1 and rGABRE-T_F2, were flanking both sites
of the mutation which was located in the middle of the primers. All four oligonucleotides had
closely matched melting temperatures (Tm) for optimal amplification which were calculated
using the following website: URL:http://eu.idtdna.com/analyzer/applications/oligoanalyzer/
default.aspx. Figure 2.1 illustrates the different amplification steps used in order to generate
the respective deletion.
ATG
deletion
EcoRI
5’ 3’
PCR 1
ε subunit sequence in pcDNA3
PCR 3
EcoRI XhoI
εT
rGABRE-T_F1
rGABRE-T_R1
rGABRE-T_F1 rGABRE-T_R2
Product 2
XhoI
PCR 2
rGABRE-T_R2
rGABRE-T_F2
Product 1
5’ 3’
3’5’
Figure 2.1: Side-directed mutagenesis using overlap PCR to create the εT subunit.
The forward primer rGABRE-T_F1 is located before the start codon of the ε subunit sequence and
contains an EcoRI restriction site. The reverse primer rGABRE-T_R1 is spanning the sequence im-
mediate before and after the 26 amino acid mutation, excluding the sequence which was deleted.
The second primer pair consists of the reverse complement of rGABRE-T_R1 (rGABRE-T_F2) and
rGABRE-T_R2. The latter is located after the stop codon of the ε subunit sequence extending into the
multiple cloning site of the vector and including a XhoI restriction site. PCR products 1 and 2 were
used as templates in PCR 3, using oligonucleotides rGABRE-T_F1 and rGABRE-T_R2. rGABRE-
T_R1 and rGABRE-T_F2 which are comprised in PCR products 1 and 2 anneal together resulting in
the amplification of the whole length εT subunit sequence.
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2.1.8.2 Polymerase chain reaction
All PCRs were performed using Pfu DNA polymerase (Promega) or PhusionTM high fidelity
DNA polymerase (Finnzymes). Both enzymes exhibit proofreading activity to minimise er-
rors due to incorporation of wrong bases by the enzyme. PCR 1 and 2 (see Figure 2.1) were
assembled in sterile 0.5 ml PCR tubes as follows:
Pfu DNA polymerase 10 × buffer (200 mM Tris-HCl (pH 8.8 at 25°C),
100 mM KCl, 100 mM (NH4)2SO4, 20 mM MgSO4, 1.0% Triton® X-
100 and 1 mg/ml nuclease-free BSA, Promega)
5 µl
dNTP mix (10 mM each, Sigma) 1 µl
Forward primer (200 ng/µl) 1 µl
Reverse primer (200 ng/µl) 1 µl
DNA template (1 pg/µl (PCR 1) or 5 pg/µl (PCR 2)) 1 µl
pfu DNA polymerase (2-3 U/µl, Promega) 1 µl
DEPC-treated water to a final volume of 50 µl
Negative controls contained water instead of the DNA template. PCRs were performed in a
thermal cycler (TC-512 or TC-3000, Techne) at the following conditions:
Initial Denaturation 94°C 5 min
32 cycles
Denaturation 94°C 1 min
Annealing 59°C 1 min
Extension 72°C 4.5 min
Final extension 72°C 10 min
PCR products were visualised on a 1% agarose gel (Section 2.1.4) and amplicons of the right
size, ~960 bp (PCR 1) and ~2100 bp (PCR 2), were excised from the gel with a clean scal-
pel and purified using a GFXTM PCR DNA and Gel Band Purification Kit (GE Healthcare)
according to the manufacturer’s instructions. Purified PCR products were ethanol precipita-
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ted (Section 2.1.6). The two PCR products then served as template DNA for a further PCR
(PCR 3) using the forward primer of the first (rGABRE-T_F1) and the reverse primer of the
second primer pair (rGABRE-T_R2) and PhusionTM high fidelity DNA polymerase (Finn-
zymes). The PCR was assembled as follows:
5 × Phusion® HF buffer (containing 7.5 mM MgCl2) 10 µl
10 mM dNTPs (200 µM each, Sigma) 1 µl
Forward primer (200 ng/µl) 1 µl
Reverse primer (200 ng/µl) 1 µl
purified PCR product 1 (1 in 10 dilution) 1 µl
purified PCR product 2 (undiluted) 0.5 µl
DMSO (100 %) 1 µl
Phusion® DNA Polymerase (2 U/µl) 0.5 µl
DEPC-treated water to a final volume of 50 µl
Negative controls contained water instead of purified PCR products. The PCR was carried
out in a Techne TC-3000 thermal cycler at the following conditions:
Initial Denaturation 98°C 30 sec
35 cycles
Denaturation 98°C 10 sec
Annealing 64°C 30 sec
Extension 72°C 1.5 min
Final extension 72°C 10 min
The resulting product was visualised on a 1% agarose gel. The amplicon of the right size
(~3000 bp) was excised from the gel, purified and ethanol precipitated (see above).
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2.1.8.3 Ligation of the εT subunit cDNA into the pcDNA3+ vector
The purified εT subunit cDNA (PCR product 3) was digested in a 0.5 ml microfuge tube as
follows:
Purified PCR product 3 14.5 µl
pcDNA3.1+ vector (20 ng/µl) 1.5 µl
10 × buffer H (0.9 M Tris-HCl, 100 mM MgCl2, 0.5 M NaCl, pH 7.5, Promega) 2 µl
EcoRI (12 U/µl, Promega) 1 µl
XhoI (10 U/µl, Promega) 1 µl
DEPC-treated water to a final volume of 20 µl
The sample was incubated for 2 hours at 37°C before it was again ethanol precipitated to
purify the DNA (Section 2.1.6). Afterwards, the digested PCR product was ligated into the
linearised pcDNA3.1+ vector in a final volume of 10 µl, by adding 1 µl T4 DNA ligase (1-
3 U/µl, Promega) and 1 µl 10× reaction buffer (300 mM Tris-HCl (pH 7.8 at 25°C), 100 mM
MgCl2, 100 mM DTT and 10 mM ATP, Promega) and incubating it at 4°C overnight. On
the following day, the ligated product (10 µl) was transformed into 50 µl competent E. coli
cells (Section 2.1.2). Bacterial colonies, containing plasmid DNA, were cultured overnight
and subsequently purified using GenEluteTM Plasmid Miniprep Kit (Section 2.1.3). 0.5 µl
of purified plasmid DNA was digested using EcoRI and XhoI in a final volume of 20 µl as
described above and subsequently visualised on a 1% agarose gel in order to display the
insertion of the εT subunit DNA into the vector. Samples, which contained an insert, were
sent for DNA sequencing (Section 2.1.7) to confirm their correct identity and orientation in
the pcDNA3.1+ vector.
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2.2 GABAA receptor subunits & fluorescence proteins
2.2.1 Recovery of vectors harbouring GABAA receptor subunits
Rat GABAA receptor α3, β2, γ2L and ε subunit cDNAs were kindly provided by Prof. Erwin
Sigel (Institute of Biochemistry and Molecular Medicine, University of Bern, Switzerland)
and Dr Maurice Garret (Laboratoire de Neurophysiologie, Bordeaux, France). The α3 subu-
nit cDNA was subcloned into the pcDNA3.1+ vector (Invitrogen), the β2 and γ2L subunit
cDNAs were in the pCMV vector and the ε subunit cDNA was present in the pcDNA3 vector
(Invitrogen; see Appendix A for vector maps). Plasmids that harboured the α3, β2 and γ2L
cDNAs were recovered from filter paper by cutting out the area on the paper, where the DNA
was placed, with sterile scissors and transferring the paper to sterile 1.5 ml microfuge tubes.
Next, 50 µl 10 mM Tris-HCl (pH 7.6) was added to the tubes; they were vortexed, incubated
at room temperature (18-25°C) for 5 minutes and briefly centrifuged for 30 seconds. The
supernatants containing the plasmid DNAs were transferred into fresh tubes and stored at
-20°C for further use. The ε-subunit-containing vector was obtained as aqueous stock solu-
tion (0.2 mg/ml) and stored at -20°C. The human GABAA receptor α1 subunit was present
in the pBS vector (Stratagene) and stored in ethanol at -20°C.
2.2.2 Recovery of pRK5-Clomeleon and pEYFP H148Q/I152L vectors
The pRK5-Clomeleon plasmid was generously provided by Dr Thomas Kuner (Institute of
Anatomy and Cell Biology, Heidelberg University, Germany) and recovered from filter paper
as described above (Section 2.2.1), but instead of Tris-HCl, 50 µl 0.1 % (v/v) DEPC-treated
water was added to the filter paper in the microfuge tube. This was vortexed, incubated
at room temperature (18-25°C) for 5 minutes and briefly centrifuged for 30 seconds. The
supernatant, containing the plasmid DNA, was transferred to a fresh tube and stored at -
20°C until further use.
A pcDNA3.1+ vector containing the coding sequence for the pEYFP H148Q/I152L mutant
protein was kindly supplied by Prof. Alan Verkman (Department of Medicine, University
of California, San Francisco, USA). The vector was obtained as aqueous stock solutions
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(0.2 mg/ml) and stored at -20°C.
2.2.3 Examination of received vectors
Before the cDNAs described above (Sections 2.2.1 & 2.2.2) could be used in experiments,
their sequence identity was analysed. On this account, the plasmid vectors were transformed
into competent E. coli Xl1 blue cells and subsequently purified and, in case of the GABAA
receptor subunits, digested using restriction endonucleases (Promega) listed in Table 2.2
(Sections 2.1.2 to 2.1.4). After digesting the plasmid cDNAs, they were visualised on a 1%
agarose gel (Section 2.1.4) to verify the presence of GABAA receptor subunit cDNA in the
vector. Finally, GABAA receptor subunit as well as pEYFP H148Q/I152L cDNAs and the
pRK5-Clomeleon plasmid were sent for sequencing (Section 2.1.7).
Table 2.2: Restriction enzymes used to digest different GABAA receptor cDNAs
Enzymes 10 × buffer (buffer composition)
α3 HindIII, XbaI Buffer B (60 mM Tris-HCl, 60 mM MgCl2, 0.5 M NaCl, 10 mM DTT, pH 7.5)
β2 EcoRI, XbaI Buffer H (0.9 M Tris-HCl, 100 mM MgCl2, 0.5 M NaCl, pH 7.5)
γ2L EcoRI, XbaI Buffer H
ε EcoRI, XbaI Buffer H
α1 HindIII, EcoRI Buffer E (60 mM Tris-HCl, 60 mM MgCl2, 1 M NaCl, 10 mM DTT, pH 7.5)
2.2.4 Subcloning
The sequencing results revealed that the α3 subunit cDNA was present in the wrong orienta-
tion in the pcDNA3.1+ vector and had to be reversed. The α1 subunit cDNA was present in
the pBS vector and needed to be re-cloned into a mammalian expression vector (pcDNA3.1+)
in order to express the subunit in mammalian cells in later experiments. Furthermore, for the
purpose of cRNA synthesis using T7 RNA polymerase (Section 2.3.1), the β2 and γ2L su-
bunit cDNAs were sub-cloned into the pcDNA3.1+ vector. Plasmids containing the GABAA
receptor subunit cDNAs were digested using restriction endonucleases as described before
(Sections 2.1.4 and 2.2.3).
In case of the α3 subunit, the plasmid was digested using EcoRI restriction endonuclease
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only (this is where the subunit cDNA was cloned originally into the multiple cloning site
of the vector). Next, the digested vector was ethanol precipitated (Section 2.1.6) and the
DNA pellet was resuspended in 8 µl 0.1 % (v/v) DEPC-treated water. Afterwards, vector
and subunit cDNA were religated using 1 µl T4 DNA ligase (1-3 U/µl; Promega) with 1 µl
10 × reaction buffer (300 mM Tris-HCl (pH 7.8 at 25°C), 100 mM MgCl2, 100 mM DTT
and 10 mM ATP) at 4°C overnight.
The pBS vector containing the α1 subunit was digested using HindIII and EcoRI restriction
endonucleases. The β2 and γ2L subunit cDNAs were digested using EcoRI and XbaI res-
triction endonucleases. 30 ng pcDNA3.1+ vector was digested for each subunit cDNA using
the respective restriction enzymes in a separate microfuge tube (Sections 2.1.4 and 2.2.3).
Digested plasmids containing the subunit cDNAs were run on a 2 % (w/v) agarose gel and
visualised by UV trans illumination (Section 2.1.4). Bands corresponding to α1, β2 and
γ2L subunit cDNAs were excised from the gels with a clean scalpel and purified using a
GFXTM PCR DNA and Gel Band Purification Kit (GE Healthcare; Section 2.1.8.2). Purified
subunit cDNAs as well as digested pcDNA3.1+ vector DNA were ethanol precipitated and
subsequently ligated using T4 DNA ligase (see above).
Ligation products were transformed into competent E. coli XL1 blue cells, amplified and
then isolated from the bacterial cultures. Subsequently, purified plasmid DNA was digested
and visualised on a 2 % (w/v) agarose gel. Plasmid DNAs containing an insert of the correct
size were sent for sequencing to confirm their identity and correct orientation in the vectors
(Sections 2.1.2 to 2.1.7).
2.3 Electrophysiological recordings in Xenopus oocytes
2.3.1 Making cRNA from cDNA
cRNA was made from cDNA using a T7 mMessage mMachine® Kit (Ambion) accor-
ding to the manufacturer’s protocol. GABAA receptor subunit cDNAs were present in the
pcDNA3.1+ (α3, α1, β2, γ2L and εT) or the pcDNA3 vector (ε); these vectors contain a
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promoter sequence for T7 RNA polymerase. At first, the plasmid DNA was linearised by
cutting it after the end of the GABAA receptor subunit sequence. For this, 5 µg plasmid
DNA, containing the different GABAA receptor subunit cDNAs, respectively, was digested
using XbaI restriction endonuclease (8-12 U/µl, Promega) and 10 × buffer D (10 mM Tris-
HCl (pH 7.4), 300 mM NaCl, 0.1 mM EDTA, 1 mM DTT, 0.5 mg/ml BSA, 50 % glycerol)
in a total volume of 40 µl (Section 2.1.4). 2 µl of each linearised product was visualised on
a 1.5 % (w/v) agarose gel to confirm the completion of the digest, which was then termina-
ted by adding 1/20 volume 0.5 M EDTA (pH 8), 1/10 volume 3 M NaAc (pH 5.2) and 2 ×
volume 100 % (v/v) ethanol and incubated at -20°C for 30 minutes. Next, plasmid DNAs
were centrifuged for 15 minutes at 13,000 rpm and 4°C. Supernatants were removed and
DNA pellets resuspended in 0.1 % (v/v) DEPC-treated water to yield a final concentration of
0.5 µg/µl. Capped cRNA was transcribed in vitro using the T7 mMessage mMachine® Kit.
The transcription reaction was set up at room temperature (18-25°C) in the following order
and with a final volume of 20 µl:
Nuclease-free water 4 µl
2 × NTP/CAP (15 mM of each ATP, CTP, UTP, 3 mM GTP, 12 mM cap analog) 10 µl
10 × reaction buffer 2 µl
linearised cDNA template (0.5 µg/µl) 2 µl
T7 enzyme mix 2 µl
The mixture was incubated at 37°C for 70 minutes. Subsequently, 1 µl TURBO DNase
(2 U/µl) was added to each sample, which was incubated at 37°C for a further 15 minutes.
The resulting cRNA was recovered by performing a lithium chloride precipitation. 30 µl
nuclease-free water and 30 µl lithium chloride precipitation solution (7.5 M lithium chloride,
50 mM EDTA) were added to the cRNA and precipitated at -20°C for 40 minutes. The mi-
crofuge tube was then centrifuged at 13,000 rpm, 4°C for 15 minutes and the supernatant was
carefully removed. The cRNA pellet was washed with 70 % ethanol and once more centrifu-
ged for 15 minutes before the ethanol was removed and the cRNA pellet was resuspended in
an appropriate amount of nuclease-free water. Concentrations of the cRNAs were measured
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using a UV spectrophotometer (DU530 or DU800, Beckman) as described in Section 2.1.5.
2 µl aliquots of cRNA samples at concentrations of 1 µg/µl or 2.5 µg/µl were stored at -80°C
until needed. Remaining cRNA was stored in 2.5 × volume 100 % (v/v) ethanol at -80°C.
2.3.2 Selection of Xenopus laevis oocytes
All following experiments using Xenopus laevis oocytes were performed in the laboratory
of Dr Ian Mellor (University of Nottingham). Oocytes that had been enzymatically separa-
ted and defolliculated with 2 mg/ml collagenase type 1A for 40-60 minutes were provided.
Healthy, large, round stage V and VI oocytes (1 to 1.2 mm diameter and 1.2 to 1.3 mm
in diameter, respectively) featuring a distinctive two-toned colour scheme (dark brown ani-
mal hemisphere and yellow vegetal hemisphere) were selected for GABAA receptor subunit
cRNA expression (Figure 2.2).
Figure 2.2: (A) Healthy and (B) impaired Xenopus laevis oocytes
The selection of healthy oocytes with a distinctive two-toned colour scheme and spherical or round
shape is vital for an effective expression of foreign proteins (from http://www.rothamsted.ac.uk/ppi/
staff/TonyMiller/plantele_xenopus.html)
44
Chapter 2. Materials and Methods
2.3.3 Injection of cRNA into Xenopus laevis oocytes
Oocytes were injected on the same day or one day after removal from the animal. Injection
pipettes were pulled from glass capillaries (No. 4878, World Precision Instruments, Inc.) in
one stage using a vertical pipette puller (Model 700C, David Kopf Instruments). Pipette tips
were shortened by gently tapping them against the lid of a sterile 35 mm Petri dish to a dia-
meter of approximately 15 µm. Subsequently, the pipette was backfilled with sterile-filtered
paraffin oil, using a hypodermic needle (25G) and 2 ml syringe, to seal the pipette from air.
It was then mounted onto a 50 nl microinjector (A203XVB, World Precision Instruments,
Inc.). The pipette was gradually filled with 4 µl cRNA mixture, containing one or more
cRNAs and sterile, DEPC-treated water. Selected oocytes were lined up in a 35 mm Petri
dish containing filter-sterilised modified Barth’s solution (96 mM NaCl, 2 mM KCl, 1.8 mM
CaCl2, 1 mM MgCl2, 5 mM HEPES, 2.5 mM pyruvic acid, 0.5 mM theophylline, 0.05 mg/
ml gentamycin; pH 7.5) and several silicone strips to keep oocytes separated and in place.
Oocytes were impaled with the injection pipette and 50 nl cRNA mixture was injected into
each oocyte at the following ratios: 1:1 for α3β2 receptors, 1:1:1 for α1/α3β2ε/εT receptors
(12.5 ng of each subunit per oocyte) and 1:1:10 for α3β2γ2L receptors (6.25 ng of α3 and
β2 subunit cRNA and 62.5 ng of γ2L subunit cRNA per oocyte). Oocytes were incubated
in modified Barth’s medium at 18°C for a minimum of 36 hours to allow GABAA receptor
expression. Oocytes, when injected with cRNAs encoding for α1 or α3, β2 and ε subunits,
were incubated in the presence of 100 µM Picrotoxin to block current through spontaneously
open channels. Oocytes were checked every day and dead oocytes were removed from the
medium. Barth’s medium was changed on the second day and on a regular basis afterwards.
2.3.4 Two-electrode voltage-clamp
Microelectrodes were pulled from thin wall borosilicate glass tubes (1.5 /1.12 OD/ID (mm);
Model no. TW150F-4, World Precision Instruments, Inc.) using a programmable, horizontal
pipette puller (P-97, Sutter Instruments) in two steps. Next, microelectrodes were bent in the
middle to about 150 degree using a spirit burner and backfilled with 3 M KCl using a modi-
fied 1 ml syringe to about two thirds full. To remove air bubbles in the microelectrode tip, it
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was gently flicked until bubbles disappeared. It was then inserted into a microelectrode hol-
der mounted on a headstage (H2-RA, Axon Instruments) controlled by a micromanipulator
(Leitz). Microelectrodes had a resistance of 0.5 to 3 MΩ when submerged in the frog Ringer
solution (95 mM NaCl, 2 mM KCl, 2 mM CaCl2, 5 mM HEPES; pH 7.5). An oocyte was pla-
ced into the oocyte bath chamber (RC-3Z, Warner Instruments) and constantly perfused with
a frog Ringer solution at a flow rate of approximately 6-8 ml/min. Two microelectrodes were
impaled into the oocyte; one electrode recorded the voltage, the other injected the current (Fi-
gure 1.8, Chapter 1). Oocytes were clamped at a chosen holding potential, normally -60 mV,
using a GeneClamp 500 (Axon Instruments) or Axoclamp 2-A (Axon Instruments) amplifier.
Data were recorded to the hard disk of a PC using Strathclyde Electrophysiology Software
WinEDR2.9.2. (Dr J. Dempster, Department of Physiology and Pharmacology, University
of Strathclyde, UK). All drugs were bath applied by switching from frog Ringer solution
to drug solution using a ValveLink 8 or ValveBank 8 perfusion system (Automate Scienti-
fic). Oocytes were washed for at least four minutes between each drug application to avoid
receptor desensitisation. GABAA receptor agonists were applied alone and antagonists and
allosteric modulators were administered simultaneously with GABA at a concentration that
produced 20 % of the maximum response (EC20). GABA alone at EC20 concentrations ser-
ved as control. GABA, muscimol and zinc sulphate were prepared as 10 mM stock solutions
and picrotoxin was dissolved as a 100 µM stock solution in frog Ringer and diluted before
use. Flunitrazepam and etomidate were dissolved in 100 % (v/v) DMSO before dilution into
frog Ringer solution. The final solution did not exceed a DMSO level of 0.1 % (v/v), which
had no effect either alone or on GABA-elicited currents (Figure B.1 in Appendix B). All
experiments were performed at room temperature (18-25°C). A minimum of two batches of
oocytes were used per experiment.
2.3.5 Data analysis
Two-electrode voltage-clamp data were analysed using Strathclyde Electrophysiology Soft-
ware WinEDR V2.9.2 (Dr J. Dempster, Department of Physiology and Pharmacology, Uni-
versity of Strathclyde, UK) by measuring the amplitudes of peak-currents of recorded traces.
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Concentration-response curves were fitted using GraphPad Prism 5.0 software (San Diego,
USA). Data were normalised and shown as percentage of the maximal response or percen-
tage of the control response, respectively, and fitted using a non-linear regression fit with
variable slope to the following equation:
response =
 100/(1 + 10
((logEC50−X)×n)) for agonists and positive modulating drugs
100/(1 + 10((log IC50−X)×n)) for antagonists
(2.2)
Where X is the log of drug concentration, EC50/IC50 is the drug concentration evoking a
half-maximal response and n is the Hill coefficient. Data are given as means ± standard
error of the mean (SEM). EC50/IC50 values from different receptor subtypes were analysed
statistically using unpaired Student’s t-test and considered significant when p < 0.05.
2.4 Patch clamping mammalian cells
Glass coverslips (VWR) were cut into ~5.5 mm × 22 mm pieces using a diamond cutter.
Coverslip pieces were then sterilised by baking them at 180°C for 3 hours. Transiently
transfected HEK293 cells were reseeded at a low density onto sterile pieces of glass coverslip
in 35 mm Petri dishes (Nunc) 24 hours after transfection with GABAA receptor cDNAs (see
Sections 2.5.4 and 2.6.3). Recordings were performed using the whole-cell patch-clamp
configuration 24 to 48 hours after plating (Figure 1.9, Chapter 1).
Whole-cell recordings were performed in the laboratory of Dr Ian Mellor (University of Not-
tingham). Glass borosilicate capillaries (Model no. 1B150-4, World Precision Instruments,
Inc.) were pulled in two steps using a programmable, horizontal pipette puller (P-97, Sutter
Instruments). Pipettes were filled approximately two thirds with pipette solution (140 mM
CsCl, 1 mM CaCl2, 1 mM MgCl2, 11 mM EGTA and 5 mM HEPES; pH 7.2 adjusted with
CsOH) and air bubbles in the tip were removed by gently tapping the pipette. It was then
inserted into a pipette holder mounted on a CV 201AU headstage (Axon Instruments), which
was controlled by a micromanipulator (PCS - 5000 Series, Burleigh). Pipettes had a resis-
tance of ~5 to ~8 MΩ when lowered into the bath. A RC-27 bath chamber (Warner Ins-
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truments) was placed on the stage of a microscope (Olympus). Coverslips with cells were
transferred into the chamber and continuously perfused with a mammalian Ringer solution
(135 mM NaCl, 5.4 mM KCl, 1 mM CaCl2, 1 mM MgCl2, 5 mM HEPES and 10 mM Glu-
cose; adjusted to pH 7.4 with NaOH). Membrane currents were recorded using an Axopatch
200A amplifier (Axon Instruments). Cells were clamped at a holding potential of -50 mV.
Drugs were bath applied using a QMM micromanifold (ALA Scientific Instruments, Inc.)
by switching from mammalian Ringer solution to drug solution. 2 second pulses of agonists
or antagonists at specific concentrations were applied using a DAD-12 superfusion system
(ALA Scientific Instruments, Inc.). Cells were washed for at least 30 seconds between each
drug application. The amplifier, perfusion system and data recording to a PC were control-
led and synchronized by Strathclyde Electrophysiology Software WinWCP V2.9.2 (Dr J.
Dempster, Department of Physiology and Pharmacology, University of Strathclyde, UK).
All experiments were carried out at room temperature (18-25°C).
2.5 Cell culture
2.5.1 Culturing HEK293 cells
HEK293 cells were kindly provided by Prof. Anne Stephenson (The School of Pharmacy,
University of London, UK). Cells were grown in sterile-filtered Dulbecco’s modified Eagle’s
medium (DMEM), containing 4.5 g/l glucose and 4 mM L-glutamine, supplemented with
10 % (v/v) fetal bovine serum (FBS) and intermittently with 10 ml/l Penicillin-Streptomycin
(10,000 U/ml penicillin and 10 mg/ml streptomycin). Cells were maintained at 37°C in
a humidified atmosphere with 95 % (v/v) air and 5 % (v/v) carbon dioxide. Cells were
routinely grown in 75 cm2 or 25 cm2 tissue culture flasks (Sarstedt/Iwaki) and sub-cultured
twice a week (when 80-90 % confluent). For this, the growth medium was pipetted out
and cells were washed once with Dulbecco’s phosphate buffered saline (DPBS; 130 mg/l
CaCl2·2 H2O, 200 mg/l KCl, 200 mg/l KH2PO4, 100 mg/l MgCl2·6 H2O, 8 g/l NaCl, 2.16
g/l Na2HPO4·7 H2O) to remove traces of serum. Next, cells were incubated with trypsin/
EDTA (900 mg/l NaCl, 500 mg/l Trypsin, 200 mg/l Versene (EDTA)·2 Na·2 H2O) at 37°C
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until they detached from the plastic flask and fresh growth media was added to quench the
action of the trypsin/EDTA. Cells were centrifuged at 300 rcf, 22°C for 5 minutes (Models
5415R, Eppendorf or Universal 320R, Hettich); the supernatant was discarded and the cell
pellet resuspended in 1 ml fresh medium by pipetting the cells gently up and down several
times. Afterwards, a suitable quantity of cells was transferred into a tissue culture flask
containing fresh growth medium and incubated as stated above. Cells were cultured for
about 20 passages before a new stock was regenerated. All reagents were purchased from
Lonza.
2.5.2 Long term storage of HEK293 cells in liquid nitrogen
For cryopreservation, HEK293 cells of a low passage number were grown and harvested as
described above (Section 2.5.1). Cell pellets were carefully resuspended with a pipette until
cells were free of clusters. Next, cells were counted using a hemocytometer with Neubauer
improved grid pattern (C-Chip (DHC-N01), Incyto) by transferring 20 µl resuspended cells
to a microfuge tube containing an appropriate volume of growth medium, depending on the
size of the tissue culture vessel where cells grew in. Cells were further diluted 1:1 (final
concentration of 4 to 6 × 106 cells per ml) using a Trypan blue solution (0.4 % in 0.81 %
NaCl and 0.06 % K2HPO4, Sigma), which stained non-viable cells blue. 10 µl of the mixture
were loaded into the counting chamber and viable cells were counted in 5 large squares. The
number of viable cells per ml was calculated as follows:
no. of cells counted
5
× dilution factor× 104 = cells/ml (2.3)
Afterwards, cells were pelleted again and resuspended in sufficient freezing medium (DMEM
supplemented with 10 % (v/v) FBS and 5 % (v/v) DMSO) to get a final concentration of
2 × 106 cells per ml. 1 ml of cell suspension was pipetted into each cryovial and frozen at
-80°C for 24 hours before vials were transferred into liquid nitrogen for long term storage.
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2.5.3 Thawing cells stored in liquid nitrogen
Cryovials of HEK293 cells from frozen stock were thawed quickly by incubating the vials
at 37°C and transferring the cells to 20 ml prewarmed growth medium. Next, the cell sus-
pension was centrifuged at 300 rcf, 22°C for 5 minutes and cell pellets were resuspended in
1 ml fresh growth medium before transferring them to a tissue culture flask containing fresh
growth medium and incubating them at 37°C, 95 % (v/v) air and 5 % (v/v) carbon dioxide
until 80 to 90 % confluent (Section 2.5.1).
2.5.4 Transient transfection of HEK293 cells
Cells were seeded into different tissue culture vessels (depending on the number of cells
needed) in DMEM containing 10 % FBS, but no antibiotics, and grown for 24 hours as
described in Section 2.5.1 and Table 2.3.
Table 2.3: Transient transfection using TransPassTM D2 in different culture vessels
Culture vessel No. of cells
seeded
Volume of
medium
total amount plas-
mid DNA in DMEM
TransPassTM
D2
24-well plate 1.5 × 105 250 µl 0.7 µg in 50 µl 1.75 µl
6-well plate 7.2 × 105 1 ml 3 µg in 250 µl 8.75 µl
T25 flask 1.85 × 106 3.2 ml 9 µg in 600 µl 22 µl
T75 flask 5.55 × 106 9.6 ml 27 µg in 1800 µl 66 µl
After 24 hours, cells were 70-80 % confluent and transfected using TransPassTM D2 trans-
fection reagent (New England Biolabs) according to the manufacturer’s protocol. Briefly,
plasmid DNA was pipetted into DMEM as in Table 2.3, when transfecting several different
DNAs the quantity was divided equally or at certain ratios. Next, 22 µl TransPassTM D2 was
added, mixed carefully and incubated for 20 to 30 minutes at room temperature (18-25°C)
to facilitate formation of tranfection complexes. Subsequently, the mixture was added to the
cells and incubated for 4 to 6 hours as described before (Section 2.5.1). Medium containing
excess transfection complexes was then replaced by fresh growth medium in order to prevent
toxic effects to the cells. Transient transfection was optimised using pRK5-Clomeleon as a
reporter protein (Section 2.5.4.1).
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2.5.4.1 Evaluation of transient transfection efficiency
Transient transfection efficiency was optimised by transfecting HEK293 cells with pRK5-
Clomeleon, which served as fluorescence marker of transfected cells. Cells were seeded into
and transfected in 24-well plates as described in Section 2.5.4, but varying the number of
cells as well as the plasmid DNA to TransPassTM D2 transfection reagent ratio. Approxi-
mately 24 hours after the transfection, cells were removed from the wells by using trypsin/
EDTA (as described in 2.5.1). Transfection efficiency was examined by placing cells in solu-
tion onto a glass microscope slide and visualising them using an Olympus BX51 fluorescence
microscope. A minimum of 1000 cells were counted per experiment using CellF software
(Olympus) in order to determine the ratio of transfected (fluorescent) cells versus untrans-
fected cells. The conditions resulting in highest transfection efficiency after performing each
experiment in duplicates were used for all further transient transfection experiments (Section
2.5.4, Table 2.3).
2.5.5 Reseeding cells into appropriate tissue culture plasticware
Typically, cells had to be reseeded into cell culture plastic ware suited for respective expe-
riments 24 hours after transient transfection. For this, cells were washed once using DPBS
and subsequently detached from the surface by adding trypsin/EDTA and incubating them at
37°C until dissociated from the plastic. Sufficient growth medium was added to the cells to
quench the trypsin/EDTA. Cells were then centrifuged at 300 rcf for 5 minutes at room tem-
perature (18-25°C). Cell pellets were resuspended and counted (Section 2.5.2); the required
number of cells was plated into microtiter plates or coverslips placed in 35 mm Petri dishes
and incubated further until usage in respective experiments (see below).
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2.6 Assay development to screen compound libraries
2.6.1 A cell-based assay using the chloride-ion indicator Clomeleon
2.6.1.1 Excitation and emission spectra of Clomeleon
Sequencing the pRK5-Clomeleon plasmid revealed a discrepancy of one amino acid with the
sequence data provided by Dr Thomas Kuner. Therefore, the excitation and emission spectra
of Clomeleon were investigated using a spectrofluorometer (QuantaMaster, Photon Techno-
logy International,Inc.). HEK293 cells were seeded into 24-well plates and transfected 24
hours later with GABAA receptor subunit cDNA (α3 and β2 and γ2L) and pRK5-Clomeleon
at a ratio of 1:1:1:1 (Section 2.5.4). On the next day, cells were reseeded onto sterile covers-
lips (10 × 24 mm, Chance Propper Ltd.) placed in 35 mm dishes (Nunc) at a cell density of
7 to 10 × 105 in 500 µl medium. Cells were incubated as described above (Scetion 2.5.1)
until the following day.
Excitation and emission screens were performed using a spectrofluorometer (QuantaMaster,
Photon Technology International,Inc.). Cells on a coverslip were immersed into a fluorime-
ter cuvette (Sigma) containing mammalian Ringer solution (Section 2.4), which was subse-
quently fitted into the spectrofluorometer. The emission scan was performed at wavelengths
of 450 nm to 650 nm, with an excitation of 440 nm; the excitation scan was carried out from
350 nm to 485 nm with the emission being set to 527 nm. Both were performed with cells
transfected with Clomeleon alone or Clomeleon and α3β2γ2L GABAA receptors. Additio-
nally, untransfected HEK293 cells, a cuvette with mammalian Ringer solution and a cuvette
alone were scanned as controls. Experiments were performed at 37°C.
2.6.1.2 Evaluating a screening assay using Clomeleon
HEK293 cells were seeded into 25 cm2 tissue culture flasks and 24 hours later transfected
with GABAA receptor subunit cDNAs (α3 and β2 or α3, β2 and γ2L) and pRK5-Clomeleon
at ratios of 1:1:1 or 1:1:1:1, respectively (Section 2.5.4). On the following day, cells were pla-
ted into Poly-D-Lysine coated, black 96-well plates with clear, flat bottom (BD Biosciences)
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at cell densities of 1.5 × 105 and 2 × 105 cells per well in 200 µl medium. Poly-D-Lysine
coating enhanced cell growth and attachment to the wells and black polystyrene plates were
used to lower background noise and well-to-well crosstalk. Cells were incubated for another
day before performing the assay using a FLUOstar Optima microplate reader (BMG Lab-
tech) fitted with one reagent injector, a 430 ± 10 nm excitation and 480 ± 10 nm and 520-P
emission filters.
On the day of the assay, the growth medium was removed from each well and replaced with
90 µl prewarmed mammalian Ringer solution (Section 2.4) per well. Cells were then incuba-
ted for a further one hour (as described in 2.5.1) before placing the plate into the FLUOstar
Optima plate reader, which was set to excite and read Clomeleon emission from the bottom
of the plate. Baseline fluorescence was measured for 20 seconds (0.2 second intervals) for
both Clomeleon emission wavelengths (480 nm and 520 nm), together as well as separa-
tely. Next, 10 µl GABA (1 mM) in mammalian Ringer solution was injected into each well
(100 µM final GABA concentration). To intermix the added solution, the plate was shaken
for 1 second before the fluorescence signal was continued to be read for a further 30 seconds
at 0.2 second intervals. Experiments were performed at 37°C and repeated twice. Data were
analysed by normalising averaged baseline fluorescence signal to 100 % and fluorescence
signals recorded after GABA solution injection were shown as percentage of baseline fluo-
rescence. Data are given as means ± SEM.
2.6.2 Setting up an iodide-flux assay
The assay was set up as described in Tang & Wildey (2004) and Tang & Wildey (2006).
HEK293 cells were seeded into 25 cm2 tissue culture flasks and transfected 24 hours later
with GABAA receptor subunit cDNAs (α3, β2 and γ2L, ratio 1:1:1; Section 2.5.4). On
the following day, cells were plated into Poly-D-Lysine coated 96-well microplates with
flat bottom (BD Biosciences) at cell densities of 25 × 103 cells per well in 100 µl growth
medium. At a later date, cells were tested at lower densities of 12.5 × 103 and 17.5 × 103
cells per well. Cells were incubated for another day before proceeding with the iodide-flux
assay. Untransfected HEK293 cells served as negative controls.
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DMEM was removed from the wells and cells were loaded with 100 or 200 µl filter-sterilised,
prewarmed iodine-loading buffer (150 mM NaI, 2 mM CaCl2, 0.8 mM NaH2PO4, 1 mM
MgCl2, 5 mM KI, 2 % FBS; adjusted to pH 7.4 with NaOH). Subsequently, cells were
incubated for a further 4 hours at 37°C, 95 % (v/v) air, 5 % (v/v) carbon dioxide to allow cell
loading. Cells were then washed 3 to 4 times with 200 µl DPBS to remove excess iodide,
before adding 100 µl DPBS containing increasing concentrations of GABA and incubated
for a further 5 minutes at room temperature (18-25°C). Next, the DPBS containing GABA
and the ’effluxed’ iodide was transferred to a fresh plate. Cells on the first plate were lysed by
adding 100 µl lysis buffer (1 % (v/v) triton X-100). Colorimetric detection was accomplished
on both plates (lysed cells as well as DPBS) by adding to each 100 µl detection buffer II
(2 mM Ce(NH4)4(SO4)4·2H2O, 5.2 % (v/v) fuming H2SO4 in distilled H2O) followed by
100 µl detection buffer I (1.25 % (v/v) NH4OH solution, 100 mM As2O3, 3.2 % (v/v) fuming
H2SO4, 467.38 mM NH4Cl). Subsequently, the plate was incubated at room temperature for
15 minutes. Next, it was inserted into a microplate reader (ASYS, Expert 96), shaken for 2
seconds to evenly disperse the liquid and the OD405 was read.
The results obtained were rather random, therefore, several assay modifications and optimi-
sations were tested. Since the OD405 readings were relatively low, not only less cells were
seeded, but also it was examined whether the results could be improved by diluting the lysed
cells and DPBS (1:2 and 1:5) before performing the colorimetric assay. In order to test func-
tionality of GABAA receptors, cells were incubated in DPBS with 50 µM bicuculline and 1
or 100 µM GABA or in DPBS containing 50 µM picrotoxin and 1 or 100 µM GABA as well
as 1 or 100 µM GABA and DPBS alone. Untransfected cells served as controls. Different
agonist incubation times of 10 seconds up to 5 minutes (DPBS containing 10 µM GABA)
were also investigated to optimise efflux. In every assay for every test variable 8 replicates
were prepared per plate. Different setups were repeated at least 2 times.
A standard curve was generated by adding 100 µl per well in a 96-well plate of ascending
concentrations of NaI (3 nM to 300 µM) as well as distilled water as negative control. Af-
terwards, 100 µl detection buffer II and 100 µl detection buffer I were added into each well,
contents were mixed and incubated at room temperature for 10 to 70 minutes before reading
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the OD405 on the microplate reader. 8 standard replicates per NaI concentration were pre-
pared and the experiment was repeated 3 times on different days. Data points were averaged.
The assay detection limit was defined as minimal NaI concentration that fulfils the following
argument (Tang & Wildey, 2004):
OD405sample −OD405control > 3SDcontrol (2.4)
Where OD405sample is the OD405 of the sample containing NaI, OD405control is the OD405
of the control sample that contains no NaI and SDcontrol is the standard deviation (SD) of the
control.
OD405 readings of the iodide-flux assay were averaged and the SD was calculated. Values
were analysed statistically using unpaired Student’s t-test and considered significant when
p < 0.05. In some cases, channel conductivity (% activity) was calculated as follows (Tang
& Wildey, 2004):
(OD405sample −OD405low)/(OD405high −OD405low)× 100 (2.5)
Where OD405sample was the reading of the wells incubated with different GABA concentra-
tions, OD405high was the reading of the cells treated with the highest concentration of GABA
and OD405low was measured from cells incubated with distilled water instead.
2.6.3 Setup and optimisation of a mutant YFP-based assay
HEK293 cells were seeded into 25 cm2 or 75 cm2 tissue culture flasks. On the next day,
when 70 - 80 % confluent, cells were transfected with GABAA receptor subunit cDNAs and
the pEYFP H148Q/I152L vector (as described in 2.5.4). GABAA receptor subunit cDNAs to
pEYFP H148Q/I152L vector ratios were as listed below:
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α1 : β2 : pEYFP H148Q/I152L → 1:1:2
α3 : β2 : pEYFP H148Q/I152L → 1:1:2
α1 : β2 : ε : pEYFP H148Q/I152L → 1:1:1:2
α3 : β2 : ε : pEYFP H148Q/I152L → 1:1:1:2
α3 : β2 : γ2L : pEYFP H148Q/I152L → 1:1:1:2
Untransfected cells served as control cells. On the following day, cells were plated into Poly-
D-Lysine coated, black-sided 96-well plates with clear, flat bottom (BD Biosciences) and
incubated for a minimum of a further 24 hours. For assay optimisation, different numbers
of cells were seeded per well (in 200 µl growth medium). Approximately 1.5 × 105 cells
per well (in 200 µl medium) were decided to give the best results and used in all further
experiments.
On the day of the assay, one hour prior to the start of an experiment, growth medium was
removed from the wells and replaced by 50 µl prewarmed NaCl bathing solution per well
(140 mM NaCl, 5 mM KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 10 mM Glucose;
pH 7.3 using NaOH). Following incubation, the plate was placed into a FLUOstar Optima
microplate reader (BMG Labtech) fitted with two reagent injectors, a 500 ± 10 nm excita-
tion and a 520-P emission filter. Assays were performed at 37°C. The mutant YFP-H148Q/
I152L was excited and its emission was measured from the bottom of the plate; each well
was scanned orbitally at a radius of 3 mm. Baseline fluorescence was recorded for 5 seconds
(one second intervals) before injection of 150 µl NaI test solution only (140 mM NaI, 5 mM
KCl, 2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, 10 mM Glucose; pH 7.3 using NaOH)
or NaI test solution supplemented with GABA or picrotoxin at specific concentrations (in-
jection speed 100 µl/sec). After solution was injected, the fluorescence signal was recorded
at 0.5 second intervals for a further 30 seconds. Experiments were repeated 3 times, each
with at least 3 wells on the same plate and at least one of the replicates was performed on a
separate plate.
As it became clear that the assay was functional, GABA concentration-response relation
curves were determined for α1β2, α1β2ε and α3β2γ2 receptors by injecting ascending
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GABA concentrations (in NaI test solution) ranging from 30 nM to 3 mM. By adding NaI test
solution containing flunitrazepam (1 µM final concentration) and an EC30 concentration of
GABA to cells expressing α3β2γ2 receptors it was demonstrated that the assay was suitable
to detect positive modulation of the receptors. Flunitrazepam stock solution was prepared
by dissolving it in 100 % (v/v) DMSO. Before the assay, flunitrazepam was diluted into NaI
test solution. The final solution did not exceed a DMSO level of 0.5 % (v/v), which had no
effect on GABA-elicited currents (Figure B.2 in Appendix B).
2.6.3.1 Data analysis
Data were analysed by subtracting the averaged fluorescence measured from non-transfected
control cells (baseline fluorescence and after addition of NaI test solution) resulting in the net
fluorescence signal. This was then normalised by setting the averaged baseline fluorescence
to 100 % and fluorescence changes (after adding solutions) were calculated as percentage of
the baseline fluorescence. The percentage of fluorescence quench was calculated as follows
(Gilbert et al., 2009a):
% fluorescence quench = (1− (F final/F BF))× 100 (2.6)
FBF is the averaged baseline fluorescence signal and Ffinal is the averaged final fluorescence
signal. Values were presented as means ± SEM. To assess the assays quality without test
compounds the Z’factor was calculated as described below (Zhang et al., 1999):
Z ′ = 1− (3σc+ + 3σc-)|µc+ − µc-| (2.7)
σc+ or σc- represent the SD of positive and negative controls, µc+ or µc- states the means
of positive and negative controls. Positive controls were readings from cells treated with a
high GABA concentration (100 µM), for negative controls NaI test solution only was applied
to the cells. Concentration-response curves were fitted using GraphPad Prism 5.0 software
(San Diego, USA). Data were shown as percentage of baseline fluorescence and fitted using
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a non-linear regression fit with variable slope according to the following equation:
response =
{
bottom + (top + bottom)/(1 + 10((logEC50−X)×n)) (2.8)
Where X is the log of drug concentration, EC50 is the drug concentration evoking a half-
maximal response, n is the Hill coefficient and the response starts at bottom and goes to top.
Data are given as means ± SEM.
2.7 Compound screening using mutant YFP-H148Q/I152L
2.7.1 Chemical compound library
800 compounds covering a broad range of structural motifs and biological space were acqui-
red from the Maybridge HitFinderTM collection of screening compounds (Maybridge Ltd.).
Compound quality was guaranteed to have a minimum of 90 % purity. Compounds were
arrayed individually in ten separate 96-well plates (80 compounds per plate) as dry films of
1 µmol per compound and stored at -80°C until usage.
Compounds were resuspended in 100 µl DMSO per well. Plates were placed on an orbi-
tal shaker (Stuart) and left until compounds were dissolved. Subsequently, 20 µl aliquot
plates were prepared. All plates were sealed using parafilm and stored at -20°C until needed.
Concentrations of these compound stock solutions ranged from ~10.1 to ~11.9 mM.
2.7.2 Screening assay
HEK293 cells were seeded in 75 cm2 flasks, transfected with α1, β2, ε or α3, β2, γ2L
GABAA receptor subunit cDNAs and YFP-H148Q/I152L cDNA and reseeded into Poly-D-
Lysine coated 96-well plates (Sections 2.5.4, 2.6.3). On the next day, the assay was perfor-
med as described in Section 2.6.3. Application of 100 µM GABA, 1 mM picrotoxin with an
EC30 GABA concentration as well as EC30 GABA with or without 0.5 % DMSO (all were
applied in NaI test solution) served as controls.
58
Chapter 2. Materials and Methods
1 µl of compound stock solution was transferred manually, using a multichannel pipette, to
each well of the microtiter plate containing 50 µl NaCl bath solution. Next, the plate was
returned to the plate reader and shaken for 10 seconds to intermix the added compound.
150 µl of low concentration GABA (EC30) in NaI test solution was injected into the first well
and the fluorescence signal was read for 30 seconds (0.5 second intervals), before GABA in
NaI test solution was added to the next well to measure the fluorescence signal for 30 seconds
until all compounds were screened for their possible modulating or antagonist activity. Time
elapsed between the addition of a chemical compound to the wells until the injection of NaI
test solution and subsequent fluorescence measurement was between approximately 5 and
60 minutes. In later assays this time was reduced to shorter periods.
The initial screening was performed with relatively high compound concentrations (final
concentrations were between 50.3 and 59.29 µM). Due to the high number of ’hit’ com-
pounds, which enhanced or inhibited submaximal GABA-evoked receptor activity, the scree-
nings were repeated several times using gradually decreased compound concentrations (com-
pound solutions were further diluted using DMSO). During these preliminary screens, each
compound was tested in singlets until the number of ’hit’ compounds was whittled down suf-
ficiently. The remaining ’hit’ compounds were then tested in at least three wells on the same
plate, repeated at least three times. Compounds applied with NaI test solution only were
examined for possible agonist activity of ’hit’ compounds and cells transfected with YFP-
H148Q/I152L cDNA only served as control cells to rule out compound activity via receptors
expressed endogenously in the cells. Data were analysed as in Section 2.6.3 described.
2.7.2.1 Data analysis
The effect of test compounds was compared to the EC30 GABA-control response and analy-
sed statistically using Student’s t-test. Results were considered significant when p < 0.05.
2.7.3 Further testing of ’hit’ compounds
A selection of ’hit’ compounds which exhibited receptor modulation or inhibition during the
preliminary screening assay was further tested in Xenopus laevis oocytes expressing α1β2ε
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or α3β2γ2 receptors using the two-electrode voltage-clamp technique (Section 2.3). Test
compounds were dissolved in DMSO as 100 mM stock solutions before dilution into frog
Ringer solution. The final solution did not exceed a DMSO level of 0.1 % (v/v), which had
no effect either alone or on GABA-elicited currents (Figure B.1, Appendix B).
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Pharmacological characterisation of the
α3β2ε GABAA receptor subtype
3.1 Introduction
3.1.1 The GABAA receptor ε subunit
The GABAA receptor ε subunit belongs to a minor receptor population with unknown func-
tion (Olsen & Sieghart, 2009). Its expression in the brain is restricted to specific areas, mainly
areas in the forebrain, such as the hypothalamus, as well as nuclei containing major modula-
tory systems of the brain, including cholinergic cell groups (Moragues et al., 2000; Sieghart
& Sperk, 2002). The latter also express the α3 subunit. The ε subunit is clustered together
with the α3 and θ subunits on chromosome Xq28 of the human genome (Wilke et al., 1997)
and it has been shown that these subunits are co-expressed in several areas of the brain (Mo-
ragues et al., 2000; Sieghart & Sperk, 2002). It is therefore likely that they form functional
receptor channels in some brain areas. Heterologous expression studies have shown that the
ε subunit can replace the γ subunit to form functional GABAA receptors, when co-expressed
with α and β subunits (Davies et al., 1997; Whiting et al., 1997). These receptors respond to
a wide range of allosteric modulators, but exhibit unusual characteristics compared to other
known native GABAA receptors, such as increased desensitisation rate, high agonist sensiti-
vity and spontaneous channel opening (see Section 1.2.5.1, Chapter 1; Whiting et al., 1997;
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Neelands et al., 1999).
The subunit compositions of ε-containing receptors in vivo and their precise functions are
largely unknown. Previously, the pharmacological profile of ε-subunit-containing receptors
has been investigated in heterologous expression systems in several different subunit combi-
nations. Nonetheless, despite co-expression of α3 and ε subunits in a number of brain areas,
only one study examined pharmacological properties of recombinant receptors containing
these subunits in conjunction with the β1 subunit (Ranna et al., 2006). However, the β2 su-
bunit is more abundant and the most widely expressed β subunit in the brain. In several areas
of the brain, α3 and ε subunits are co-expressed with β2 subunits, for example in hypotha-
lamus and amygdala (Zhang et al., 1991; Moragues et al., 2000; Pirker et al., 2000; Sieghart
& Sperk, 2002) and it is likely that these subunits may form functional receptors in some of
those areas. In order to learn more about the role of the ε subunit it is, therefore, important
to know the pharmacological profile of α3β2ε receptors.
In this study, pharmacological properties of the α3β2ε receptor subtype were investigated
and compared with α3β2 and α3β2γ2 receptors. The initial plan was to express cDNA
encoding the different subunits in HEK293 cells, which were also used later in the cell-based
screening assay (see Chapters 4 and 5). In this way, not only the pharmacological profile
of this novel subunit combination could be examined, but the correct subunit assembly in
HEK293 cells could be investigated too (which would be advantageous for setting up the
screening assay). However, problems with the electrophysiological rig at Nottingham Trent
University caused a slight change in the project and electrophysiological recordings were
instead performed in Xenopus laevis oocytes microinjected with cRNA in the laboratory of
Dr Ian Mellor at the University of Nottingham.
3.1.2 ε subunit splice variants
As mentioned in Chapter 1 (Section 1.2.2), subunit splicing adds even more complexity and
diversity to the GABAA receptor family. It has been shown, that several of the GABAA
receptor subunits exist in different splice variants, including α2, α4, α5, α6, β2, β3, γ2, γ3
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and ε subunits (Simon et al., 2004). Often, there are two different splice forms, a long and a
short version of the protein, for example the β2 and γ2 subunits exist in both forms. In the
case of the γ2 subunit, the long form exhibits an eighth amino acid insertion into the large
intracellular loop between TM3 and TM4, introducing a site for phosphorylation by protein
kinase C (PKC; Whiting et al., 1990).
The ε subunit gene consists of nine exons (Sinkkonen et al., 2000; Simon et al., 2004) and
several mRNA splice variants have been demonstrated in brain as well as in several other
peripheral tissues. Four splice forms were described by Wilke et al. (1997): (1) the full
length, functional transcript, which is expressed in brain, but also found in heart and spinal
cord, (2) a version where the first three exons are spliced out and (3) a variant like 2, but with
an additional deletion in the centre of exon four; both variants are expressed in peripheral
tissues, but not found in the brain, and (4) a deletion of exon one only. Moreover, Sinkkonen
et al. (2000) described a 483 amino acid long insertion encoding a Pro/Glx motif, which
was identified exclusively in rodents. However, Moragues et al. (2000) identified a rodent
ε version lacking this long insertion, and, therefore, resembling the human sequence to a
greater extent. It was demonstrated that both versions are expressed in the brain as well as
mRNA of a further, truncated version (described below, Figure 3.2; Kasparov et al., 2001).
Davies et al. (2002) investigated the functionality of the long rodent splice variant by expres-
sing it in HEK293 cells. Functional properties as well as the transcripts expression pattern
were examined, but failed to show its incorporation into functional channels. However, since
there was no premature stop codon and the sequence is in frame, it was concluded that there
may be a different function of this long transcript. The splice properties of the ε subunit
are relatively unusual compared to other subunits, since splicing can be introduced at several
different positions. Many of the truncated subunit transcripts are found in several different
tissues, where they may exhibit unknown functions, and, also, several splice variants exist in
the brain.
In this project, the truncated ε subunit version (εT) found in brain (Kasparov et al., 2001)
was generated and functionally examined. This variant possesses a 26 amino acid deletion,
starting in the centre of TM2 until the end of the extracellular loop between TM2 and TM3
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(Figures 3.1 and 3.2). In order to find further clues about the role of this unusual subunit,
it was investigated whether the truncated version forms functional channels in vitro when
co-expressed with the α3 and β2 subunits.
TM1 TM2
Rat ε IVFQNYIPSSVTTMLSWVSFWIKIEAAAARASVGVSSVLTMATLG
Rat εT IVFQNYIPSSVTTMLSWVSFWIKIEAAAARASV............
TM2 TM3
Rat ε TFSRKNFPRVSYLTALDFYIAICFVLCFCTLLEFTV
Rat εT ..............ALDFYIAICFVLCFCTLLEFTV
Figure 3.1: Alignment of the partial rat GABAA receptor ε subunit amino acid sequence
(single-letter code) in the region of TM1 to TM3.
The truncated version (εT; accession number AF255385) shows a 26 amino acid deletion from
the middle of TM2 to the start of TM3, compared to the full length version (accession number
AF255612).
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Figure 3.2: Structure of the ε subunit; amino acid sequence is displayed in single-letter code.
Orange circles represent the 26 amino acid deletion in the truncated subunit version.
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3.2 Results
3.2.1 Agonist sensitivity
α3β2, α3β2ε and α3β2γ2 GABAA receptor subtypes were expressed in Xenopus laevis
oocytes and examined using the two-electrode voltage-clamp technique. To characterise the
pharmacological and biophysical properties of the receptors, they were first examined for
their sensitivity to the agonists GABA and muscimol. In all cases both agonists elicited
concentration-dependent inward currents (see Figure 3.3 for GABA-evoked traces), whereas
no currents were detected upon the application of 1 mM GABA in oocytes expressing α3,
β2, γ2 and ε subunits alone (n = 10 for α3, β2 and ε subunits and n = 16 for γ2 subunits).
It is noteworthy that maximal currents elicited by GABA were relatively small in α3β2ε
receptors compared to α3β2 and α3β2γ2 receptors (Figure 3.3).
GABA GABA GABA
GABA GABA
500 nA
50 sec
GABA
GABA GABA GABA GABA
50 sec
250 nA
GABA
50 sec
500 nA
GABAA
B
C
Figure 3.3: Sample current traces evoked by ascending GABA concentrations in oocytes
expressing α3β2 (A), α3β2ε (B) and α3β2γ2 subunit receptors (C).
Sample currents were elicited by GABA concentrations of 1 µM, 10 µM, 100 µM and 1 mM. The
holding potential was -60 mV.
Concentration-response curves of GABA as well as muscimol for the different receptor sub-
types are depicted in Figures 3.4 and 3.5 and EC50 and Hill slope data obtained are summa-
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rised in Table 3.1. EC50 values differed significantly between the receptor subtypes. α3β2ε
receptors were the most sensitive receptors to both agonists, whereas the α3β2γ2 receptor
subtype was the least sensitive. In addition to the high agonist sensitivity, the α3β2ε receptor
subtype also exhibited a moderate Hill slope for both agonists, whereas Hill slopes for the
other two receptor types were more steep (Table 3.1).
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Figure 3.4: GABA concentration-response
curves for GABAA receptors expressed in
Xenopus laevis oocytes.
GABA concentration-response curves of α3β2
(n = 11), α3β2ε (n = 12) and α3β2γ2 recep-
tor subtypes (n = 10). The data correspond to
means ± SEM; n states the number of oocytes
examined. EC50 values and Hill coefficients are
presented in Table 3.1. Curves were fitted using
a non-linear regression fit with variable slopes
as described in Section 2.3.5.
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Figure 3.5: Muscimol activation of
GABAA receptors expressed in Xenopus
laevis oocytes.
Muscimol concentration-response curves of
α3β2 (n = 6), α3β2ε (n = 6) and α3β2γ2
receptor subtypes (n = 7). Data correspond to
means ± SEM; n represents the number of oo-
cytes tested. EC50 values and Hill coefficients
are presented in Table 3.1. Curves were fitted
using a non-linear regression fit with variable
slopes as described in Section 2.3.5.
Table 3.1: Effects of GABA and muscimol on different GABAA receptor subtypes
GABA Muscimol
EC50 (µM) Hill slope EC50 (µM) Hill slope
α3β2 3.30 ± 1.17 (n = 11) 0.82 ± 0.18 0.53 ± 1.65 (n = 6) 1.24 ± 0.14
α3β2ε 0.23 ± 0.89 (n = 12) 0.44 ± 0.13 0.06 ± 1.02 (n = 6) 0.54 ± 0.06
α3β2γ2 39.57 ± 1.35 (n = 10) 0.77 ± 0.10 2.77 ± 1.37 (n = 7) 1.08 ± 0.18
Data represent mean values (± SEM). EC50 and Hill slope values were obtained by non-linear regres-
sion fit with variable slopes as described in Section 2.3.5. n represents the number of oocytes used per
experiment. GABA EC50 values were significantly different in oocytes expressing α3β2ε (p < 0.001)
and α3β2γ2 receptors (p < 0.0001), when compared with values obtained for α3β2 receptors (un-
paired t-tests). Likewise, muscimol EC50 values differed significantly in oocytes expressing α3β2ε
(p < 0.0001) and α3β2γ2 receptors (p < 0.01; compared to α3β2 receptors).
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3.2.2 Current-voltage relationships
Current-voltage relations for the α3β2, α3β2ε and α3β2γ2 GABAA receptor subtypes were
determined by administrating submaximal GABA concentrations (EC20) at different holding
potentials (ranging from -90 to -10 mV; Figure 3.6). The reversal potential for α3β2 re-
ceptors was -26.95 ± 1.96 mV (n = 5), for α3β2γ2 receptors it was -20.57 ± 0.77 mV
(n = 4) and for α3β2ε receptors -24.53 ± 6.99 mV (n = 6). These values are consistent with
the chloride equilibrium potential in oocytes (approximately -25 mV) and, therefore, provide
confirmation for chloride-ion flux across the membrane upon agonist binding (Dascal, 1987).
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Figure 3.6: Current-voltage relationships of GABA-induced currents in Xenopus oocytes ex-
pressing α3β2, α3β2ε and α3β2γ2 receptors.
Reversal potentials for α3β2, α3β2ε and α3β2γ2 receptors were -26.95 ± 1.96 mV (n = 5),
-24.53 ± 6.99 mV (n = 6) and -20.57 ± 0.77 mV (n = 4), respectively. Data represent x-axis in-
tercepts ± SEM; n represents the number of oocytes examined. Data were fitted by linear regression
analysis.
3.2.3 Effect of zinc
It is known that zinc ions inhibit GABAA receptor function and are most potent on α- and
β-subunit-containing receptors and least potent on receptors containing α, β and γ subunits
(Draguhn et al., 1990). Receptors containing the ε or δ subunits have been shown to exhi-
bit medium sensitivity to zinc inhibition (Whiting et al., 1997; Krishek et al., 1998). Thus,
zinc can be used as a marker for subunit co-assembly (i.e. relative insensitivity to zinc in-
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dicates the existence of the γ subunit in the receptor complex). To verify correct subunit
co-assembling, increasing concentrations of zinc with submaximal GABA concentrations
(EC20) were applied to Xenopus oocytes expressing α3β2, α3β2ε or α3β2γ2 receptor sub-
types. GABA-induced currents in the receptor subtypes examined were inhibited with dis-
tinct potency by zinc (Figure 3.7). GABAA receptors containing the α3β2 subunits were
most sensitive to zinc inhibition with an IC50 value of 0.51 ± 1.18 µM (n = 7). Oocytes
expressing α3β2ε receptors were about 90 times less sensitive to the action of zinc and ex-
hibited an IC50 of 46.67 ± 1.08 µM (n = 8; p < 0.01, unpaired t-test). Receptors containing
the α3β2γ2 subunits were least sensitive to zinc. Their IC50 was 587.49 ± 1.17 µM (n = 7;
p < 0.01, compared with α3β2, unpaired t-test).
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Figure 3.7: Zinc concentration-response curves for GABAA receptors expressed in Xenopus
laevis oocytes.
Concentration-response curves for the inhibition of GABA (EC20 concentration) by zinc in oocytes
expressing α3β2 (n = 7), α3β2ε (n = 8) and α3β2γ2 receptor subtypes (n = 7). Currents were
normalised to the maximal response induced by GABA. IC50 values are specified in the text (Section
3.2.3). Data correspond to means ± SEM; n represents the number of oocytes examined. Curves
were fitted using a non-linear regression fit with variable slopes as described in Section 2.3.5.
3.2.4 Application of the benzodiazepine flunitrazepam
In order to gain further confirmation for the correct subunit co-assembling, modulation by the
benzodiazepine flunitrazepam was tested in oocytes expressing α3β2γ2 and α3β2ε receptor
subtypes, respectively. It is known that the benzodiazepine binding site consists of residues
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from both α and γ subunits (Pritchett et al., 1989b) and ε-subunit-containing receptors are
insensitive to benzodiazepines (Whiting et al., 1997). Currents evoked by GABA (EC20)
were enhanced with 1 µM flunitrazepam by 68.5 ± 10.01 % (compared to GABA alone)
in oocytes expressing α3β2γ2 receptors (n = 4). This positive receptor modulation further
verified presence and assembly of the γ subunit into the receptor complex. In contrast,
α3β2ε receptors showed no response to 1 µM flunitrazepam administration (97.26± 2.33 %
of GABA control response, n = 6, p < 0.0001; see Figure 3.8).
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Figure 3.8: Effect of flunitrazepam on GABAA receptors expressed in Xenopus laevis oo-
cytes.
Oocytes expressing α3β2γ2 receptors were positively modulated by 1 µM flunitrazepam
(168.5 ± 10.01 % of GABA control response, n = 4); data were determined by application of GABA
(EC20) alone (control) or co-administered with 1 µM flunitrazepam. In contrast, flunitrazepam did
not affect GABA-control currents in oocytes expressing the α3β2ε receptor subtype (97.26± 2.33 %
of control response, n = 6). Currents were normalised to the maximal response induced by GABA at
EC20 concentrations. Columns represent mean values (± SEM). *** indicates a significant difference
between the two receptor subtypes (p < 0.0001).
3.2.5 Constitutive activity of the α3β2ε GABAA receptor subtype
Previous studies have shown that ε-subunit-containing receptors exhibit spontaneous acti-
vity in the absence of GABA (Neelands et al., 1999; Davies et al., 2001; Maksay et al.,
2003; Wagner et al., 2005). It was also noticed that those receptors required an unusually
large holding current to clamp the cells at a specific voltage. The latter was also evident in
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this study and it was tested whether α3β2ε receptors also exhibit constititive receptor ac-
tivity. Administration of 100 µM picrotoxin to oocytes expressing α3β2ε receptors caused
clear “outward” currents of 21.49± 1.98 % (of total response capacity (maximal GABA res-
ponse + response to picrotoxin = 100 %), n = 8; Figure 3.9 B), indicating agonist-independent
receptor activity. In contrast, picrotoxin had only a marginal effect on oocytes expressing α3
and β2 subunits (n = 5; Figure 3.9 A). Furthermore, it was evident throughout all experi-
ments that oocytes expressing α3β2ε receptors exhibited large baseline (leak) currents when
clamped at -60 mV.
GABA PTX
200 nA
25 sec
100 %
21.49 ± 1.98 %
GABA PTX
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B
Figure 3.9: Representative current traces evoked by 1 µM GABA and 100 µM picrotoxin
in oocytes expressing α3β2 subunits (A) and by 1 mM GABA and 100 µM picrotoxin in
oocytes expressing α3β2ε receptor subtypes (B).
3.2.6 Effect of etomidate on α3β2ε GABAA receptors
Anaesthetics, such as etomidate, exhibit potentiation and at high concentrations direct acti-
vation of GABAA receptors (Thompson et al., 1996; Pistis et al., 1997). The receptor mo-
dulation has been shown to be dependent on the type of β subunit expressed in the receptor
71
Chapter 3. Characterisation of the α3β2ε GABAA receptor
subtype (Hill-Venning et al., 1997). Here, the influence of the presence of the ε subunit in
the α3β2 receptor complex was investigated in view of modulation and direct activation by
etomidate. Data were compared with those obtained for the α3β2 receptor subtype. Eto-
midate enhanced GABA-elicited currents (EC20) in oocytes expressing the latter by up to
402.1 ± 77.27 % (n = 8; Figure 3.10 A and C). In contrast, the level of etomidate efficacy
was greater in oocytes expressing the α3β2ε receptors (up to 917.3± 83.45 %; n = 7; Figure
3.10 B and C). However, α3β2ε receptors were significantly less sensitive to etomidate (EC50
13.34 ± 1.18 µM; p < 0.0001) compared to α3β2 receptors (EC50 1.71 ± 0.31 µM). Both
receptor subtypes were also activated in the absence of GABA by 100 µM etomidate alone.
Oocytes expressing the α3β2ε receptor showed a greater level of activation (651.5± 57.35 %
of GABA control response (EC20), n = 6) compared to α3β2 receptors (146.7 ± 1.24 % of
GABA control response, n = 3; Figure 3.10 D).
72
Chapter 3. Characterisation of the α3β2ε GABAA receptor
α3β2ε α3β2
0
200
400
600
800 ***______________
%
 o
f  c
o n
t r
o l
 G
A B
A  
r e
s p
o n
s e
-8 -7 -6 -5 -4 -3
0
200
400
600
800
1000
α3β2ε
α3β2
100
log [Etomidate, M]
%
 G
A B
A  
c o
n t
r o
l  r
e s
p o
n s
e
1000 nA
200 sec
α3β2
GABA
Etomidate 0.1 1 10 30 100
1000 nA
200 sec
α3β2ε
GABA
Etomidate 1 3 10 30 100
C DA B
C D
Figure 3.10: Effect of etomidate on oocytes expressing α3β2 and α3β2ε receptor subtypes,
respectively.
(A) and (B) Current traces evoked by application of GABA (EC20) alone or with successive concen-
trations of etomidate (in µM) in oocytes expressing the α3β2 (A) and α3β2ε receptor subtypes (B).
Horizontal bars represent drug application. (C) Etomidate concentration-response relationships were
determined by administering increasing concentrations of etomidate with GABA (EC20). Application
of GABA at EC20 concentrations alone served as control (set to 100 %). Datapoints are means ±
SEM (n = 8 for α3β2 and n = 7 for α3β2ε). Curves were fitted using a non-linear regression fit
with variable slopes as described in Section 2.3.5. Currents were normalised to the maximal response
induced by GABA at EC20 concentrations. EC50 values are specified in the text (Section 3.2.6); n
represents the number of oocytes examined. (D) Columns represent mean direct activation of the re-
ceptors by 100 µM etomidate (± SEM; α3β2 receptor activation: 146.7 ± 1.24 % of GABA control
response, n = 3; α3β2ε receptor activation: 651.5 ± 57.35 % of GABA control response, n = 6).
Currents were normalised to the maximal response induced by GABA at EC20 concentrations. ***
indicates a significant difference between the two receptor subtypes (p < 0.001).
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3.2.7 Expression of a truncated ε splice variant
Recently, Kasparov et al. (2001) described a truncated ε subunit version (εT) expressed in the
rat brain that exhibits a 26 amino acid deletion starting in the middle of TM2 of the subunit.
The εT subunit was generated using site-directed mutagenesis and co-expressed with α3 and
β2 subunits in Xenopus laevis oocytes, in order to investigate, whether the εT subunit could
form functional channels with α3 and β2 subunits in vitro. Initially, GABA concentration-
response relations were investigated (see Figure 3.11 A). EC50 values for α3β2εT receptors
were 6.48± 0.98 µM (Hill slope: 0.7± 0.24, n = 6). These results were very similar to results
obtained for the α3β2 receptor (EC50: 3.30 ± 1.17 µM, p = 0.07; see Section 3.2.1). Fur-
thermore, the concentration-response curves to zinc inhibition for these two receptor types
were also greatly similar (IC50 0.78 ± 0.84 µM, n= 7, p = 0.33, compared to results obtained
for α3β2 receptors; Figure 3.11 B). These findings suggest that the εT subunit examined
here was probably not incorporated into functional channels in Xenopus laevis oocytes and
channels expressed consisted solely of α3β2 receptors.
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Figure 3.11: Concentration-response curves for GABA activation and zinc inhibition in oo-
cytes expressing α3β2εT receptor subtypes.
(A) GABA concentration-response curves of α3β2 (n = 11), α3β2ε (n = 12), α3β2γ2 (n = 10) and
α3β2εT receptor subtypes (n = 6). EC50 values are specified in the text (Sections 3.2.1 and 3.2.7).
(B) Concentration-response curves for the inhibition of an EC20 concentration of GABA by zinc in
oocytes expressing α3β2 (n = 7), α3β2ε (n = 8), α3β2γ2 (n = 7) and α3β2εT receptor subtypes
(n = 7). Currents were normalised to the maximal response induced by GABA at EC20 concentra-
tions; IC50 values are specified in the text (Sections 3.2.3 and 3.2.7). Data correspond to means ±
SEM; n represents the number of oocytes examined. Curves were fitted using a non-linear regression
fit with variable slopes as described in Section 2.3.5.
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3.3 Discussion
3.3.1 Pharmacological characteristics of the ε subunit
The GABAA receptor ε subunit represents a minor subunit population with restricted ex-
pression pattern in the brain. There have been only a few studies investigating the func-
tions and characteristics of recombinant and native receptors, and the exact role, receptor
subtype structure, and assembling characteristics remain widely unknown. In this study,
co-expression of the ε subunit with the α3 subunit (both genes are clustered on the Xq28
chromosome; Wilke et al., 1997) and the β2 subunit, which is the most widespread β subunit
in the brain (Olsen & Sieghart, 2008), were examined. It is likely that α3 and β2 subunits
form functional receptors with the ε subunit in some areas of the brain. The data obtai-
ned emphasise that the inclusion of the ε subunit into the α3β2 GABAA receptor complex
confers distinct pharmacological properties to the receptor which also differ significantly
from properties of α3β2γ2 receptors.
The inclusion of the ε subunit conferred high GABA sensitivity to the α3β2 receptor subtype
and results obtained were consistent with results seen in previous studies by Neelands et al.
(1999) and Whiting et al. (1997), although in these latter studies the α1 instead of the α3
subunit was expressed with the ε and β3 or β1 subunits, respectively. In contrast, Ranna
et al. (2006) expressed α3β1ε receptor subtypes and reported a reduced sensitivity to GABA
compared to α1- and ε-subunit-containing receptors (Whiting et al., 1997; Neelands et al.,
1999). A study by Ebert et al. (1994) demonstrated reduced GABA sensitivity in α3β1γ2
receptors, compared to α3β2γ2 receptors and it was shown that both α and β subunits are
able to contribute to the affinity to GABA (Ebert et al., 1994; Ducic et al., 1995). This
could explain the differences observed in this study compared to the work by Ranna et al.
(2006). Muscimol is a structural GABA analogue found in the mushroom Amanita muscaria
(Snodgrass, 1978) and its potency is known to be higher when compared to GABA (Harris
et al., 1997). Consistent with this, in this study, all receptor subtypes expressed showed
higher sensitivity to muscimol compared to GABA. Again, ε-containing receptors were the
most potent subtype to the agonist.
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The Hill coefficients of GABA and muscimol agonist curves measured in oocytes expressing
α3β2ε receptors were lower when compared to Hill slopes of α3β2 and α3β2γ2 receptors.
This was also reported previously by Maksay et al. (2003) and Whiting et al. (1997). The rea-
son for this is not known. In contrast to αβ or αβγ receptors, which usually need binding of
two agonist molecules to sufficiently open the receptor channel, ε-subunit-containing recep-
tors may have only one agonist binding site, as described above (Section 1.2.5.1, Chapter 1;
Jones & Henderson, 2007; Bollan et al., 2008). The low Hill coefficient seen in ε-containing
receptors would support the hypothesis of one agonist binding site in ε-containing receptors,
because the Hill slope reflects the minimal number of interacting binding sites in positively
cooperating reactions (Abeliovich, 2005). However, an additional explanation could be that
the lower Hill slopes are partly due to the increased desensitisation rate seen in ε-subunit-
containing receptors, since desensitisation also influences the Hill coefficient (Celentano &
Wong, 1994; Dominguez-Perrot et al., 1996; Whiting et al., 1997).
Zinc inhibition has been suggested to be a good marker for correct GABAA receptor assem-
bly, as GABAA receptors containing α and β subunits are highly sensitive to zinc inhibition,
whereas receptors which include the γ subunit are less affected by the action of zinc (Dra-
guhn et al., 1990). Receptors containing the δ or ε subunit have been shown to exhibit
medium sensitivity to zinc inhibition. The results obtained here were in consent with this in-
formation. IC50 values for all three receptor subtypes were similar to the results obtained by
Neelands et al. (1999) and Whiting et al. (1997) and indicated correct subunit co-assembling
of the three receptor subtypes by showing significant differences in sensitivity to zinc inhi-
bition.
It is well known that the presence of the γ subunit within the GABAA receptor complex is
needed for benzodiazepine binding to the receptor and recombinant receptors, substituting
the γ with the ε subunit, have been shown to be insensitive to benzodiazepine modulation
(Davies et al., 1997; Whiting et al., 1997). Here, the benzodiazepine flunitrazepam was ap-
plied to further test the correct assembly of α3β2ε and α3β2γ2 receptors. As expected,
GABA-induced currents in α3β2γ2 receptors were potentiated by 1 µM flunitrazepam, whe-
reas the current measured in oocytes expressing the α3β2ε receptor remained unchanged to
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the GABA-evoked control response. Although there is a lack of a benzodiazepine binding
site in ε-containing receptors, there may be a similar modulatory site for a yet unknown
compound at the interface of ε and α subunits.
Sensitivity of GABAA receptors to the intravenous anaesthetic etomidate is known to be de-
pendent on the β subunit expressed in the receptor subtype, with β2 and β3 subunits being
highly sensitive to etomidate potentiation compared to the β1 subunit, which is least sensi-
tive (Belelli et al., 1997; Hill-Venning et al., 1997). Etomidate potentiates GABAA receptors
at lower concentrations as well as directly activates receptors at high concentrations. It was
shown that the ε subunit confers distinct pharmacological properties in response to etomi-
date when incorporated into the α3β2 GABAA receptor. Currents evoked by submaximal
GABA concentrations (EC20) were enhanced to a greater level in α3β2ε receptors compa-
red to α3β2 receptors. However, inclusion of the ε subunit into the α3β2 receptor complex
resulted in an approximately eightfold higher EC50 value compared to the α3β2 receptor.
Previous studies had also shown that including a third subunit, γ or ε, into the αβ receptor
complex reduces the potency of certain anaesthetic agents (Thompson et al., 1998). Etomi-
date at high concentrations triggered a GABA-mimetic effect in both receptor subtypes. The
potentiation of the GABA-control response, however, was greater in α3β2ε receptors com-
pared to α3β2 receptors. Previous studies by Thompson et al. (1998) demonstrated a greater
level of potentiation in α1β2 compared to α1β2ε receptors. The reason for this difference is
not clear, since the β subunit is the major determinant of sensitivity to the modulating effects
of etomidate (Hill-Venning et al., 1997). Nevertheless, Hill-Venning et al. (1997) showed
that α3-subunit-containing receptors can contribute to differences in maximal potentiation
by etomidate compared to other α subunits, and Ranna et al. (2006) and Thompson et al.
(1998) demonstrated that the inclusion of the ε subunit into αβ1 receptors can have some in-
fluencing effects on GABA-mimetic properties. It was shown that direct receptor activation
by etomidate is normally minimal or absent in receptors containing the β1 subunit. However,
inclusion of the ε into the receptor complex resulted in small direct effects.
As also seen in previous recombinant expression studies, receptors containing the ε subunit
exhibited spontaneous receptor activity (Whiting et al., 1997; Neelands et al., 1999; Maksay
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et al., 2003). The level of spontaneous activity in α3β2ε receptors was similar to the results
obtained by Mortensen et al. (2003) expressing α1β3ε receptors in Xenopus oocytes. Fur-
thermore, a large holding current was required to sustain a potential of -60 mV in Xenopus
laevis oocytes, which was not seen in the other receptor combinations investigated, indica-
tive for constitutive receptor activity (Neelands et al., 1999; Maksay et al., 2003). This was
confirmed when applying picrotoxin, a channel blocking agent, to oocytes expressing the re-
ceptor, resulting in “outward” currents, which demonstrated the blockade of spontaneously
open channels (Maksay et al., 2003). Several amino acids located in the channel-lining TM2
are involved in chloride conduction, sensitivity to channel blockers and channel gating of
GABAA receptors and the related nAChRs (Filatov & White, 1995; Labarca et al., 1995;
Scheller & Forman, 2002). Different mutations of amino acids in the TM2 have identified
several residues that increase unliganded openings of the receptors and play a role in channel
gating, for example the 9’ leucine residue. Another residue critical for channel gating is the
15’ serine residue. Mutations of the latter amino acid residue have been shown to influence
channel gating and spontaneous receptor activity in β1, α1 and α2 GABAA receptor subunits
(Findlay et al., 2001; Scheller & Forman, 2002; Miko et al., 2004). The ε subunit is the only
GABAA receptor subunit with a glycine residue at this position. Point mutations of the 15’
serine in β1 subunits to glycine or tryptophan increased spontaneous currents blocked by
picrotoxin (Findlay et al., 2001; Miko et al., 2004). Therefore, it is likely that the presence
of the glycine residue at this position entails constitutive receptor activity in ε-containing
receptors (Wagner et al., 2005). As mentioned before, whether or not native ε-containing
receptors exhibit constitutive activity is still not clear, and functional implications of such a
receptor type in vivo would depend on many factors, such as the location of the receptor.
It is important to verify the correct receptor assembly, because it is known that α3β2γ2
receptors can sometimes assemble as a mixture of α3β2 and α3β2γ2 receptors (Boileau
et al., 2002, 2003). However, Jones & Henderson (2007) showed by applying zinc with
high GABA concentrations that the majority of receptors formed by α, β and ε subunits
consisted of all three subunits at a transfection ratio of 1:1:1 and αβ receptors are mostly
absent. To verify correct subunit co-assembling, it was shown that α3β2γ2 receptors were
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relatively insensitive to zinc and GABA-control responses were enhanced by application of
flunitrazepam. α3β2ε receptors were also assembled correctly, which was demonstrated
by medium zinc sensitivity, an outward current after the application of the channel blocker
picrotoxin, a high leak current when voltage clamped at -60 mV and relatively small GABA-
evoked currents compared to currents obtained from other receptor subtypes.
3.3.2 Investigation of a truncated ε subunit variant
Several previous studies reported a number of different splice variants seen in the human and
rodent ε subunit (Whiting et al., 1997; Sinkkonen et al., 2000; Kasparov et al., 2001). In
rodent brain, an appropriate spliced mRNA, a large version, including a Pro/Glx motif, and
a truncated version have been described. The latter exhibits a 26 amino acid deletion in the
second putative TM domain. Since such a deletion would have a major impact on receptor
structure and function, and the role of the ε subunit is still not understood, it was investigated
whether the truncated version would form functional receptors with the α3 and β2 subunit
in Xenopus laevis oocytes. GABA concentration-response relationships were very similar
to the ones seen in α3β2 receptors. The same applied to the inhibition of the receptor by
zinc. These results suggested that the truncated subunit is not incorporated into the receptor,
which does not seem to come as a surprise, due to the fact that amino acids of the TM2
and the entire extracellular loop between TM2 and TM3 are missing. Those amino acids
have been shown to be important for channel pore formation (TM2) and channel gating upon
agonist binding (extracellular loop between TM2 and TM3). Therefore, a deletion would
have a major impact on receptor structure and function (Smith & Olsen, 1995; Kash et al.,
2004). Furthermore, a recently published study by Pape et al. (2009) showed Western blot
analysis of ε subunit expression in the spinal cord and hypothalamus of twelve days old rats.
The results revealed a 70 kDa band (appropriate spliced ε subunit) and a large ε subunit
version of 120 kDa (the large version described by Moragues et al. (2000)), but no band
which would correspond to the truncated version. These findings indicate that the truncated
version is not translated into proteins in these brain regions, which would support our results.
Although a number of ε splice variants have been investigated, none of the splice forms have
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been shown to be incorporated into functional receptors in vitro or in vivo up until now.
3.3.3 Summary
In summary, the rat GABAA receptor ε subunit as well as a truncated ε splice version together
with the α3 and β2 subunits were co-expressed in Xenopus laevis oocytes and pharmacolo-
gical properties of α3β2ε receptors were examined. This subunit combination has not been
investigated previously, but it is likely that α3β2ε receptors exist in certain areas of the brain
in vivo. Data obtained revealed that the α3β2ε receptor exhibits unusual pharmacological
characteristics, previously described in other ε-subunit-containing receptor subtypes. Fur-
thermore, it was shown that receptors were enhanced to a greater level by the anaesthetic
etomidate compared to α3β2 receptors. However, as stated previously, inclusion of a third
subunit into the αβ receptor complex also lowered etomidate potency in α3β2ε receptors.
So far, no subunit-selective pharmacology could be recognised. Nevertheless, the ε subunit
may represent an important pharmaceutical target for future drug development and further
research is needed to uncover the promiscuous role of this subunit. It was also shown that
the truncated ε splice variant was not included into functional α3β2 receptor channels in
Xenopus laevis oocytes.
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Development of an assay to screen
compound libraries
4.1 Introduction
The structural diversity of GABAA receptors and the plethora of drug binding sites make
them attractive targets for drug discovery, especially since it was demonstrated that the va-
rious subunits regulate different drug effects (Section 1.2.4, Chapter 1; Möhler, 2006). Al-
though several studies have been conducted in order to identify the pharmacological profile
of ε-subunit-containing receptors, no subunit-specific pharmacology could be identified (Da-
vies et al., 1997; Whiting et al., 1997; Thompson et al., 1998; Neelands et al., 1999; Maksay
et al., 2003; Ranna et al., 2006). However, these receptors possibly have specific modulatory
binding sites which may be important for future drug development. The next aim of this pro-
ject was to set up a cell-based system to screen the ε-containing receptor against compounds
from a commercially available library and, with luck, to identify compounds that modulate
this specific GABAA receptor subtype.
As described in Section 1.3, Chapter 1, screening ion channels for modulating compounds is
a challenging research area, however, several assay technologies are available. Electrophy-
siological recordings are the gold standard method to measure ion channel function (Smith
& Simpson, 2003; Verkman & Galietta, 2009). However, they are very labour intensive
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and, hence, time consuming. Therefore, in the majority of studies the primary screening for
compounds is performed via high throughput assays to detect lead compounds. Many scree-
ning methods require specialised measurement devices, such as voltage/ion probe readers,
FLIPRs or scintillation counters and only few can be set up easily and at low costs using
commercially available measuring devices. In this project, a suitable method was sought to
screen ε-subunit-containing GABAA receptors for novel modulatory compounds. Such com-
pounds are thought to be important to uncover the role of the GABAA receptor ε subunit and
they may even act as future drugs on these receptor subtypes. The assay technologies applied
in this study were first set up using α3β2 or α3β2γ2 receptors before testing constitutively
open ε subunit receptors, which may add some additional challenges to the setup.
4.1.1 Clomeleon
GFP was originally isolated from jellyfish (Aequorea victoria) and has been used extensively
in the field of molecular biology as a fluorescence probe (Tsien, 1998; Wachter et al., 1998).
YFP, a derivative of GFP, exhibits enhanced brightness and a longer wavelength compared
to other GFP variants. It is the only fluorescent protein that can be quenched by small anions
and, thus, it can be used as a chloride-ion indicator (Wachter & Remington, 1999; Jayara-
man et al., 2000). Kuner & Augustine (2000) have constructed a FRET-based, ratiometric,
genetically-encoded chloride-ion indicator protein termed Clomeleon. It was generated by
linking a CFP, which is insensitive to chloride, to a YFP using a flexible recombinant To-
bacco Etch Virus (rTEV) protease peptide linker. In the absence or at low concentrations of
chloride in the cell, upon excitation of the CFP, Clomeleon emits energy to the YFP, which
can be measured at ~530 nm (Figure 4.1 A). At rising concentrations of chloride (e.g. upon
GABAA receptor activation), chloride binds to the YFP. This changes its absorption coeffi-
cient and leads to a reduction of the FRET efficacy and increased CFP emission that can be
measured at 485 nm (Figure 4.1 B, C). The ratio of fluorescence emission of the YFP to that
of the CFP is chloride concentration dependent.
Clomeleon has been shown to be a good indicator of intracellular chloride concentrations
in living cells, for example neurons, as well as in transgenic mice, where it was used to
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Figure 4.1: Clomeleon is a FRET-based chloride-indicator protein consisting of two distinct
fluorescence proteins.
(A) At no or low concentrations of chloride, the excited CFP (donor) transfers most of its energy
to the linked YFP (acceptor). (B) If chloride (depicted as orange circle) binds to the YFP, FRET
efficiency is reduced leading to increased CFP emission. (C) Emission spectrum of Clomeleon in the
presence of different concentrations of chloride ions (in mM; from Kuner & Augustine, 2000).
83
Chapter 4. Assay development
monitor chloride distribution and concentration changes (Kuner & Augustine, 2000; Haver-
kamp et al., 2005; Duebel et al., 2006; Berglund et al., 2008). It was also applied to measure
chloride shifts after GABAA receptor activation in cultured hippocampal neurons (Kuner &
Augustine, 2000). However, it has not been used in compound screening assays before. Clo-
meleon has several advantages over other chloride indicators: it has a good signal-to-noise
ratio, cannot be influenced by other physiologically important anions, it can be easily loaded
into cells via transfection methods, its fluorescence is very stable and it can be targeted to
specific locations/cells (Kuner & Augustine, 2000; Bregestovski et al., 2009). Its relative
large size (~59 kDa) prevents diffusion from the cell and it is possible to determine abso-
lute chloride concentration changes. However, there are several disadvantages, including its
sensitivity to pH changes, the slow response kinetics and low chloride affinity as well as the
different bleaching of the CFP and YFP. This could lead to an overestimation of the chlo-
ride concentration and, thus, careful setup and optimisation are important for a successful
application.
In this study, it was examined whether Clomeleon can be used in a cell-based screening assay
by expressing it together with GABAA receptors in HEK293 cells. The cells were seeded into
96-well microtitre plates and it was tested whether GABAA receptor activation would result
in a fluorescence shift from 530 to 485 nm by comparing the baseline fluorescence before
adding the receptor agonist with the fluorescence signal afterwards. If GABA application
could elicit a change of the fluorescence signal, the compound screening assay could be
optimised.
4.1.2 Iodide-flux method
Chloride ion channels are not only permeable to chloride, but also to other small anions, na-
mely NO3-, Br-, I-, HCO3-, SCN- and small organic acids (Tang & Wildey, 2004; Verkman &
Galietta, 2009). However, chloride is the most abundant anion in biological systems, hence,
the name chloride channels. Anions can pass through the channels in either direction (influx
or efflux) according to the electrochemical driving force. Movement of ions can be directly
quantified using ion flux assays, which can be used to characterise ion channel functions.
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Flux assays often employ radiolabelled tracers, such as 36Cl- or 125I-. Ion channels are acti-
vated in the presence of a known concentration of tracer ions and ion flux through the opened
channels takes place. Subsequently, the medium is moved to a new plate, cells are lysed and
radioactive tracer concentration in both cell lysate and medium, are measured. Receptor ac-
tivity, inhibition or modulation can be detected by determining the ratio of intracellular to
extracellular radioactivity. The signal strength is dependent on tracer ion concentration and
the number of cells (Gill et al., 2003). Screening assays using radiolabelled tracer molecules
are robust, easy to perform and provide data with high sensitivity. However, there are some
major concerns with this method. The application of radioactive tracers raises safety issues
and also implies relatively high costs of the material and the special requirements for its
disposal.
In this project a non-radioactive, colorimetric iodide-flux assay was tested, where iodide acts
as the indicator of chloride channel activity (Tang & Wildey, 2004, 2006). The assay was
derived from the Sandell-Kolthoff (SK) reaction (Sandell & Kolthoff, 1937; Tang & Wildey,
2004):
Ce4+(yellow) + As3+
I-→ Ce3+(colourless) + As4+ (4.1)
The principle of the reaction is that the iodide catalyses the conversion of yellow-coloured
cerium ions (Ce4+) to colourless Ce3+ by arsenic III acids. The remaining Ce4+ in the sample
can be detected by reading the absorbance at a wavelength of 405 nm. The OD405 readings
enable to draw conclusions to the intra- and extracellular iodide concentrations and, thus, ion
flux upon receptor activation (Figure 4.2).
The colorimetric ion flux technology has the advantages of lower costs and improved sa-
fety. Furthermore, the method does not require a confluent cell monolayer and already small
concentrations of iodide can be detected due to the low intracellular concentration (Tang
& Wildey, 2004). Since test compounds are removed from the cells after incubation, there
is also the benefit that they cannot interfere with the assay readout of the lysed cells, a
problem that commonly leads to false positive results in other screening formats, such as
fluorescence-based methods. However, flux assays have certain disadvantages, including
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Figure 4.2: Assay principle of the colorimetric iodide-flux assay.
(A) Iodide-loaded cells in iodide-free solution. (B) Channels open upon agonist binding and iodide
exerts into extracellular solution due to electrochemical gradient (adapted from Lynch, 2005)
low temporal resolution, the long cell-loading incubation times, low informational content,
reduced reproducibility and a high signal-to-noise ratio that is influenced by the channel
expression levels (Xu et al., 2001; Gill et al., 2003). A further drawback of the assay is the
relative short stability of the sample-buffer mixture making a fast reading and optimal timing
necessary. The high signal-to-noise ratio is presumably the reason why the assays Z’-factor
obtained by Tang & Wildey (2004) was relatively low (0.42), which indicates a small signal
detection window (Zhang et al., 1999). The Z’-factor provides a mean to assess the quality
and optimisation of an assay in regard to the assay’s signal dynamic range as well as data
variation (Zhang et al., 1999). Z’-factors between 1 and 0.5 represent an assay with excellent
quality, whereas smaller values indicate a smaller signal separation between the positive and
negative controls. Values near zero or negative Z’-factors indicate that the assay was either
not optimised or that a robust setup is not achievable in this format.
In this project, the iodide-flux assay was performed and optimised by expressing α3β2γ2
GABAA receptors in HEK293 cells, which were seeded into 96-well plates. Cells were loa-
ded prior to the assay with iodide. Receptors were activated and iodide efflux from the cells
was determined by performing the SK assay with both, cell lysates and supernatants. By
assessing the OD405 readings, the iodide concentration in the samples, which gives infor-
mation on the receptor activity, could be determined (Tang & Wildey, 2004; Lynch, 2005).
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4.1.3 YFP-based assays
As displayed below, the attempted assays described before were not suitable for screening
of GABAA receptors transiently expressed in HEK293 cells. Therefore, a further method
was examined applying a YFP-based assay format. This assay was similar to the first as-
say examined, applying the chloride-indicator protein Clomeleon (Section 4.1.1), as it was
based on the halide sensitivity of YFPs. However, the assay used a single fluorophore with
increased sensitivity to halides that could be used to detect anionic influx into a cell using a
fluorescence plate reader (Kruger et al., 2005).
Due to the fact that YFP has a low sensitivity to chloride, YFP variants were constructed,
among others the YFP-H148Q (Wachter & Remington, 1999). This mutant version showed
an improved sensitivity to chloride (Kd 100 mM; Kd represents the anion concentration at
a half-maximal YFP quench) as well as iodide (Kd 21 mM; Jayaraman et al., 2000). Io-
dide does not occur naturally in cells and can be toxic at high concentrations. In order to
prevent such effects, solutions applied to cells should contain low iodide concentrations.
Hence, sensitivities for chloride and iodide of YFP-H148Q were still too low and YFPs with
enhanced properties were sought. Galietta et al. (2001a) generated random mutations of
certain amino acid residues at the halide binding site. This approach identified several mu-
tant YFP variants that showed improved halide sensitivity. The mutant version YFP-H148Q/
I152L exhibited a very high iodide affinity (Kd 3 mM) as well as improved chloride sensiti-
vity (Kd 88 mM). Performing assays with iodide rather than chloride has the advantage that
anion co-transporters or exchangers, for example NKCC (Na+-K+-Cl- co-transporter) or AE1
(anion exchanger 1), transport iodide less efficiently than chloride (Galietta et al., 2001b).
In this project, the YFP mutant version YFP-H148Q/I152L was used as a chloride-indicator
protein in a cell-based screening assay as described by Kruger et al. (2005). It was shown
that YFP-H148Q/I152L is suitable for screening assays by permitting detection of fluores-
cence signal changes upon GABAA receptor activation. This is because, in a medium that
contains a high concentrations of iodide, activation of the GABAA receptor will result in a
reduction of intracellular fluorescence as iodide enters the cell, which can be measured using
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a fluorescence plate reader (Figure 4.3).
Iodide.GABAA receptor; GABA;/       mutant YFP;
intracellular
extracellularA B
Figure 4.3: Schematic diagram showing the principle of the YFP-H148Q/I152L screening
assay.
(A) Cells co-expressing the mutant YFP-H148Q/I152L and GABAA receptors were present in an
iodide-containing solution. (B) GABA application triggers the channels to open and iodide enters
the cells upon the electrochemical gradient. Subsequently, the YFP-H148Q/I152L inside the cells is
quenched, reducing the fluorescence signal emitted.
This assay format has a range of advantages over other existing methods: (1) it does not
require time-consuming cell loading or washing steps, (2) the YFP mutant version exhibits
excellent optical properties and photostability, (3) it can be excited in the visible range of
light, (4) it is genetically encoded and can be targeted to the required cell type, (5) its kinetics
are faster compared to voltage-sensitive dyes, (6) due to its high molecular weight of 27 kDa,
it is retained in cells and (7) stable expression of the protein(s) of interest is not required
(Galietta et al., 2001b; Bregestovski et al., 2009; Gilbert et al., 2009a). A disadvantage of the
YFP-H148Q/I152L is its relatively slow kinetics (Bregestovski et al., 2009). Nevertheless,
different YFP mutant variants have successfully been used in screening assays of cystic
fibrosis transmembrane conductance regulator protein (CFTR) chloride transport agonists
(Galietta et al., 2001a). Furthermore, it was shown that the mutant YFP is suitable for HTS
of GlyR and GABAA receptors (Kruger et al., 2005; Gilbert et al., 2009b).
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4.2 Results
4.2.1 Evaluating a screening assay using Clomeleon
The chloride-sensitive protein Clomeleon was first scanned for its excitation and emission
spectrum using a spectrofluorometer. This was to test protein functionality, because the
DNA sequence acquired from sequencing differed in one amino acid from the sequence
received from Dr Thomas Kuner. HEK293 cells were transfected with Clomeleon alone or
Clomeleon and α3β2 subunit receptors; untransfected cells served as negative control. Cells
were excited at a wavelength of 440 nm and emission was scanned over a range of 460
to 650 nm. The obtained spectrum showed a large peak at a wavelength of 527 nm and a
smaller peak at 475 nm (Figure 4.4). Control scans with untransfected cells, mammalian
Ringer solution and the cuvette alone resulted in one or two minor peaks in case of the first
two controls, which were of different wavelengths compared to the two large peaks obtained
for Clomeleon (Figure 4.4). An excitation spectrum obtained for wavelengths from 350 to
450 nm, when measuring emission at 527 nm, showed no clear peak, but a gradual increase
of the signal (Figure 4.5). Furthermore, it was tested whether a shift in the fluorescence
signal could be measured by manually adding GABA (100 µM final concentration) to the
cuvette, but no change of the Clomeleon emission could be detected. It was suggested that
receptor activity may be too fast paced to see a change using the equipment.
Excitation and emission scans of Clomeleon were similar to those described by Kuner & Au-
gustine (2000) and the protein was, therefore, further tested in a microtitre screening assay
setup using a fluorescence plate reader. Clomeleon was expressed in HEK293 cells together
with GABAA receptor α3 and β2 subunits. On the day of the assay, baseline fluorescence
was measured for 20 seconds, before adding 10 µl mammalian Ringer solution with GABA
(100 µM final concentration) to each well and further reading the fluorescence signal for
another 30 seconds at either 527 or 480 nm. Readings obtained from the assay setup did not
show the expected fluorescence shift from 527 nm to 480 nm. Instead, there was little or no
change at both wavelengths. Figure 4.6 A represents the normalised gross fluorescence si-
gnals obtained at 527 as well as 480 nm over 30 seconds after addition of the agonist GABA.
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Figure 4.4: Emission scan of the chloride-indicator Clomeleon expressed in HEK293 cells.
Fluorescence signal of cells expressing Clomeleon versus untransfected cells (A) and spectrum of
cells expressing Clomeleon and α3β2 GABAA receptors as well as of mammalian Ringer solution
alone and a cuvette only (B). Dashed lines highlight the two peaks of the fluorescence signal emitted
by Clomeleon.
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Figure 4.5: Excitation spectrum of HEK293 cells expressing Clomeleon and α3β2 GABAA
receptors.
Figure 4.6 B displays the normalised net fluorescence signals after subtracting the signal of
untransfected control cells. Data depicted show a small, non-significant decrease of fluores-
cence signal compared to baseline fluorescence after agonist injection at both wavelengths.
This was most likely an artefact of the assay setup, since the signal at both emission wave-
lengths decreased and no increase could be seen for CFP emission. Altering cell densities
could not improve the measurement’s outcome.
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Figure 4.6: Fluorescence signal of Clomeleon in HEK293 cells also expressing α3β2
GABAA receptors after addition of GABA.
(A) Gross fluorescence signal. (B) Net fluorescence signal. Fluorescence was measured at emission
wavelengths of 527 nm or 480 nm for 30 seconds after injecting GABA (100 µM final concentration).
Data correspond to means ± SEM; n states the number of wells measured. Fluorescence was nor-
malised by setting the averaged baseline fluorescence (BF) to 100 % and fluorescence changes (after
adding GABA) were calculated as percentage of the baseline fluorescence.
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4.2.2 Iodide-flux assay
Due to the fact that the Clomeleon-based assay setup did not provide the required outcome, a
colorimetric iodide-flux screening assay, based on the modified SK method, was tested next.
Tang & Wildey (2004) demonstrated that a modified SK reaction could indicate GABAA
receptor activity in WSS-1 cells by measuring iodide concentration changes after incuba-
tion of iodide-loaded cells with the agonist GABA. In order to determine the assays linear
range and sensitivity, standard curves were established by measuring the OD405 of increa-
sing concentrations of NaI subjected to the SK reaction (Figure 4.7). The linear range of the
assay was estimated from the standard curves in Figure 4.7 B; it was between 300 nM and
3 µM after 15 minutes incubation time and between 100 nM and 1 µM after 30 minutes incu-
bation time, demonstrating a shift towards the left, depending on the assay incubation time.
Further, it was evident that the OD405 readings of the SK reaction decrease with incubation
time (Figure 4.7 B). The assays lowest detection limit after 15 minutes incubation time was
estimated from the standard curve data as described in Section 2.6.2. The OD405control was
2.972 with a SD of 0.030. The determined lowest detection limit was 407 nM (OD405 at
407 nM was 2.88, ∆OD405 was 0.092 and 3SDControl was 0.09; Figure 4.7 A).
After obtaining a standard curve, HEK293 cells were transfected with α3β2γ2 GABAA re-
ceptors and seeded into 96-well microtitre plates. At first it was tested whether it was pos-
sible to measure a GABA concentration-dependent effect performing the assay as described
by Tang & Wildey (2004, 2006). Figure 4.8 and Table 4.1 illustrate the results obtained from
cell lysates subjected to the SK assay. Those did not show a clear GABA concentration-
dependent pattern, but rather random values. The same applied to the % activity of the
receptors which was calculated as described in Section 2.6.2 (Tang & Wildey, 2004). Fur-
thermore, OD405 values of untransfected control cells were expected to be low, due to a high
iodide concentration in the cells, however, the values obtained were relatively high and si-
milar to the data from cells expressing α3β2γ2 receptors. It is worth mentioning that results
shown were not reproducible, but varied widely, despite repeating the assay several times.
The OD405 of the cell supernatant, the DPBS solution containing different agonist concen-
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Figure 4.7: NaI flux assay standard curve. (A) NaI concentrations of 3 µM to 25 nM were
applied to the modified SK method. OD405 was read after 15 minutes incubation time. (B)
The modified SK assay was performed on samples containing different NaI concentrations
(300 µM to 3 nM). OD405 was determined after different incubation times ranging from 10
to 70 minutes. Data were averaged from eight data points ± SEM.
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Figure 4.8: A modified SK assay was used to measure chloride conductivity in HEK293
cells expressing α3β2γ2 GABAA receptors (yellow columns) and untransfected HEK293
cells (white columns).
Before the assay, cells were loaded with iodide-loading buffer and incubated with increasing concen-
trations of GABA as described in the text. OD405 was measured after 15 minutes incubation of SK
reaction. Values were means ± SD from 16 data points from two different microtitre plates. * indi-
cates p < 0.05 compared to highest GABA concentration of 10 mM.
Table 4.1: OD405 readings and analysis of results obtained from modified SK assay in
HEK293 cells expressing α3β2γ2 GABAA receptors.
α3β2γ2 receptors untransfected cells
GABA 0 µM 100 pM 1 nM 10 nM 100 nM 1 µM 10 µM 100 µM 1 mM 10 mM 10 mM 0 µM
OD405 mean 2.387 1.854 2.279 2.303 1.696 1.740 1.904 2.037 1.927 1.857 1.321 1.706
SD 0.464 0.936 0.579 0.575 0.917 0.747 0.907 0.957 0.859 0.691 0.636 1.029
% activity 0.00 100.66 20.28 15.73 130.41 122.06 91.12 65.94 86.84 100.00
Cells were loaded with iodide-loading buffer and incubated with increasing concentrations of GABA
as described in the text. The SK assay was conducted for 15 minutes before determining OD405
readings. Mean values were calculated from 16 data points from two different microtitre plates, %
activity as described in Section 2.6.2.
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trations added to the iodide-loaded cells, was also investigated. After the incubation time,
the supernatant was transferred to a separate plate and further subjected to the SK assay. De-
pending on GABAA receptor activity, the supernatant should contain distinct concentrations
of iodide. Compared to the results obtained from lysed cells, the OD405 readings of the
supernatant were very low throughout, indicating a high extracellular concentration of io-
dide (Figure 4.9 A). Because the assay has a relatively small detection range (see above) and
iodide concentration of supernatant seemed to be very high in all samples, it was examined
whether diluting the supernatants would improve the results. It was therefore transferred to a
new plate after incubation and diluted 1:2 or 1:5. Although the OD405 readings were higher
with increased dilution, the results did again show no concentration-dependent pattern but
seemed arbitrary (Figure 4.9 B, C). Furthermore, supernatants from untransfected control
cells had a relatively low OD, indicating iodide efflux from the cells into the supernatant via
other means than the examined GABAA receptors.
GABA incubation time for iodide-loaded cells was examined by performing a time-response
course in order to establish the optimal time to improve the assay outcome. After washing
the cells, they were incubated with 10 µM GABA in DPBS or DPBS only for 10, 20, 30 or
45 seconds or 1, 2, 3 or 5 minutes. The results obtained from the cell lysate, after performing
the SK assay, are shown in Figure 4.10. OD405 readings for cells treated with GABA or
DPBS were similar and overall relatively high. Figure 4.11 represents OD405 values from
the supernatants (undiluted or diluted) after performing the SK assay. Samples from the
undiluted plate have low OD405 values throughout, indicating a high iodide concentration.
Therefore, samples were diluted in the following tests to be able to distinguish between
different iodide concentrations. Although there were significant differences between GABA
and DPBS treated cells in some cases, results obtained varied on each plate tested (see also
Figures B.3 and B.4, Appendix B). Due to the discrepancies obtained throughout, it was
difficult to decide on an optimal GABA incubation time. Therefore, the incubation time of
five minutes applied by Tang & Wildey (2004) was further applied.
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Figure 4.9: SK assay determining iodide efflux from HEK293 cells expressing α3β2γ2
GABAA receptors (yellow columns) and untransfected HEK293 cells (white columns).
Before the assay, cells were loaded with iodide-loading buffer and incubated with increasing concen-
trations of GABA as described. The solution containing GABA was transferred to a separate plate.
The SK assay was performed on undiluted (A), 1:2 (B) and 1:5 (C) diluted supernatant. After 15
minutes incubation the OD405 was measured. All values were means± SD from eight data points on
one microtitre plate. * indicates p < 0.05, ** = p < 0.01, *** = p < 0.001 compared to highest GABA
concentration of 10 mM.
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Figure 4.10: OD405 values from iodide-flux assay in HEK293 cells expressing α3β2γ2
GABAA receptors. Before performing the SK assay, 10 µM GABA (yellow columns) or
DPBS (white columns) were incubated for ten seconds to five minutes, respectively.
Readings represent data from SK assay from undiluted cell lysate. Values are means ± SD from six
data points each on three microtitre plates. * indicates p < 0.05 comparing GABA-treated cells with
their respective DPBS controls.
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Figure 4.11: Iodide-flux assay. HEK293 cells expressing α3β2γ2 GABAA receptors were exposed to GABA for different incubation times.
Before performing the SK assay, 10 µM GABA in DPBS (yellow columns) or DPBS only (white columns) were incubated for ten seconds to five minutes. DPBS
was transferred to new plates and the SK assay was performed on undiluted supernatant (A), on supernatant diluted 2:3 (B), 1:2 (C) or 1:5 (D). OD405 values
are means ± SD from six data points. * indicates p < 0.05, ** = p < 0.01, *** = p < 0.001 comparing GABA-treated cells with their respective DPBS-incubated
controls.
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In a further attempt, the influence of the cell density was examined. The effect of different
concentrations of GABA at a cell density of 25 × 103 cells per well was compared with its
effect on decreased densities of 17.5 × 103 and 12.5 × 103 cells per well. The SK assay was
performed on lysed cells as well as the undiluted supernatant. The latter showed very low
OD405 readings throughout, indicating a high concentration of iodide (Figure 4.12 B). In
contrast, the readings for the lysed cells differed between different cell densities and GABA
concentrations. In general, the readings had a tendency towards higher values for higher
GABA concentrations, indicating a low iodide concentration inside the cells (Figure 4.12 A),
which would be the desirable assay outcome, but the results obtained were not consistent.
Due to the fact that the data obtained so far did not show well-defined results, it was investi-
gated whether the observed iodide efflux from HEK293 cells was GABA receptor-mediated
by applying bicuculline and picrotoxin to the cells. Bicuculline is a competitive antagonist
of GABAA receptors. Treating the receptors expressed with bicuculline would inhibit the io-
dide flux compared to GABA alone in case of a GABA-mediated response. Exposing cells to
the non-competitive channel blocker picrotoxin would indicate GABAA receptor blockade.
The results showed comparatively high readings for all samples of cell lysate, indicating
low iodide concentration inside the cells (Figure 4.13 A). There were some significant dif-
ferences between the various treatments. However, the values were random, for example
OD405 readings of cells exposed to 1 µM GABA were significantly higher than those of
cells treated with 100 µM, although there should have been lower iodide concentrations in
the latter cells. Readings obtained from the cell supernatant solutions showed low OD405
values for all wells, except for those containing DPBS with GABA and picrotoxin (Figure
4.13 B). The latter exhibited similar OD405 readings to the data obtained for cell lysates,
indicating a low iodide concentration in the cell supernatants, thus blocking iodide efflux
from those cells. Untransfected control cells were treated with GABA alone or GABA and
picrotoxin and showed similar OD405 values as transfected cells. Interestingly, in picrotoxin
treated control cells iodide efflux was also blocked (Figure 4.13 B).
Although optimisation of the iodide-flux assay setup was tested extensively, results varied
and no robust assay setup could be achieved. Since iodide efflux was high in transfected and
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Figure 4.12: SK assay measuring iodide flux in HEK293 cells expressing α3β2γ2 GABAA
receptors. Different cell densities were seeded: 12.5 × 103 cells per well (yellow columns),
17.5 × 103 cells per well (blue columns) and 25 × 103 cells per well (white columns).
Before the assay, cells were loaded with iodide-loading buffer and incubated with increasing concen-
trations of GABA as described. The SK assay was performed on undiluted cell lysate (A) and su-
pernatant (B). After 15 minutes incubation, the OD405 was measured. All values were means ± SD
from eight data points on one microtitre plate. * indicates p < 0.05 and ** = p < 0.01 compared to
highest GABA concentration of 1 mM.
101
Chapter 4. Assay development
DP
BS
M 
GA
BA
µ1 
M 
GA
BA
+5
0 µ
M 
BI
C
µ1 1 µ
M 
GA
BA
+5
0 µ
M 
PT
X
M 
GA
BA
µ
10
0 
M 
GA
BA
+5
0 µ
M 
BI
C
µ
10
0 
M 
GA
BA
+5
0 µ
M 
PT
X
µ
10
0 1 µ
M 
GA
BA
+5
0 µ
M 
PT
X
1 µ
M 
GA
BA
0
1
2
3
4
*** *** ***
*
O
D
40
5
*
A
B
PB
S
M 
GA
BA
µ1 
M 
GA
BA
+5
0 µ
M 
BI
C
µ1 1 µ
M 
GA
BA
+5
0 µ
M 
PT
X
M 
GA
BA
µ
10
0 
M 
GA
BA
+5
0 µ
M 
BI
C
µ
10
0 
M 
GA
BA
+5
0 µ
M 
PT
X
µ
10
0 1 µ
M 
GA
BA
+5
0 µ
M 
PT
X
1 µ
M 
GA
BA
0
1
2
3
*
**
**
***
O
D
40
5
Figure 4.13: OD405 readings of SK assay after applying GABA, bicuculline and picrotoxin
to HEK293 cells expressing α3β2γ2 GABAA receptors.
Cells were loaded with iodide-loading buffer and subsequently incubated with 50 µM bicuculline or
50 µM picrotoxin and 1 µM GABA (yellow columns) or 100 µM GABA (blue columns). Untransfec-
ted control cells were also exposed to picrotoxin and 1 µM GABA (white columns). The SK assay
was performed on undiluted cell lysate (A) and cell supernatant (B). After 15 minutes incubation time,
OD405 was measured. All values were means ± SD from eight data points each on two microtitre
plates. * indicates p < 0.05, ** = p < 0.01 and *** = p < 0.001 compared to DPBS treatment only
(grey column). OD405 readings from experiments using PTX were also compared.
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untransfected cells and the last assay attempt using the channel blocker picrotoxin indicated
the possibility that the observed iodide efflux may be in part due to spontaneous channel
activity, HEK293 cells expressing α3β2γ2 GABAA receptors were investigated using the
patch-clamp method. Administration of 100 µM picrotoxin to the cells showed small out-
ward currents in cells expressing the receptors with an agonist-independent receptor activity
of 9.04 ± 1.75 % of total response capacity (maximal GABA response + response to picro-
toxin = 100 %, n = 8; Figure 4.14). 1
2 sec
500 pA
GABA PTX
A B
Figure 4.14: Representative current traces evoked by 100 µM GABA (A) and 100 µM picro-
toxin (B) in HEK293 cells expressing α3β2γ2 GABAA receptors.
4.2.3 Optimisation of a YFP-based screening assay
A third possible assay option, a YFP mutation with increased chloride and iodide sensi-
tivity, was tested using a fluorescence plate reader. HEK293 cells transiently transfected
with the mutated YFP-H148Q/I152L as well as α3β2γ2 GABAA receptors were seeded into
96-well plates. On the following day, cells were incubated in NaCl bath solution an hour
before the assay. Afterwards, the microtitre plates were put into a fluorescence plate reader
and NaI test solution only or together with 100 µM GABA were injected into the wells and
changes in the fluorescence signal were measured. The latter resulted in a clear fluorescence
decrease, which could be prevented by injecting 100 µM GABA together with 1 mM picro-
toxin (Figure 4.15 A). These results indicated that α3β2γ2 GABAA receptor activity, elicited
by a high agonist concentration could be detected with this assay. It was, therefore, further
1During this set of experiments GABA concentration-response relations were also examined for the α3β2γ2
receptors (see Figure B.6, Appendix B).
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tested in HEK293 cells transfected with YFP-H148Q/I152L and α3β2 or α3β2ε GABAA
receptors. Cells expressing the former receptors also exhibited a fluorescence quench, which
was not seen when picrotoxin was applied. However, the fluorescence quench was only
12.41± 3.55 % (n = 9) compared to 54.62± 4.14 % (n = 15) obtained from cells expressing
α3β2γ2 receptors (Figure 4.15 B). When examining cells expressing α3β2ε receptors, the
fluorescence signal did not show distinct changes after adding the agonist or channel blo-
cker (n = 9; Figure 4.15 C). From the results obtained, it was suggested that the assay could
probably be used for certain GABAA receptor combinations, such as the α3β2γ2 subtype.
However, the assay seemed unsuitable for the receptor subtype containing the ε subunit,
since no receptor activity could be detected.
Since the various subunit combinations resulted in different assay outcomes, i.e. different
percentage of fluorescence quench, it was tested whether another α subunit, namely the
human α1 subunit, would improve the fluorescence readings when combined with β2 and
ε subunits. HEK293 cells expressing α1β2 and α1β2ε, respectively, were examined as
described above and produced some interesting results. Cells expressing the α1β2 receptor
showed a 39.4 ± 3.32 % quench (n = 9) which was significantly different compared to
the results obtained with the α3β2 receptor (p > 0.0001, unpaired t-test; Figure 4.16 A).
Similarly, a fluorescence quench of 24.65± 2.13 % (n = 9) was measured in cells expressing
α1β2ε receptors after adding 100 µM GABA to the wells (Figure 4.16 B). This could be
prevented by adding a high concentration of picrotoxin.
In order to assess the quality of the assay, the Z’-factor for each receptor subtype was cal-
culated as described in Section 2.6.3.1 (Equation 2.7, Chapter 2). Although the fluorescence
quench for α3β2γ2 receptors was the highest obtained, the Z’-factor was 0.48. Further Z’-
factors were -0.16 for α3β2, 0.58 for α1β2 and -0,01 for α1β2ε.
Next, GABA concentration-response relations were examined in cells expressing α3β2γ2,
α1β2 and α1β2ε receptors, respectively. Figure 4.17 displays that different subunit combina-
tions resulted in different GABA concentration-response curves, when investigating GABA
concentrations ranging from 30 nM to 3 mM. α3β2γ2 receptors were most sensitive to
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Figure 4.15: Net fluorescence signal of mutant YFP-H148Q/I152L in HEK293 cells expres-
sing α3-subunit-containing GABAA receptors.
Fluorescence was measured for 30 seconds after addition of NaI test solution only or together with
100 µM GABA or with 100 µM GABA and 1 mM picrotoxin in cells expressing α3β2γ2 (A), α3β2
(B), α3β2ε (C) GABAA receptors. Data correspond to means ± SEM; n states the number of wells
measured. Net fluorescence was normalised by setting the averaged baseline fluorescence to 100 %
and fluorescence changes (after adding solutions) were calculated as percentage of baseline fluores-
cence.
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Figure 4.16: Net fluorescence signal of mutant YFP-H148Q/I152L in HEK293 cells expres-
sing α1-subunit-containing GABAA receptors.
Fluorescence was measured for 30 seconds after addition of NaI test solution only (n = 9) or together
with 100 µM GABA (n = 9) or with 100 µM GABA and 1 mM picrotoxin (n = 9) in cells expressing
α1β2 (A) and α1β2ε (B) GABAA receptors. Data correspond to means ± SEM; n states the number
of wells measured. Net fluorescence was normalised by setting the averaged baseline fluorescence to
100 % and fluorescence changes (after adding solutions) were calculated as percentage of the baseline
fluorescence.
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GABA (EC50 3.37 ± 0.42 µM, n = 14). α1β2 receptors had an EC50 of 8.47 ± 0.48 µM
(n = 10) and α1β2ε receptors where least sensitive with an EC50 of 17.1 ± 5.4 µM (n = 9).
The Hill slope for α1β2ε receptors was lower (1.17 ± 2.70) compared to those obtained for
α3β2γ2 (2.26 ± 0.36) and α1β2 (2.57 ± 0.14) receptors. However, the difference was not
significant.
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Figure 4.17: GABA concentration-response relations examined for GABAA receptors ex-
pressed in HEK293 cells using the YFP-based screening assay.
Time-course showing GABA-induced net fluorescence quench using increasing concentrations of
GABA in cells expressing (A) α3β2γ2, (C) α1β2 and (D) α1β2ε receptor subtypes. (B) GABA
concentration-response curves of α1β2 (n = 10), α1β2ε (n = 9) and α3β2γ2 receptor subtypes
(n = 14). Data correspond to means ± SEM; n states the number of wells measured. EC50 va-
lues and Hill coefficients are stated in the text. Curves were fitted using a non-linear regression fit
with variable slopes as described in Section 2.6.3.
1 µM of the benzodiazepine flunitrazepam (together with the EC30 concentration of GABA)
was applied to cells expressing YFP-H148Q/I152L and α3β2γ2 GABAA receptors. Results
were compared to the action of an EC30 concentration of GABA alone (Figure 4.18). In
cells exposed to 2.45 µM GABA alone, the fluorescence drop was 30.3 ± 5.88 % compa-
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red to the baseline fluorescence, whereas it was 39 ± 5.76 % in cells exposed to 2.45 µM
GABA with 1 µM flunitrazepam, demonstrating the positive modulation of the receptor by
the benzodiazepine.
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Figure 4.18: Fluorescence signal change after addition of 1 µM flunitrazepam to HEK293
cells expressing α3β2γ2 GABAA receptors.
Fluorescence was measured for 30 seconds after addition of NaI test solution only (n = 8) or together
with 100 µM GABA (n = 12), 2.45 µM GABA (n = 12) or 2.45 µM GABA and 1 µM flunitrazepam
(n = 9) in cells expressing α3β2γ2 receptors. Concentrations are final concentrations per well. Data
correspond to means ± SEM; n states the number of wells measured. Net fluorescence was norma-
lised by setting the averaged baseline fluorescence to 100 % and fluorescence changes (after adding
solutions) were calculated as percentage of the baseline fluorescence.
4.3 Discussion
4.3.1 Clomeleon-based screening assay
The results presented in this chapter highlight that chloride-ion channel screening is challen-
ging. Several methods had to be tested to find a suitable assay technique. The different assays
were first tested and optimised with cells expressing α3β2 or α3β2γ2 receptors, since those
subtypes did not exhibit constitutive receptor activity. The latter meant a further challenge
for the assay setup when using ε-containing receptors.
The initial plan was to set up a cell-based system to screen for compounds that modulate the
GABAA receptor using the chloride-ion indicator protein Clomeleon (Kuner & Augustine,
2000). It had been shown that Clomeleon is suitable for chloride concentration measure-
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ments in neurons of the hippocampus as well as transgenic mice (Kuner & Augustine, 2000;
Duebel et al., 2006). However, Clomeleon had not been used in a cell-based screening as-
say to scan GABAA receptors for modulating compounds as attempted in this project. The
excitation and emission spectra obtained from HEK293 cells expressing Clomeleon were
in consent with the data published by Kuner & Augustine (2000). Therefore, Clomeleon
was next expressed with α3β2 GABAA receptors and the cells were seeded into 96-well
microtitre plates. Using a fluorescence plate reader, the fluorescence signal was monitored
before and after adding a high concentration of the agonist GABA to the cells. However,
data obtained did not result in the expected fluorescence shift, with no or occasionally small,
non-significant signal changes compared to baseline fluorescence. This slight fluorescence
reductions could be measured in few wells at both emission wavelengths of Clomeleon. It
was suggested that these changes were not Clomeleon-specific, but rather an artefact of the
assay setup. This is because fluorescence was only read at a small-sized area of the wells. In
some cases, cells probably got detached from the plate when injecting the agonist-solution
which lead to reduction of cells in the area of the signal detection, decreasing the fluores-
cence signal. It was supposed that chloride-sensitivity of Clomeleon was too low to detect
receptor mediated changes in the cells even at high agonist concentrations and, thus, no
chloride-specific signal changes could be detected. In fact, the physiological range of chlo-
ride concentrations in different cell types lies between 3 to 60 mM (Rohrbough & Spitzer,
1996; Kuner & Augustine, 2000; Berglund et al., 2008; Markova et al., 2008; Bregestovski
et al., 2009), but sensitivity of Clomeleon to chloride is much lower (KApp > 160 mM).
Hence, it was concluded that Clomeleon is not suitable for the intended assay type due to its
low chloride-sensitivity.
Since the initially planned screening assay setup did not produce the desired outcome and
proved unsuitable for screening compounds, an alternative screening technique had to be
found. There were two possible methods, which seemed suitable due to their relatively easy
setup and no need for specialised measuring devices: a colorimetric-flux assay and a YFP-
based screening assay.
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4.3.2 Colorimetric iodide-flux assay
The next assay tested was the colorimetric iodide-flux assay described by Tang & Wildey
(2004, 2006) which was based on a modified SK method. For this, HEK293 cells expres-
sing the α3β2γ2 receptor were loaded with iodide. Subsequent application of GABA to
the cells caused the ion channel receptors to open, triggering iodide efflux through the ion
channel receptors into the supernatant solution. By determining the intra- and extracellular
iodide concentrations, it would be possible to evaluate GABAA receptor activity. No or low
concentrations of GABA result in low receptor activity, hence, the amount of iodide in the
cells should be high, resulting in low OD405 values, whereas applying high concentrations
of GABA results in high receptor activity. This causes most of the iodide to flow out of the
cells due to the electrochemical gradient, causing a low intracellular iodide concentration
and, hence, high OD405 values (see Equation 4.1). When determining extracellular iodide
concentrations, OD405 values should be low at high receptor activity and high at low or no
receptor function.
Standard curves obtained after increasing incubation times displayed a clear reduction of the
OD405 readings over time, confirming the relatively short stability of the mixture of iodide-
containing samples and detection buffers reported by Tang & Wildey (2004). The minimal
detection limit estimated from the standard curve was higher than the one described by Tang
& Wildey (2004). This may arise from the fact that the OD values obtained here were lower
and probably due to well-to-well variations, since the 3 × SD is comprised to evaluate the
detection limit. The assays linear range was determined from the NaI standard curves exhi-
biting a range of about 300 nM to 3 µM after 15 minutes assay incubation time or after 30
minutes between 100 nM and 1 µM. The lower value determined after 30 minutes was simi-
lar to the value presented by Tang & Wildey (2004), who reported a linear range of 130 nM
to 13 µM after 30 minutes incubation time. However, the upper linear range limit gained
was 10-fold lower than the one described by Tang & Wildey (2004), who showed a 100-fold
molar linear range of the method. Thus, the SK assay detection range obtained here was
relatively small compared to the data represented by Tang & Wildey (2004). The reasons for
these variations are not clear, since detection buffers used were prepared as described (Tang
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& Wildey, 2004, 2006). There may have been slight variations in NaI solutions or detec-
tion buffers due to fluctuation in measuring, weighing or pipetting, however, it is unlikely
that these deviations are responsible for the indicated differences, especially since standard
curves were repeated a few times using different solutions and buffers.
Next, the assay was tested in HEK293 cells transiently transfected with α3β2γ2 GABAA re-
ceptors using 96-well microtitre plates. As mentioned above, high OD405 values indicate a
low iodide concentration inside the cells, whereas low OD405 readings represent high intra-
cellular iodide concentrations. However, readings obtained from cell lysates after applying
ascending GABA concentrations to the cells were rather random and did not show specific
ion flux or GABA concentration-related patterns. Furthermore, untransfected control cells
exhibited similar OD405 readings as transfected cells, although they did not express the exo-
genous GABAA receptors. Cell supernatants were also subject to the modified SK reaction.
The supernatant solution was iodide free before adding it to the cells and should contain
different concentrations of iodide depending on the level of receptor activation and, hence,
the iodide efflux level. OD405 readings obtained from undiluted supernatants were low,
indicating high iodide concentrations in the wells and confirming that iodide effused from
the cells. Due to the small detection window, supernatant solutions were diluted in order to
detect differences in the iodide concentrations per well that could distinguish GABAA re-
ceptor activity in the differently treated wells. However, the data obtained were not GABA
concentration-related but random in transfected as well as untransfected cells. The fact that
readings from untransfected control cells were similar to the ones obtained from cells tran-
siently expressing GABAA receptors indicated a very low signal-to-noise ratio. This could
be due to an imperfect removal of extracellular iodide after loading the cells or due to a
continuous leakage of iodide from the cells before receptor stimulation (Zheng et al., 2004).
However, cells were washed three to four times after the loading step, which most likely
excludes the former possibility. A non-specific iodide leakage through the cell membrane
could happen via passive diffusion, chloride pumps or spontaneous active GABAA receptors
and may be one possible explanation for the low signal-to-noise ratio (Smith et al., 2001).
After repeating the assay a few times with no clear concentration-dependent effects, dif-
111
Chapter 4. Assay development
ferent assay components were varied and tested in order to improve and optimise the assay
and to increase the signal-to-noise ratio. The agonist incubation time is an important factor
for ideal flux responses that are dependent on the balance between ion channel activation
and desensitisation (Smith et al., 2001). Also, iodide-leakage that may play a part in the
low signal-to-noise ratio detected, could probably be reduced with shorter agonist incuba-
tion time which should then result in more accurate readings. Different GABA incubation
times between ten seconds to five minutes were examined to optimise iodide efflux from the
cells. Data obtained were compared with control data from DPBS incubation at the different
time points in order to subtract non-specific iodide efflux from efflux induced by GABA.
Supernatant data from certain time points differed significantly between GABA- and DPBS-
treated cells. However, the test results were inconsistent and not reproducible. Also, often
GABA-treated and control cell OD405 values were similar or occasionally flux from control
cells seemed to be significantly more than from GABAA receptor expressing cells, although
the opposite was expected. Due to the discrepancies obtained throughout the data, no optimal
incubation time could be determined and it was decided to use the incubation time suggested
by Tang & Wildey (2004) while other test variables were tried to be optimised instead. The
question remained, why could the signal-to-noise ratio not be improved by different agonist
incubation times and why were the results so difficult to reproduce?
It was also tested whether changes in cell density would improve the assay outcome. In pre-
vious experiments, iodide concentrations in the supernatants were relatively high whereas
it was low in cell lysates, which could indicate high receptor activity, which may have not
been suitable for the small detection range of the assay. Thus, it was examined whether lower
cell numbers would improve intra- and extracellular iodide concentrations for better OD405
readouts. At all cell densities tested OD405 values were very low for supernatant solutions
and no differences could be seen between the different cell densities without further super-
natant dilutions. However, results obtained from cell lysates with 25 × 103 or 17.5 × 103
cells per well showed significant differences in OD405 readouts between different GABA
concentrations, but no concentration-related pattern could be detected. Cell lysates of wells
containing 12.5× 103 cells per well, however, exhibited a significant lower reading for 1 µM
112
Chapter 4. Assay development
GABA compared to the three higher concentrations tested. Although this could have been
a concentration-related difference, it was assumed, considering the high error bars obtained,
that this was part of the variation seen throughout the plates and, hence, overlooked and not
further examined. By hindsight, it would have been perspicacious to further decrease the
number of cells. However, since the results were again not well-defined and Tang & Wildey
(2004) used 2.5 × 104 WSS-1 cells per well, it was decided to continue with cell densi-
ties used by Tang & Wildey (2004), because WSS-1 cells, which stably express GABAA
receptors, were derived from HEK293 cells (Wong et al., 1992).
Due to the fact that all assay optimisation attempts failed to improve the assay by producing a
well-defined signal window, the functionality of the expressed GABAA receptors was investi-
gated by applying the competitive antagonist bicuculline and the channel blocker picrotoxin.
Again, OD405 data obtained for cell lysates were relatively high; only few differences were
seen between the distinctly treated transfected and untransfected cells. However, results ob-
tained from the supernatants were interesting. In all but the picrotoxin-treated wells, OD405
values were very low indicating a high iodide efflux from the cells. However, picrotoxin-
treated cells, transfected as well as untransfected, exhibited significantly higher OD405 va-
lues, indicating a low concentration of iodide and, thus, blockage of the iodide-efflux from
the cells. Since picrotoxin is a chloride channel blocker, the results indicated that mainly
chloride channels were responsible for the iodide leakage detected in previous experiments,
rather than chloride pumps or spontaneously active channels. Although, patch-clamp expe-
riments using α3β2γ2 receptor expressing HEK293 cells revealed small constitutive activity
of the expressed GABAA receptors. It is not clear why iodide concentrations were very high
in cell supernatants containing bicuculline, since bicuculline is a receptor antagonist.
The colorimetric iodide-flux assay setup exhibited difficulties that could not be successfully
amended when trying to optimise certain assay parameters. An important feature of com-
pound screening assays is the assays reliability as well as a good information content and a
robust assay setup (Xu et al., 2001), which could not be achieved with this assay format using
HEK293 cells. There were three major issues, the variability between replicates, the random
readings between different treatments and the fact that transfected as well as untransfected
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cells had similar results. It is likely that several factors contributed to the assays failure. One
is that the assay’s detection range was very small. Therefore, already small iodide carry-
overs could completely invalidate an experiment. Great care was taken to avoid carry-overs,
but since the many pipetting steps involved were carried out manually, this may have been
one contributing factor for the assays random readings and poor reproducibility between ex-
periments. Another cause could have been the variable receptor population among the cells
and especially between the different experiments due to variations in transient transfection
efficacy. It is proposed that transient transfection efficiencies vary between 10 to 50 %, de-
pending on cell type, cDNA and transfection reagent (Witchel et al., 2002; Thomas & Smart,
2005; Gilbert et al., 2009b) and it is likely that many cells in the wells were untrasfected.
This heterogeneous cell population also likely added to the low signal-to-noise ratio seen
throughout (Lynch, 2005). In comparison, Tang & Wildey (2004) demonstrated the assays
functionality and reproducibility in cells expressing GABAA receptors stably and even then
the Z’-factor that determines the assay’s quality lay below 0.5, indicating a relatively small
signal window that is not ideal for the assay’s application in HTS (Zhang et al., 1999; Tang
& Wildey, 2004). Even when considering a relatively low transfection efficacy, one question
remained: why was the iodide efflux in cells expressing the GABAA receptors and control
cells similar? It was suggested that agonist-independent iodide fluctuations, due to passive
diffusion, active chloride pumps and spontaneous receptor activity (at least in transfected
cells) partly contributed. A study by Galietta et al. (2001b) showed that the assay tempe-
rature can significantly influence basal halide permeability. In most cell types, non-specific
halide permeability is significantly reduced when performing an assay at 37°C compared to
room temperature, where it was relatively high. This likely explains the high iodide-efflux
measured from untransfected control cells. Nevertheless, results obtained from applying pi-
crotoxin to the cells indicated that the observed iodide-efflux blockade probably occurred
via chloride channels. HEK293 cells endogenously express β3, γ3 and ε GABAA receptors
(Thomas & Smart, 2005). They also express GlyR β subunits. However, the latter do not
form functional homomeric channels (Lynch, 2009). There have been reports that endoge-
nously expressed GABAA receptors can trigger GABA-activated currents (Ueno et al., 1996;
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Thomas & Smart, 2005), however, patch-clamp studies on untransfected cells performed in
this project did not detect GABA-activated currents. It is also worth mentioning that pre-
incubation of cells with iodide-containing buffers can affect cell viability (Galietta et al.,
2001b), which may have also contributed to the assay’s outcome. Although the reasons for
the assay’s failure are not entirely clear, it was clearly not reliable or robust in the current as-
say format using transiently transfected HEK293 cells. Therefore, a further alternative plate
reader assay was examined.
4.3.3 YFP-based screening assay
The final screening assay setup tested was based on the iodide-sensitivity of the mutant
YFP-H148Q/I152L that can be used to determine iodide influx into cells via membrane
proteins, such as the GABAA receptor (Galietta et al., 2001a; Kruger et al., 2005; Gilbert
et al., 2009b). By using this assay format with HEK293 cells expressing YFP-H148Q/I152L
and α3β2γ2 receptors, it could be demonstrated that it was possible to measure changes
in the fluorescence signal due to iodide influx into the cells upon GABAA receptor activa-
tion. The fluorescence change obtained was around 50 % and, thus, similar in magnitude
as seen in other studies using GABAA receptors (Kruger et al., 2005; Gilbert et al., 2009b).
Gilbert et al. (2009b) detected a larger fluorescence quench with α1β1 receptors compared
to changes obtained when adding a γ subunit to the receptor complex, whereas here the
largest fluorescence quench was obtained from γ2-containing receptors compared to α1β2
receptors. Several studies have investigated kinetic properties of different receptor isoforms,
concluding that GABAA receptor channel gating is dependent on receptor subunit composi-
tion (Verdoorn, 1994; Gingrich et al., 1995; Lavoie et al., 1997; Haas & Macdonald, 1999).
It was shown that the γ2L subunit confers longer duration openings and longer bursts of
opening to a receptor subtype, compared to αβ-containing receptors (Haas & Macdonald,
1999), which could explain the higher fluorescence quench obtained. It was proposed that
the fluorescence variation seen for the different receptor subtypes could be due to the distinct
kinetics and gating properties of the receptor subtypes investigated, that conducted different
levels of iodide influx. A further factor may be differences in transfection efficiency as shown
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by Gilbert et al. (2009b). It is unclear why α3β2ε receptors could not trigger sufficient iodide
influx to reduce the level of fluorescence inside the cells whereas a reduction in fluorescence
could be measured in cells expressing α1β2ε receptors. The spontaneous receptor activity is
most likely one factor contributing to the lower fluorescence quench achieved in ε-containing
receptors. Furthermore, Whiting et al. (1997) reported a rapid desensitisation rate in α1β1ε
receptors expressed in HEK293 cells. This would explain a lower and less sufficient iodide
influx compared to other receptor subtypes exhibiting slower deactivation and desensitisation
rates.
Before testing different GABA concentrations and compounds using the assay setup, its qua-
lity was evaluated and results obtained for different GABAA receptor subtypes were compa-
red among each other by determining the assays’ Z’-factors. The Z’-factor incorporates the
assay’s signal dynamic range as well as data variation between replicates, without interfe-
rence of test compounds (Zhang et al., 1999). Results obtained indicated that the setup of
the assay is acceptable when using cells expressing both α1β2 (Z’ = 0.58) and α3β2γ2 re-
ceptors (Z’ = 0.48; Inglese et al., 2007a). However, in cells expressing α1β2ε receptors the
signal window was relatively small that positive and negative signal variation bands overlap-
ped slightly, which caused a negative Z’-factor. Although the assays outcome was improved
and a fluorescence quench could be detected when substituting the α3 subunit with the α1
subunit, the assay’s quality using cells expressing the ε subunit was not ideal. Hence, it
was decided to screen the compound library on both α3β2γ2 receptors as well as on α1β2ε
receptors. Cells expressing the latter were used despite the small signal window, as it was
proposed that positively modulating as well as inhibiting compounds could still be identified
by using this method.
Next, GABA concentration-response relations were investigated. By this means it was pos-
sible to compare the results of the assay with data obtained from electrophysiological me-
thods as well as to determine a suitable submaximal GABA concentration for the screening
assay. The findings gained were very different to the ones obtained from electrophysiolo-
gical recordings (see Section 3.2.1, Chapter 3). EC50 values from cells expressing α3β2γ2
receptors were lower than those from cells expressing α1β2 and α1β2ε receptors; the latter
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exhibited the highest values. Using electrophysiological recordings in oocytes it was shown
that the ε subunit confers high agonist sensitivity to the receptor (Section 3.2.1, Chapter 3),
which was also shown in several other studies (Whiting et al., 1997; Neelands et al., 1999;
Maksay et al., 2003; Ranna et al., 2006). Furthermore, in case of α3β2γ2 receptors, the
EC50 value of the plate reader assay was lower compared to the ones obtained from oocytes
(39.37 µM) or HEK293 cells (14.65 µM; Figure B.6, Appendix B) using electrophysiological
methods, whereas the EC50 value for α1β2ε receptors was higher than the one obtained in
oocytes (3.55 µM; Figure B.5, Appendix B). Kruger et al. (2005) measured concentration-
response relations in cells expressing the mutant YFP and α1 GlyR using an imaging-based
assay system as well as a fluorescence plate reader. It was reported that the EC50 values ob-
tained with the latter method were five-times higher compared to the former technique. Due
to the high deviation seen with the fluorescence plate reader assay, compared to the other
systems tested, the reliability of the assay format was doubted (Kruger et al., 2005). Howe-
ver, it is not surprising that the results obtained here vary, considering the variation between
the different measuring techniques. The YFP-based assay was performed in a plate reader
that measured values from the whole cell population in the wells, the measuring time was
extended and an indirect, secondary effect (the YFP quench) was detected. In comparison,
electrophysiological recordings are performed on single cells for a short time and current
flow across the membrane upon receptor activation can be measured directly (Wafford et al.,
2009). Furthermore, mutant YFP variants exhibited relatively slow chloride association and
disassociation kinetics (iodide binding kinetics were not shown; Galietta et al., 2001a) and
Colquhoun (1998) stated that to gain precise concentration-response curves fast agonist ap-
plication is vital due to the fast desensitisation rates of ion channels.
By comparing the fluorescence signals of rising concentrations of GABA it was decided to
use EC30 GABA concentrations when screening the compounds. This is because fluores-
cence signals obtained for EC30 GABA concentrations could be clearly distinguished bet-
ween positive (high GABA concentration) and negative controls (NaI test solution only or
GABA (EC30) with picrotoxin). This was in consent with work done by Wafford et al. (2009),
who also used EC30 concentrations, although in a different screening assay type (FLIPR).
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Benzodiazepines are known to positively modulate GABAA receptors and flunitrazepam po-
tentiated submaximal GABA concentrations in α3β2γ2 receptors (Section 3.2.4, Chapter 3).
Using the YFP-based assay setup it could be demonstrated that the potentiating effect by
flunitrazepam could also be detected with the fluorescence plate reader.
The different tests performed using the YFP-based screening assay demonstrated that the
assay was suitable to detect GABA-induced receptor activity when using cells expressing
α3β2γ2 and, to a certain degree α1β2ε receptors. It was also shown that the fluorescence
signal change was GABA concentration-dependent and that the benzodiazepine-induced
potentiation of a submaximal GABA concentration could be detected in cells expressing
α3β2γ2 receptors. This confirmed the suitability of the assay for pharmacological investi-
gations.
4.3.4 Summary
The results presented in this chapter clearly display the difficulties associated with setting
up a chloride-ion channel screening assay. The data show that a specific assay setup, that
works for a certain cell line and chloride channel or GABAA receptor subtype, not necessa-
rily works equally well with other receptor (sub)types or cell lines, even after optimisation
steps. For example, attempts were made to optimise many parameters when setting up the
iodide-flux assay. However, at the end it could be concluded that the assay format described
by Tang & Wildey (2004) was unsuitable when using transiently transfected HEK293 cells
expressing GABAA receptors. Nevertheless, an acceptable assay to screen certain GABAA
receptor subtypes was found. However, there were certain limitations and difficulties when
investigating spontaneously open ε-containing receptors and special care should be taken
when evaluating screening results, due to the small signal detection window of the assay.
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Screening a chemical compound library
using the mutant YFP-H148Q/I152L
5.1 Introduction
Not much is known about the ε-subunit-containing GABAA receptor. Studies conducted pre-
viously could not determine a subunit-specific pharmacological profile and its functions in
vivo are still not known. It was proposed that ε-containing receptors have a specific modula-
tory site, similar to the benzodiazepine binding site. For these reasons, the next aim of this
study was to screen an ε-containing GABAA receptor subtype against a chemical compound
library and, with luck, to find compounds that modulate receptor activity in the presence of
GABA. ε-subunit-selective compounds will be of great use to elucidate the subunit’s role
in vivo by indicating ε-specific pharmacological effects or possibly a specific phenotype.
Furthermore, amino acids important for the compound’s binding site could be identified by
using molecular approaches, which would further help to study the subunit’s role. Moreover,
a novel lead compound could be a possible future drug acting on the receptor, for example
to treat AD (Section 1.4, Chapter 1).
Several cell-based screening assays are available, such as flux or YFP-based assays, and
many aspects have to be considered when developing and setting up a suitable approach, for
example assay format and detection instrumentation (Inglese et al., 2007b). In the previous
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chapter (Chapter 4), a number of screening assay formats were tested for their suitability to
screen compounds against certain GABAA receptor subtypes. A cell-based screening assay
using the mutant YFP-H148Q/I152L gave robust data when using HEK293 cells expressing
α3β2γ2 receptors. Results obtained for ε-containing receptors exhibited a relatively small
signal dynamic range, limiting the assay’s suitability. However, it was proposed that effects
of inhibiting and enhancing compounds could be distinguished from submaximal GABA-
control responses. Due to the lack of other alternative assay formats, the YFP-based assay
was applied to screen compounds and search for α3β2γ2 and α1β2ε GABAA receptor sub-
type modulators. By this means, the effects and specificity of hit compounds of the two
receptor subtypes could be compared, and ε-subunit-specific compounds could be identified
more easily. A similar study by Wafford et al. (2009) sought compounds specific to the δ
subunit and also compared effects of the hit compounds with their effect on αβγ receptors.
The compound library purchased (Maybridge HitFinder™Collection) comprised of drug-
like molecules with a broad range of structural motifs and biological space. The collection is
rich in diverse pharmacophores, and compounds follow Lipinski guidelines (Lipinski et al.,
2001). The Maybridge HitFinder™Collection consists of 14,400 compounds in total, of
which a small selection of 800 compounds has been tested here. Due to the fact that nothing
is known about specific compound-binding sites on the ε subunit, it was important to screen
compounds with great structural diversity, which is a key factor concerning chemical libra-
ries, especially since the drug target site is unknown (Gillet, 2008). It is likely that similar
compound structures would exhibit similar activities. Therefore, chances to find chemical
leads are enhanced when using a broad range of structural motifs. Finally, serendipity is
also an important factor to find an ε-subunit-selective compound among the 800 compounds
investigated in this study.
The aim of this chapter was to identify subtype-selective compounds modulating α1β2ε
and α3β2γ2 GABAA receptor subtypes by performing preliminary screens using the mu-
tant YFP-H148Q/I152L. Afterwards, it was aimed to confirm the identity of hit compounds
and further examine the compounds in more detail using the two-electrode voltage-clamp
technique.
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5.2 Results
5.2.1 Preliminary screening
Test compounds were screened against both α3β2γ2 and α1β2ε GABAA receptor subtypes.
Note that compounds were designated ’TS-’ and in addition numbered (1-41). The preli-
minary screen was carried out using relatively high concentrations of the compounds (final
concentrations between 50.3 and 59.29 µM). 1 µl of a compound (in DMSO, see Sections
2.7.1 and 2.7.2, Chapter 2) was added to each well containing 50 µl NaCl bath solution,
and an EC30 concentration of GABA in NaI test solution was subsequently injected into
the wells. By this means, compounds were identified that exhibit positive or negative mo-
dulatory effects on the receptor subtypes by exhibiting a reduced or increased fluorescence
quench compared to cells treated with EC30 GABA concentrations only or cells subjected
to GABA (EC30) and 0.5 % DMSO (compound vehicle only negative control). The results
acquired indicated that the majority of test compounds had no effect on the receptors. In the
case of α1β2ε receptors 73.74 % of all compounds were inactive; Figure 5.1 represents a
selection of negative screening results. In comparison, 87.31 % of test compounds had no
effect on α3β2γ2 receptors (Figure 5.2).
Figures 5.3 and 5.4 display representative results of test compounds that showed an inhibitory
(5.3 A, B and 5.4 A) or positive (5.3 C and 5.4 B, C) effect on receptor activation. In the case
of α1β2ε receptors, there were 209 compounds at this concentration range of which 151
inhibited and 58 increased the YFP fluorescence quench. In comparison, 101 compounds
seemed to evoke an explicit effect on cells expressing α3β2γ2 receptors of which 10 were
inhibiting and 91 were increasing the YFP quench.
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Figure 5.1: Sample negative results from the preliminary screening of HEK293 cells expres-
sing mutant YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after addition of 100 µM GABA (n = 3), 8.26 µM GABA
(EC30) and 1 mM picrotoxin (n = 3), 8.26 µM GABA and 0.5 % DMSO (n = 3), 8.26 µM GABA
alone (n = 3) or 8.26 µM GABA with test compound (n = 1): (A) compound TS-25 (54.37 µM), (B)
compound TS-26 (53.81 µM), (C) compound TS-27 (53.92 µM), (D) compound TS-28 (56.72 µM),
(E) compound TS-29 (52.52 µM), (F) compound TS-30 (58.47 µM). Compound concentrations are
final concentrations per well after injection of GABA. Data correspond to means ± SEM; n states
the number of wells tested. Net fluorescence was normalised by setting the averaged baseline fluo-
rescence to 100 % and fluorescence changes (after adding solutions) were calculated as percentage of
the baseline fluorescence.
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Figure 5.2: Sample negative results from the preliminary screening of HEK293 cells expres-
sing mutant YFP-H148Q/I152L and α3β2γ2 GABAA receptors.
Fluorescence was measured for 30 seconds after addition of 100 µM GABA (n = 3), 2.45 µM GABA
(EC30) and 1 mM picrotoxin (n = 3), 2.45 µM GABA and 0.5 % DMSO (n = 3), 2.45 µM GABA
alone (n = 3) or 2.45 µM GABA with test compound (n = 1): (A) compound TS-31 (54.58 µM), (B)
compound TS-32 (54.31 µM), (C) compound TS-33 (54.88 µM), (D) compound TS-34 (54.08 µM),
(E) compound TS-35 (55.66 µM), (F) compound TS-36 (57.12 µM). Compound concentrations are
final concentrations per well after injection of GABA. Data correspond to means ± SEM; n states the
number of wells measured. Net fluorescence was normalised by setting the averaged baseline fluo-
rescence to 100 % and fluorescence changes (after adding solutions) were calculated as percentage of
the baseline fluorescence.
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Figure 5.3: Representative positive screening results for HEK293 cells expressing mutant
YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after addition of 100 µM GABA, 8.26 µM GABA and
1 mM picrotoxin, 8.26 µM GABA and 0.5 % DMSO, 8.26 µM GABA alone or 8.26 µM GABA with
test compound: (A) compound TS-31 (54.58 µM), (B) compound TS-37 (55.04 µM), (C) compound
TS-38 (55.24 µM). Concentrations are final concentrations per well after injection of solutions. Data
correspond to means± SEM; n states the number of wells tested. Net fluorescence was normalised by
setting the averaged baseline fluorescence to 100 % and fluorescence changes (after adding solutions)
were calculated as percentage of the baseline fluorescence.
124
Chapter 5. Screening a chemical compound library
40
60
80
100
120
5 10 15 20 25 30 35
100 µM GABA (n = 2)
2.45 µM GABA + 1 mM PTX (n = 2)
2.45 µM GABA (n = 3)
2.45 µM GABA + 0.5 % DMSO (n = 3)
2.45 µM GABA + compound TS-39 (n = 1)
BF
Time [sec]
%
 
N
e
t f
lu
o
re
sc
e
n
ce
 
si
gn
al
40
60
80
100
120
5 10 15 20 25 30 35
100 µM GABA (n = 2)
2.45 µM GABA + 1 mM PTX (n = 2)
2.45 µM GABA (n = 3)
2.45 µM GABA + 0.5 % DMSO (n = 3)
2.45 µM GABA + compound TS-40 (n = 1)
BF
Time [sec]
%
 
Ne
t f
lu
o
re
sc
e
n
ce
 
si
gn
al
A
B
C
50
60
70
80
90
100
110
120
130
5 10 15 20 25 30 35
100 µM GABA (n = 2)
2.45 µM GABA + 1 mM PTX (n = 2)
2.45 µM GABA (n = 3)
2.45 µM GABA + 0.5 % DMSO (n = 3)
2.45 µM GABA + compound TS-41 (n = 1)
BF
Time [sec]
%
 
Ne
t f
lu
o
re
sc
e
n
ce
 
si
gn
al
Figure 5.4: Representative positive screening results for HEK293 cells expressing mutant
YFP-H148Q/I152L and α3β2γ2 GABAA receptors.
Fluorescence was measured for 30 seconds after addition of 100 µM GABA, 2.45 µM GABA and
1 mM picrotoxin, 2.45 µM GABA and 0.5 % DMSO, 2.45 µM GABA alone or 2.45 µM GABA with
test compound: (A) compound TS-39 (55.32 µM), (B) compound TS-40 (56.32 µM), (C) compound
TS-41 (55.82 µM). Concentrations are final concentrations per well after injection of solutions. Data
correspond to means± SEM; n states the number of wells tested. Net fluorescence was normalised by
setting the averaged baseline fluorescence to 100 % and fluorescence changes (after adding solutions)
were calculated as percentage of the baseline fluorescence.
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The number of compounds which had an effect on the two GABAA receptor subtypes was
very high during the initial screen. Therefore further screens were performed by gradually
decreasing the concentration of the test compounds in order to identify the most potent com-
pounds. In a second screen all compounds which indicated positive receptor modulation or
inhibition at the initial high concentrations were tested again with a tenfold diluted concen-
tration (between 5.03 and 5.93 µM). Following this scan, the number of active compounds
on α1β2ε receptors decreased to 95 (86 inhibiting and 9 enhancing the receptor activity). 32
compounds still showed an effect on cells expressing α3β2γ2 receptors (10 inhibiting and 22
increasing the fluorescence quench). A third scan was conducted with the remaining active
test compounds that were again tenfold diluted (final concentrations of compounds per well
were between 503 and 593 nM). After that there were 47 active compounds on α1β2ε re-
ceptors (41 inhibiting and 6 enhancing the receptor activity) and seven on α3β2γ2 receptors
(one showed an inhibitory and 6 enhancing effects). Figures 5.5 and 5.6 represent results
of compounds that exhibited an effect on α1β2ε and α3β2γ2 GABAA receptors, respecti-
vely, at high concentrations, but both compounds failed to produce a similar effect at a lower
screening concentration. However the number of compounds which triggered an effect in
α1β2ε receptor-expressing cells during that last scan was still relatively high. Therefore a
further dilution of the remaining test compounds was carried out (concentrations from 50.3
to 59.3 nM) and tested. 17 compounds showed an effect on cells expressing α1β2ε receptors
whereas one compound enhanced receptor activity in cells expressing α3β2γ2 receptors.
The remaining 17 active compounds for α1β2ε receptors plus 2 further compounds that en-
hanced the fluorescence signal when using the next higher concentration were subject to
further investigation. Also applied in subsequent assays were the 7 compounds exhibiting an
effect on cells expressing α3β2γ2 receptors.
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Figure 5.5: Results obtained for decreasing concentrations of a test compound in HEK293
cells expressing α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after addition of 100 µM GABA, 8.26 µM GABA alone
(EC30), 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and 0.5 % DMSO or 8.26 µM GABA
with test compound TS-37. (A) 5.5 µM; (B) 550.4 nM. Concentrations are final concentrations per
well after injection of GABA. Data correspond to means ± SEM; n states the number of wells tested.
Net fluorescence was normalised by setting the averaged baseline fluorescence to 100 % and fluores-
cence changes (after adding solutions) were calculated as percentage of the baseline fluorescence.
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Figure 5.6: Results obtained for decreasing concentrations of a test compound in HEK293
cells expressing α3β2γ2 GABAA receptors.
Fluorescence was measured for 30 seconds after addition of 100 µM GABA, 2.45 µM GABA alone
(EC30), 2.45 µM GABA and 1 mM picrotoxin, 2.45 µM GABA and 0.5 % DMSO or 2.45 µM GABA
with test compound TS-41. (A) 5.58 µM concentration of test compound, (B) 558.2 nM. Concen-
trations are final concentrations per well after injection of solutions. Data correspond to means ±
SEM; n states the number of wells tested. Net fluorescence was normalised by setting the averaged
baseline fluorescence to 100 % and fluorescence changes (after adding solutions) were calculated as
percentage of the baseline fluorescence.
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5.2.2 Investigation of ’hit’ compounds on α1β2ε receptors
So far, test compounds were examined as singlets using only few controls (vehicle-only
controls and controls testing receptor functions). In order to rule out false positive results,
the remaining chemical compounds were examined in more detail using additional controls.
Each compound was tested in triplicates and on at least three different plates. Compounds
were applied at the lowest effective concentrations, determined before, to HEK293 cells ex-
pressing YFP-H148Q/I152L and the respective GABAA receptor subtype. NaI test solution
containing GABA at an EC30 concentration was added subsequently. Compounds were also
tested in the absence of GABA, injecting NaI test solution only. This would indicate pos-
sible GABA-independent effects of a test compound. Finally, compounds were applied at
high concentrations to HEK293 cells expressing mutant YFP-H148Q/I152L only. If fluores-
cence changes would be seen in these cells, it would indicate that a test compound acts on
endogenously expressed proteins of the cells rather than the specific GABAA receptor sub-
type. The latter two controls were more effective for compounds enhancing receptor activity.
Neither an agonist-independent effect nor an effect on endogenously expressed ion channels
could be seen from compounds that inhibit the receptors activity. However controls were
performed on all compounds in order to identify any possible irregularities.
Figures 5.7 to 5.25 display the results obtained for test compounds that showed an effect on
α1β2ε GABAA receptor activation during the initial screening assays in HEK293 cells, des-
cribed above. At a concentration of 54.58 nM, test compound TS-1 had shown an inhibiting
effect on the cells expressing the receptor subtype (Figure 5.7 A). However, after repeating
the screening assay using the compound in triplicates, the effect was less distinctive (but
significant) than before (Figure 5.7 B). Controls with test compounds only, in the absence of
GABA, or using cells expressing YFP-H148Q/I152L only, showed no YFP quench, which
was expected (see above; Figure 5.7 C, D).
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Figure 5.7: Fluorescence signal change after adding test compound TS-1 to HEK293 cells
expressing mutant YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing
compound TS-1 (54.58 nM final concentration; initial screening assay). (B) The assay was repeated at
least three times using different plates and batches of cells. Effect of compound TS-1 was significantly
different to GABA-control response (p < 0.01). (C) Data from no-GABA control plates. NaI test
solution only was added to wells containing compound TS-1 (54.58 nM final concentration). (D)
Effect of 8.26 µM GABA and 54.58 µM compound TS-1 in cells expressing YFP-H148Q/I152L only.
100 µM GABA, 8.26 µM GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and 0.5 %
DMSO and in (C) NaI test solution alone served as respective controls. Data correspond to means ±
SEM; n states the number of wells measured. Net fluorescence of values was normalised by setting
the averaged baseline fluorescence to 100 % and fluorescence changes (after adding solutions) were
calculated as percentage of the baseline fluorescence.
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Test compounds TS-2 as well as TS-3 inhibited GABA-control responses at concentrations
of 55.32 nM and 55.66 nM, respectively, during the initial screening assay. This could be
confirmed when repeating the assay using the compounds in triplicates (Figures 5.8 A, B
and 5.9 A, B). No effect could be seen in the absence of GABA or on cells expressing YFP-
H148Q/I152L only, which was expected (Figures 5.8 C, D and 5.9 C, D).
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Figure 5.8: Fluorescence signal change after adding test compound TS-2 to HEK293 cells
expressing mutant YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing
compound TS-2 (55.32 nM final concentration) in initial screening assay. (B) The assay was repeated
on at least three different plates. Effect of compound TS-2 was significantly different to GABA-
control response (p < 0.01). (C) Data from no-GABA control plates. NaI test solution only was added
to wells containing compound TS-2 (55.32 nM final concentration). (D) Effect of 8.26 µM GABA
and 55.32 µM compound TS-2 on cells expressing YFP-H148Q/I152L only. 100 µM GABA, 8.26 µM
GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and 0.5 % DMSO and in (C) NaI test
solution alone served as controls. Data correspond to means ± SEM; n states the number of wells
measured. Net fluorescence of values was normalised by setting the averaged baseline fluorescence to
100 % and fluorescence changes (after adding solutions) were calculated as percentage of the baseline
fluorescence.
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Figure 5.9: Fluorescence signal change after adding test compound TS-3 to HEK293 cells
expressing YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing
compound TS-3 (55.66 nM final concentration) in initial screening assay. (B) The assay was repea-
ted on three different plates. Effect of compound TS-3 was significantly different to GABA-control
response (p < 0.01). (C) Data from no-GABA control plates. NaI test solution only was added to
wells containing compound TS-3 (55.66 nM final concentration). (D) Effect of 8.26 µM GABA and
55.66 µM compound TS-3 on cells expressing YFP-H148Q/I152L only. 100 µM GABA, 8.26 µM
GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and 0.5 % DMSO and in (C) NaI test
solution alone served as respective controls. Data correspond to means ± SEM; n states the number
of wells measured. Net fluorescence of values was normalised by setting the averaged baseline fluo-
rescence to 100 % and fluorescence changes (after adding solutions) were calculated as percentage of
the baseline fluorescence.
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Test compound TS-4 inhibited the GABA-control response during the preliminary screening
assay (Figure 5.10 A). The assay was repeated using the compound in triplicates. The pre-
viously observed effect was less prominent, but still significant (Figure 5.10 B). Controls
with test compounds only, in the absence of GABA, or using cells expressing YFP-H148Q/
I152L only, showed no YFP quench (see above; Figure 5.10 C, D).
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Figure 5.10: Fluorescence signal change after adding test compound TS-4 to HEK293 cells
expressing YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing
compound TS-4 (54 nM final concentrations) in initial screening assay. (B) The assay was repeated
in triplicates on three different plates. Effect of compound TS-4 was significantly different to GABA-
control response (p < 0.05). (C) Data from no-GABA control plates. NaI test solution only was added
to wells containing compound TS-4 (54 nM final concentration). (D) Effect of 8.26 µM GABA and
54.01 µM compound TS-4 on cells expressing YFP-H148Q/I152L only. 100 µM GABA, 8.26 µM
GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and 0.5 % DMSO and in (C) NaI test
solution alone served as controls. Data correspond to means ± SEM; n states the number of wells
measured. Net fluorescence of values was normalised by setting the averaged baseline fluorescence to
100 % and fluorescence changes (after adding solutions) were calculated as percentage of the baseline
fluorescence.
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A similar result was obtained for compound TS-5. It inhibited the GABA-control response
during the preliminary screening assay (Figure 5.11 A), however, after repeating the assay
three times, the inhibition of the GABA-control response was less distinctive, but still signi-
ficant (Figure 5.11 B). Controls with test compounds only, in the absence of GABA, or using
cells expressing YFP-H148Q/I152L only, showed no YFP quench, which was expected (see
above; Figure 5.11 C, D).
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Figure 5.11: Fluorescence signal change after adding test compound TS-5 to HEK293 cells
expressing YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing
compound TS-5 (55.51 nM final concentration; initial screening assay). (B) The assay was repeated
three times on different plates. Effect of compound TS-5 was significantly different to GABA-control
response (p < 0.01). (C) Data from no-GABA control plates. NaI test solution only was added to
wells containing compound TS-5 (55.51 nM final concentration). (D) Effect of 8.26 µM GABA and
55.51 µM compound TS-5 on cells expressing YFP-H148Q/I152L only. 100 µM GABA, 8.26 µM
GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and 0.5 % DMSO and in (C) NaI test
solution alone served as controls. Data correspond to means ± SEM; n states the number of wells
measured. Net fluorescence of values was normalised by setting the averaged baseline fluorescence to
100 % and fluorescence changes (after adding solutions) were calculated as percentage of the baseline
fluorescence.
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The results obtained for compounds TS-6 and TS-7 also indicated the inhibition of the
GABA-control response in the first test (Figures 5.12 A and 5.13 A). These results could
be confirmed after repeating the assay, showing that the compounds triggered an effect si-
gnificantly different to the GABA-control responses (Figures 5.12 B and 5.13 B; C and D
show respective controls used).
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Figure 5.12: Fluorescence signal change after adding test compound TS-6 to HEK293 cells
expressing YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA in NaI test solution to
wells containing test compound TS-6 (55.02 nM final concentration; initial screening assay). (B)
The assay was repeated three times on different plates. Effect of compound TS-6 was significantly
different to GABA-control response (p < 0.01). (C) Data from no-GABA control plates. NaI test
solution only was added to the wells containing compound TS-6 (55.02 nM final concentration). (D)
Effect of 8.26 µM GABA and 55.02 µM compound TS-6 on cells expressing YFP-H148Q/I152L
only. 100 µM GABA, 8.26 µM GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and
0.5 % DMSO and in (C) NaI test solution alone served as controls. Data correspond to means ±
SEM; n states the number of wells measured. Net fluorescence of values was normalised by setting
the averaged baseline fluorescence to 100 % and fluorescence changes (after adding solutions) were
calculated as percentage of the baseline fluorescence.
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Figure 5.13: Fluorescence signal change after adding test compound TS-7 to HEK293 cells
expressing YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing
compound TS-7 (54.42 nM final concentration; initial screening assay). (B) The assay was repeated
three times on different plates using distinct batches of transfected cells. The effect of compound
TS-7 was significantly different to GABA-control response (p < 0.05). (C) Data from no-GABA
control plates. NaI test solution only was added to wells containing compound TS-7 (54.42 nM final
concentration). (D) Effect of 8.26 µM GABA and 54.42 µM compound TS-7 on cells expressing YFP-
H148Q/I152L only. 100 µM GABA, 8.26 µM GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM
GABA and 0.5 % DMSO and in (C) NaI test solution alone served as controls. Data correspond to
means± SEM; n states the number of wells measured. Net fluorescence of values was normalised by
setting the averaged baseline fluorescence to 100 % and fluorescence changes (after adding solutions)
were calculated as percentage of the baseline fluorescence.
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In contrast to the above compounds, test compounds TS-8 and TS-9 inhibited GABA-control
responses during the preliminary screening assay as well as when repeating the assay using
the compounds in triplicates on each plate (Figure 5.14 A, B and 5.15 A, B). No effects were
observed in the absence of GABA or in cells expressing YFP-H148Q/I152L only (Figures
5.14 C, D and 5.15 C, D).
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Figure 5.14: Fluorescence signal change after adding test compound TS-8 to HEK293 cells
expressing mutant YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing
compound TS-8 (54.39 nM final concentration; initial screening assay). (B) The assay was repeated
three times on different plates. Effect of compound TS-8 was significantly different to GABA-control
response (p < 0.01). (C) Data from no-GABA control plates. NaI test solution only was added to
wells containing compound TS-8 (54.39 nM final concentration). (D) Effect of 8.26 µM GABA and
54.39 µM compound TS-8 on cells expressing YFP-H148Q/I152L only. 100 µM GABA, 8.26 µM
GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and 0.5 % DMSO and in (C) NaI test
solution alone served as controls. Data correspond to means ± SEM; n states the number of wells
measured. Net fluorescence of values was normalised by setting the averaged baseline fluorescence to
100 % and fluorescence changes (after adding solutions) were calculated as percentage of the baseline
fluorescence.
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Figure 5.15: Fluorescence signal change after adding test compound TS-9 to HEK293 cells
expressing YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing
compound TS-9 (55.77 nM final concentration; initial screening assay). (B) Screening assay was
repeated three times on different plates. Effect of compound TS-9 was significantly different to
GABA-control response (p < 0.05). (C) Data from no-GABA control plates. NaI test solution only
was added to wells containing compound TS-9 (55.77 nM final concentration). (D) Effect of 8.26 µM
GABA and 55.77 µM compound TS-9 on cells expressing YFP-H148Q/I152L only. 100 µM GABA,
8.26 µM GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA with 0.5 % DMSO and in
(C) NaI test solution alone served as respective controls. Data correspond to means ± SEM; n states
the number of wells measured. Net fluorescence of values was normalised by setting the averaged
baseline fluorescence to 100 % and fluorescence changes (after adding solutions) were calculated as
percentage of the baseline fluorescence.
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Compounds TS-10 and TS-11 also inhibited GABA-control responses during the preliminary
screen (Figures 5.16 A and 5.17 A), but the effects were less distinctive after repeating the
assays three times (Figures 5.16 B and 5.17 B). Compound TS-10 exhibited a fluorescence
quench of about 20 % in cells expressing YFP-H148Q/I152L only that was not seen in cells
expressing GABAA receptors, indicating iodide entrance into the cells (Figure 5.16 D).
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Figure 5.16: Fluorescence signal change after adding test compound TS-10 to HEK293 cells
expressing YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing
compound TS-10 (52.63 nM final concentration; initial screening assay). (B) The assay was repeated
three times on different plates. The effect of the compound was significantly different to the GABA-
control response (p < 0.05). (C) Data from no-GABA control plates. NaI test solution only was added
to the wells containing compound TS-10 (52.63 nM final concentration). (D) Effect of 8.26 µM
GABA and 52.63 µM compound TS-10 in cells expressing YFP-H148Q/I152L only. 100 µM GABA,
8.26 µM GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and 0.5 % DMSO and in
(C) NaI test solution alone served as respective controls. Data correspond to means ± SEM; n states
the number of wells measured. Net fluorescence of values was normalised by setting the averaged
baseline fluorescence to 100 % and fluorescence changes (after adding solutions) were calculated as
percentage of the baseline fluorescence.
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In contrast, test compound TS-11 showed an increased fluorescence signal in cells expressing
YFP-H148Q/I152L only (Figure 5.17 D).
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Figure 5.17: Fluorescence signal change after adding test compound TS-11 to HEK293 cells
expressing YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing com-
pound TS-11 (56.08 nM final concentrations) in initial screening assay. (B) The assay was repeated
on three different plates. The effect of the compound was significantly different to the GABA-control
response (p < 0.05). (C) Data from no-GABA control plates. NaI test solution only was added to
wells containing compound TS-11 (56.08 nM final concentration). (D) Effect of 8.26 µM GABA and
56.08 µM compound TS-11 on cells expressing YFP-H148Q/I152L only. 100 µM GABA, 8.26 µM
GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA with 0.5 % DMSO and in (C) NaI
test solution alone served as controls. Data correspond to means± SEM; n states the number of wells
measured. Net fluorescence of values was normalised by setting the averaged baseline fluorescence to
100 % and fluorescence changes (after adding solutions) were calculated as percentage of the baseline
fluorescence.
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Test compound TS-12 inhibited receptor activity in cells expressing α1β2ε receptors. Re-
peating the assay confirmed this result (Figure 5.18 A and B). NaI test solution control and
controls with cells lacking the receptors showed no effect upon the presence of the test com-
pound (Figure 5.18 C, D).
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Figure 5.18: Fluorescence signal change after adding test compound TS-12 to HEK293 cells
expressing mutant YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing
compound TS-12 (54.2 nM final concentration; initial screening assay). (B) The assay was repeated
three times on different plates. The effect of the compound was significantly different to the GABA-
control response (p < 0.01). (C) Data from no-GABA control plates. NaI test solution only was
added to the wells containing compound TS-12 (54.2 nM final concentration). (D) Effect of 8.26 µM
GABA and 54.2 µM compound TS-12 in cells expressing YFP-H148Q/I152L only. 100 µM GABA,
8.26 µM GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and 0.5 % DMSO and in
(C) NaI test solution alone served as respective controls. Data correspond to means ± SEM; n states
the number of wells measured. Net fluorescence of values was normalised by setting the averaged
baseline fluorescence to 100 % and fluorescence changes (after adding solutions) were calculated as
percentage of the baseline fluorescence.
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Results for test compounds TS-13 and TS-14 are depicted in Figures 5.19 and 5.20. The as-
say results indicated that the compounds inhibited GABA-control responses in cells expres-
sing α1β2ε GABAA receptors. Controls performed in cells expressing mutant YFP-H148Q/
I152L only showed increased fluorescence signals compared to the other controls applied
(Figures 5.19 and 5.20 D).
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Figure 5.19: Fluorescence signal change after adding test compound TS-13 to HEK293 cells
expressing YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing com-
pound TS-13 (55.34 nM final concentrations) in initial screening assay. (B) The assay was repeated
on three different plates. The effect of compound TS-13 was significantly different to the GABA-
control response (p < 0.01). (C) Data from no-GABA control plates. NaI test solution only was added
to wells containing compound TS-13 (55.34 nM final concentrations). (D) Effect of 8.26 µM GABA
and 55.34 µM compound TS-13 in cells expressing mutant YFP-H148Q/I152L only. 100 µM GABA,
8.26 µM GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA with 0.5 % DMSO and in
(C) NaI test solution alone served as controls. Data correspond to means± SEM; n states the number
of wells measured. Net fluorescence of values was normalised by setting the averaged baseline fluo-
rescence to 100 % and fluorescence changes (after adding solutions) were calculated as percentage of
the baseline fluorescence.
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Figure 5.20: Fluorescence signal change after adding test compound TS-14 to HEK293 cells
expressing YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing com-
pound TS-14 (55.03 nM final concentration) in initial screening assay. (B) The assay was repeated
on at least three different plates. The effect of compound TS-14 was significantly different to GABA-
control response (p < 0.05). (C) Data from no-GABA control plates. NaI test solution only was
added to wells containing compound TS-14 (55.03 nM final concentration). (D) Effect of 8.26 µM
GABA and 55.03 µM compound TS-14 in cells expressing YFP-H148Q/I152L only. 100 µM GABA,
8.26 µM GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and 0.5 % DMSO and in
(C) NaI test solution alone served as controls. Data correspond to means± SEM; n states the number
of wells measured. Net fluorescence of values was normalised by setting the averaged baseline fluo-
rescence to 100 % and fluorescence changes (after adding solutions) were calculated as percentage of
the baseline fluorescence.
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Test compound TS-15 inhibited the effect of GABA at EC30 concentrations in HEK293 cells
expressing α1β2ε receptors (Figure 5.21 A, B). However, when the test compound was ap-
plied to cells expressing YFP-H148Q/I152L only, the fluorescence signal decreased slightly
to 96.56 ± 1.18 % compared to the baseline fluorescence, whereas fluorescence signals of
all other controls were higher (Figure 5.21 D).
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Figure 5.21: Fluorescence signal change after adding test compound TS-15 to HEK293 cells
expressing mutant YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing
compound TS-15 (54.97 nM final concentration; initial screening assay). (B) Assay was repeated
three times on different plates. The effect of compound TS-15 was significantly different to the
GABA-control response (p < 0.05). (C) Data from no-GABA control plates. NaI test solution only
was added to wells containing compound TS-15 (54.97 nM final concentration). (D) Effect of 8.26 µM
GABA and 54.97 µM compound TS-15 on cells expressing YFP-H148Q/I152L only. 100 µM GABA,
8.26 µM GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA with 0.5 % DMSO and in
(C) NaI test solution alone served as respective controls. Data correspond to means ± SEM; n states
the number of wells measured. Net fluorescence of values was normalised by setting the averaged
baseline fluorescence to 100 % and fluorescence changes (after adding solutions) were calculated as
percentage of the baseline fluorescence.
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The majority of chemical compounds tested that showed an effect on cells expressing α1β2ε
GABAA receptors inhibited the fluorescence quench, and there were only a few test com-
pounds enhancing receptor activity. Therefore, fluorescence quench increasing compounds
that were identified at the second lowest concentration range tested (between 503 and 593 nM)
were also examined by repeating the assays with respective controls. Test compound TS-16
triggered a fluorescence quench that was larger than the quench obtained when cells were
exposed to 100 µM GABA. This could be confirmed by repeating the assay several times
in triplicates (Figure 5.22 A, B). Applying the compound with NaI test solution only also
indicated a small effect (Figure 5.22 C). In both cases, the onset of the responses was rela-
tively slow compared to the GABA-control responses. Cells lacking the GABAA receptors
showed no change in fluorescence signal when exposed to the compound, indicating that the
response was GABAA receptor-dependent.
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Figure 5.22: Fluorescence signal change after adding test compound TS-16 to HEK293 cells
expressing YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing
compound TS-16 (539.4 nM final concentration) in initial screening assay. (B) The assay was repea-
ted several times using different plates. The effect of compound TS-16 was significantly different
to GABA-control response (p < 0.05). (C) Data from no-GABA control plates. NaI test solution
only was added to the wells containing compound TS-16 (539.4 nM final concentration). (D) Effect
of 8.26 µM GABA and 53.94 µM compound TS-16 on cells expressing YFP-H148Q/I152L only.
100 µM GABA, 8.26 µM GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and 0.5 %
DMSO and in (C) NaI test solution alone served as respective controls. Data correspond to means ±
SEM; n states the number of wells measured. Net fluorescence of values was normalised by setting
the averaged baseline fluorescence to 100 % and fluorescence changes (after adding solutions) were
calculated as percentage of the baseline fluorescence.
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In contrast, the increased fluorescence quench triggered by compound TS-17 that was ob-
served during the initial screening assay could not be confirmed when repeating the assay;
no significant change could be seen compared to the EC30 GABA-control response (Figure
5.23). Similar results were obtained for compounds TS-18 and TS-19. The compounds in-
hibited the fluorescence change evoked by GABA during the initial screens, but in further
replicates no significant effect could be observed (Figures 5.24 and 5.25).
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Figure 5.23: Fluorescence signal change after adding test compound TS-17 to HEK293 cells
expressing mutant YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing com-
pound TS-17 (570 nM final concentration; initial screening assay). (B) The assay was repeated three
times on different plates. (C) Data from no-GABA control plates. NaI test solution only was added
to the wells containing compound TS-17 (570 nM final concentration). (D) Effect of 8.26 µM GABA
and 57 µM compound TS-17 on cells expressing YFP-H148Q/I152L only. 100 µM GABA, 8.26 µM
GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and 0.5 % DMSO and in (C) NaI test
solution alone served as controls. Data correspond to means ± SEM; n states the number of wells
measured. Net fluorescence of values was normalised by setting the averaged baseline fluorescence to
100 % and fluorescence changes (after adding solutions) were calculated as percentage of the baseline
fluorescence.
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Figure 5.24: Fluorescence signal change after adding test compound TS-18 to HEK293 cells
expressing YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing
compound TS-18 (54.02 nM final concentration) in initial screening assay. (B) The screening assay
was repeated on different plates. (C) Data from no-GABA control plates. NaI test solution only was
added to wells containing compound TS-18 (54.02 nM final concentration). (D) Effect of 8.26 µM
GABA and 54.02 µM compound TS-18 on cells expressing YFP-H148Q/I152L only. 100 µM GABA,
8.26 µM GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA with 0.5 % DMSO and in
(C) NaI test solution alone served as controls. Data correspond to means± SEM; n states the number
of wells measured. Net fluorescence of values was normalised by setting the averaged baseline fluo-
rescence to 100 % and fluorescence changes (after adding solutions) were calculated as percentage of
the baseline fluorescence.
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Figure 5.25: Fluorescence signal change after adding test compound TS-19 to HEK293 cells
expressing YFP-H148Q/I152L and α1β2ε GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 8.26 µM GABA to wells containing com-
pound TS-19 (55.33 nM final concentrations) in initial screening assay. (B) The assay was repeated
on three different plates. (C) Data from no-GABA control plates. NaI test solution only was added to
wells containing compound TS-19 (55.33 nM final concentration). (D) Effect of 8.26 µM GABA and
55.33 µM compound TS-19 on cells expressing YFP-H148Q/I152L only. 100 µM GABA, 8.26 µM
GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA with 0.5 % DMSO and in (C) NaI test
solution alone served as respective controls. Data correspond to means ± SEM; n states the number
of wells measured. Net fluorescence of values was normalised by setting the averaged baseline fluo-
rescence to 100 % and fluorescence changes (after adding solutions) were calculated as percentage of
the baseline fluorescence.
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5.2.3 Investigation of ’hit’ compounds on α3β2γ2 receptors
Test compounds were also applied to HEK293 cells expressing mutant YFP-H148Q/I152L
and α3β2γ2 GABAA receptors. In contrast to cells expressing α1β2ε GABAA receptors, the
majority of compounds applied to cells expressing α3β2γ2 receptors enhanced the YFP fluo-
rescence quench during the preliminary screening tests. Furthermore, the number of active
compounds was less and only seven were left after preliminary screenings at a concentration
range of 503 to 593 nM. These were tested further by repeating the assays in several wells
per plate and also using further controls, as described above for Section 5.2.2.
Test compounds TS-10, TS-20 and TS-21 elicited enhanced quenching of the mutant YFP
compared to the GABA-control response (EC30) in cells expressing α3β2γ2 receptors during
the preliminary screens. This was confirmed when repeating the assays using triplicates per
plate (Figures 5.26 A, B, 5.27 A, B and 5.28 A, B). The compounds also caused a fluores-
cence quench when applied in the absence of GABA. However, when test compounds were
added to control cells expressing YFP-H148Q/I152L only, a fluorescence quench could also
be observed, indicating the interference of some endogenously expressed proteins (Figures
5.26 C, D, 5.27 C, D and 5.28 C, D).
Test compound TS-22 inhibited the GABA-elicited fluorescence quench during the prelimi-
nary screens (Figure 5.29 A). Repeating the test confirmed this result, although the effect
was less prominent compared to before (Figure 5.29 B). The fluorescence signal was similar
to that of the controls when applying compound TS-22 without GABA to the cells. However,
performing the assay on cells expressing mutant YFP-H148Q/I152L only, the fluorescence
signal was higher than that obtained from the respective controls (100 µM GABA, 8.26 µM
GABA, 8.26 µM GABA and 1 mM picrotoxin and 8.26 µM GABA with 0.5 % DMSO;
Figure 5.29 C, D).
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Figure 5.26: Fluorescence signal change after adding test compound TS-10 to HEK293 cells
expressing mutant YFP-H148Q/I152L and α3β2γ2 GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 2.45 µM GABA to wells containing
526.3 nM compound TS-10 (final concentrations) in initial screening assay. (B) The assay was re-
peated in triplicates on different plates. The effect of compound TS-10 was significantly different
to GABA-control response (p < 0.001). (C) Data from no-GABA control plates. NaI test solution
only was added to the wells containing compound TS-10 (526.3 nM final concentration). (D) Effect
of 8.26 µM GABA and 52.63 µM compound TS-10 on cells expressing YFP-H148Q/I152L only.
100 µM GABA, 8.26 µM GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and 0.5 %
DMSO and in (C) NaI test solution alone served as controls. Data correspond to means ± SEM; n
states the number of wells measured. Net fluorescence of values was normalised by setting the avera-
ged baseline fluorescence to 100 % and fluorescence changes (after adding solutions) were calculated
as percentage of the baseline fluorescence.
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Figure 5.27: Fluorescence signal change after adding test compound TS-20 to HEK293 cells
expressing YFP-H148Q/I152L and α3β2γ2 GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 2.45 µM GABA to wells containing
543.1 nM compound TS-20 (final concentrations) in initial screening assay. (B) The assay was repea-
ted on several different plates. The effect of compound TS-20 was significantly different to GABA-
control response (p < 0.001). (C) Data from no-GABA control plates. NaI test solution only was
added to wells containing compound TS-20 (543.1 nM final concentration). (D) Effect of 8.26 µM
GABA and 54.31 µM compound TS-20 on cells expressing YFP-H148Q/I152L only. 100 µM GABA,
8.26 µM GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA with 0.5 % DMSO and in
(C) NaI test solution alone served as controls. Data correspond to means± SEM; n states the number
of wells measured. Net fluorescence of values was normalised by setting the averaged baseline fluo-
rescence to 100 % and fluorescence changes (after adding solutions) were calculated as percentage of
the baseline fluorescence.
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Figure 5.28: Fluorescence signal change after adding test compound TS-21 to HEK293 cells
expressing YFP-H148Q/I152L and α3β2γ2 GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 2.45 µM GABA to wells containing
548.9 nM compound TS-21 (final concentrations) in initial screening assay. (B) Screening assay was
repeated on different plates. The effect of compound TS-21 was significantly different to GABA-
control response (p < 0.001). (C) Data from no-GABA control plates. NaI test solution only was
added to wells containing compound TS-21 (548.9 nM final concentration). (D) Effect of 8.26 µM
GABA and 54.89 µM compound TS-21 was investigated on cells expressing YFP-H148Q/I152L only.
100 µM GABA, 8.26 µM GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and 0.5 %
DMSO and in (C) NaI test solution alone served as controls. Data correspond to means ± SEM; n
states the number of wells measured. Net fluorescence of values was normalised by setting the avera-
ged baseline fluorescence to 100 % and fluorescence changes (after adding solutions) were calculated
as percentage of the baseline fluorescence.
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Figure 5.29: Fluorescence signal change after adding test compound TS-22 to HEK293 cells
expressing YFP-H148Q/I152L and α3β2γ2 GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 2.45 µM GABA to wells containing
545.8 nM compound TS-22 (final concentrations) in initial screening assay. (B) The assay was repea-
ted on different plates. The effect of compound TS-22 was significantly different to GABA-control
response (p < 0.01). (C) Data from no-GABA control plates. NaI test solution only was added to
wells containing compound TS-22 (545.8 nM final concentration). (D) Effect of 8.26 µM GABA and
54.58 µM compound TS-22 on cells expressing YFP-H148Q/I152L only. 100 µM GABA, 8.26 µM
GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA with 0.5 % DMSO and in (C) NaI
test solution alone served as controls. Data correspond to means± SEM; n states the number of wells
measured. Net fluorescence of values was normalised by setting the averaged baseline fluorescence to
100 % and fluorescence changes (after adding solutions) were calculated as percentage of the baseline
fluorescence.
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Compounds TS-23 and TS-16 had increased the fluorescence quench compared to the GABA-
control response in cells expressing α3β2γ2 GABAA receptors. Results from the former
could be confirmed while repeating the assay several times on different plates. The fluores-
cence quench obtained was 49.19 ± 3.27 % and therefore slightly higher than the quench
obtained for 100 µM GABA (44.15 ± 1.22 %; Figure 5.30 A, B). The compound also trig-
gered a small fluorescence quench when applied without GABA. No effect was seen in cells
lacking α3β2γ2 GABAA receptors, indicating that the observed YFP quench is GABAA re-
ceptor specific (Figure 5.30 C, D). Similar results were obtained for the latter compound,
TS-16. However, the fluorescence quench was weaker (38.15 ± 3.65 %); no effect was
seen when the compound was applied without GABA or to cells lacking the receptor (Figure
5.31).
The positive screening result obtained in the initial screening tests using test compound TS-
24 turned out to be false positive. The fluorescence quench could not be confirmed when
repeating the assays (Figure 5.32).
The number of test compounds enhancing or inhibiting GABAA receptor activity determi-
ned by the preliminary screening tests (Section 5.2.1) could be further reduced by subtracting
false-positive results and those compounds that triggered an effect on cells lacking the re-
ceptors when retesting the compounds using triplicates per plate (see above). The remaining
compounds exhibiting GABAA receptor-specific activity could now be further investigated.
There were seven compounds left exhibiting a distinctive effect on α1β2ε receptors and three
compounds that showed an effect on α3β2γ2 GABAA receptors.
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Figure 5.30: Fluorescence signal change after adding test compound TS-23 to HEK293 cells
expressing YFP-H148Q/I152L and α3β2γ2 GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 2.45 µM GABA to wells containing
546.6 nM compound TS-23 (final concentrations) in initial screening assay. (B) The assay was repea-
ted on different plates. The effect of compound TS-23 was significantly different to GABA-control
response (p < 0.001). (C) Data from no-GABA control plates. NaI test solution only was added to
wells containing compound TS-23 (546.6 nM final concentration). (D) Effect of 8.26 µM GABA and
54.66 µM compound TS-23 on cells expressing YFP-H148Q/I152L only. 100 µM GABA, 8.26 µM
GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA with 0.5 % DMSO and in (C) NaI test
solution alone served as respective controls. Data correspond to means ± SEM; n states the number
of wells measured. Net fluorescence of values was normalised by setting the averaged baseline fluo-
rescence to 100 % and fluorescence changes (after adding solutions) were calculated as percentage of
the baseline fluorescence.
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Figure 5.31: Fluorescence signal change after adding test compound TS-16 to HEK293 cells
expressing YFP-H148Q/I152L and α3β2γ2 GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 2.45 µM GABA to wells containing
539.4 nM compound TS-16 (final concentrations) in initial screening assay. (B) The assay was repea-
ted on different plates. The effect of compound TS-16 was significantly different to GABA-control
response (p < 0.05). (C) Data from no-GABA control plates. NaI test solution only was added to
wells containing compound TS-16 (539.4 nM final concentration). (D) Effect of 8.26 µM GABA and
53.94 µM compound TS-16 on cells expressing YFP-H148Q/I152L only. 100 µM GABA, 8.26 µM
GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA and 0.5 % DMSO and in (C) NaI test
solution alone served as controls. Data correspond to means ± SEM; n states the number of wells
measured. Net fluorescence of values was normalised by setting the averaged baseline fluorescence to
100 % and fluorescence changes (after adding solutions) were calculated as percentage of the baseline
fluorescence.
156
Chapter 5. Screening a chemical compound library
A B
C D
50
60
70
80
90
100
110
120
5 10 15 20 25 30 35
2.45 µM GABA + 0.5 % DMSO (n = 13)
2.45 µM GABA (n = 20)
2.45 µM GABA + 1 mM PTX (n = 12)
100 µM GABA (n = 12)
2.45 µM GABA + compound TS-24 (n = 12)
BF
Time [sec]
%
 
N
e
t  f
l u
o
r e
s c
e
n
c e
 
s i
g n
a l
50
60
70
80
90
100
110
120
5 10 15 20 25 30 35
NaI + 0.5 % DMSO (n = 16)
2.45 µM GABA (n = 11)
2.45 µM GABA + 1 mM PTX (n = 15)
100 µM GABA (n = 15)
NaI + compound TS-24 (n = 9)
NaI (n = 16)
BF
Time [sec]
%
 
N e
t  f
l u
o
r e
s c
e
n
c e
 
s i
g n
a l
70
80
90
100
110
120
130
140
5 10 15 20 25 30 35
100 µM GABA (n = 12)
8.26 µM GABA + 1 mM PTX (n = 12)
8.26 µM GABA (n = 21)
8.26 µM GABA + 0.5 % DMSO (n = 23)
8.26 µM GABA +
compound TS-24
(n = 12)
BF
Time [sec]
%
 
N e
t  f
l u
o
r e
s c
e
n
c e
 
s i
g n
a l
50
60
70
80
90
100
110
120
5 10 15 20 25 30 35
100 µM GABA (n = 4)
2.45 µM GABA + 1 mM PTX (n = 4)
2.45 µM GABA (n = 10)
2.45 µM GABA + 0.5 % DMSO (n = 4)
2.45 µM GABA + compound TS-24 (n = 1)
BF
Time [sec]
%
 
N
e
t  f
l u
o
r e
s c
e
n
c e
 
s i
g n
a l
Figure 5.32: Fluorescence signal change after adding test compound TS-24 to HEK293 cells
expressing YFP-H148Q/I152L and α3β2γ2 GABAA receptors.
Fluorescence was measured for 30 seconds after adding (A) 2.45 µM GABA to wells containing
553.6 nM compound TS-24 (final concentrations) in initial screening assay. (B) The assay was repea-
ted on different plates. (C) Data from no-GABA control plates. NaI test solution only was added to
wells containing compound TS-24 (553.6 nM final concentration). (D) Effect of 8.26 µM GABA and
55.36 µM compound TS-24 on cells expressing YFP-H148Q/I152L only. 100 µM GABA, 8.26 µM
GABA, 8.26 µM GABA and 1 mM picrotoxin, 8.26 µM GABA with 0.5 % DMSO and in (C) NaI
test solution alone served as controls. Data correspond to means± SEM; n states the number of wells
measured. Net fluorescence of values was normalised by setting the averaged baseline fluorescence to
100 % and fluorescence changes (after adding solutions) were calculated as percentage of the baseline
fluorescence.
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5.2.4 Investigation of ’hit’ compounds in Xenopus laevis oocytes
Next, a selection of the remaining test compounds was examined in more detail using the
two-electrode voltage-clamp technique by expressing α1β2ε or α3β2γ2 GABAA receptors
in Xenopus laevis oocytes. Test compound TS-3 was selected due to its significant inhibitory
effect on cells expressing the α1β2ε receptor and the fact that control experiments confir-
med the results (Figure 5.9). Applying increasing concentrations of compound TS-3 with
GABA (EC30) to Xenopus oocytes expressing α1β2ε receptors did not show significant dif-
ferences to currents obtained from GABA-control responses (n = 4; Figure 5.33 A, B) and
the inhibiting effect of the compound could not be confirmed.
The mutant YFP-based screening assays indicated that test compound TS-16 enhanced both
α1β2ε and α3β2γ2 GABAA receptors expressed in HEK293 cells (Figures 5.22 and 5.31).
It was the only test compound identified in the screening assay that enhanced the activity
of α1β2ε receptors and, therefore, further investigated. The compound’s enhancing effect
could be confirmed in oocytes expressing α3β2γ2 receptors (Figure 5.34 A, C). The GABA-
control response increased by 65.8 % when applying 10 or 100 µM compound TS-16 together
with GABA (EC20) to the oocytes. The compounds EC50 was 3.67 µM (n = 7). However, in
oocytes expressing α1β2ε receptors, no clear concentration-dependent characteristics could
be detected when applying the compound (n = 4; Figure 5.34 A, B). High concentrations of
the test compound actually triggered an “outward” current in two of four oocytes. Overall
the current traces obtained throughout for α1β2ε receptors expressed in Xenopus oocytes
were very small compared to traces from other GABAA receptor subtypes.
Since the results so far obtained for α1β2ε GABAA receptors were inexplicit, the final com-
pound tested in oocytes was compound TS-23. Compound TS-23 enhanced GABA-evoked
YFP quench in the screening assay setup using HEK293 cells expressing α3β2γ2 recep-
tors (Figure 5.30). The results obtained from oocytes confirmed the potentiation of GABA-
mediated responses by the compound. At concentrations of 10 µM or higher, the response
was about 60 % enhanced compared to the GABA-control response. The EC50 of the com-
pound was 1.42 µM (n = 5; Figure 5.35 A, B).
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Figure 5.33: Results obtained from oocytes expressing α1β2ε receptors after exposure to
test compound TS-3 and GABA at EC30 concentrations.
(A) Compound TS-3 concentration response analysis using a non-linear regression fit with variable
slopes as described in Section 2.3.5 (n = 4). Data points correspond to means ± SEM; n states the
number of oocytes examined. (B) Representative current traces evoked by GABA at EC30 concen-
trations alone or in combination with increasing concentrations of compound TS-3. Horizontal bars
represent drug application.
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Figure 5.34: Results obtained from oocytes expressing α1β2ε or α3β2γ2 receptors after
exposure to test compound TS-16 and submaximal GABA concentrations.
(A) Compound TS-16 concentration-response analysis using a non-linear regression fit with variable
slopes as described in Section 2.3.5 (n = 4 for α1β2ε and n = 7 for α3β2γ2). Data points correspond
to means ± SEM; n states the number of oocytes examined. (B) Representative current traces evoked
by GABA at EC30 concentrations alone or in combination with increasing concentrations of com-
pound TS-16 in oocytes expressing α1β2ε receptors. (C) Sample current traces triggered by GABA
at EC20 concentrations alone or in combination with increasing concentrations of compound TS-16
in oocytes expressing α3β2γ2 receptors. Horizontal bars represent drug application.
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Figure 5.35: Results obtained from oocytes expressing α3β2γ2 receptors after exposure to
test compound TS-23 and GABA at EC30 concentrations.
(A) Compound TS-23 concentration-response analysis using a non-linear regression fit with variable
slopes as described in Section 2.3.5 (n = 5). Data points correspond to means ± SEM; n states the
number of oocytes examined. (B) Sample current traces triggered by GABA at EC30 concentrations
alone or in combination with increasing concentrations of compound TS-23 in oocytes expressing
α3β2γ2 receptors. Horizontal bars represent drug application.
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5.3 Discussion
After setting up and optimising a cell-based screening assay using the mutant YFP-H148Q/
I152L, 800 chemical compounds of the Maybridge HitFinder™ Collection were screened
against α1β2ε as well as α3β2γ2 GABAA receptors expressed in HEK293 cells using a
fluorescence plate reader. As mentioned in the previous chapter, the assay setup using cells
expressing α1β2ε receptors exhibited a very small signal range and Z’-factor and its suita-
bility to screen for compounds was uncertain. However, it was proposed that YFP quench-
inhibiting or -enhancing compounds could be identified visually and, thus, the assay format
was applied due to the lack of alternative methods. By screening compounds against both
receptor subtypes it was possible to compare compound effects and to identify compounds
that were specific to one of the receptor subtypes.
In order to elicit the desired biological action, it is necessary to apply a chemical compound
at a specific concentration (Inglese et al., 2006). Moreover, the right compound concentra-
tion for the preliminary screening is often chosen according to the capacity of the secondary
screening test or further investigations (Willumsen et al., 2003). In this project, compounds
were screened initially at relatively high concentrations with the aim to evaluate the hit rate.
The majority of the test compounds did show little or no effects. This was expected since in
unbiased libraries most compounds do not exhibit activity (Zhang et al., 1999). Nevertheless,
the hit rate was relatively high and numerous compounds seemed to exhibit effects by enhan-
cing or inhibiting YFP quenches on the two receptor subtypes. The question arose whether
the chosen test compound concentration was too high, and the fluorescence change seen in
many samples may have been due to “off-target” or toxic effects, which are sometimes ob-
served at high compound concentrations (Inglese et al., 2006). In a study performing HTS
on 5-HT6Rs, which are G protein-coupled receptors, chemical compounds at a concentration
of 10 µM were applied (Kim et al., 2008). However, since the nature of the performed assays
and investigated proteins was very different, compound concentrations cannot be compared
easily. Here, in order to identify the most potent compounds, their concentrations were gra-
dually decreased and retested until a manageable number of compounds was left for further
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investigations.
When examining the preliminary screening results it is striking that the majority of com-
pounds influencing the fluorescence signal in cells expressing α1β2ε receptors are inhibiting
the GABA-evoked YFP quench. In contrast, most compounds increased the fluorescence
quench in cells expressing α3β2γ2 receptors. Furthermore, the compound concentrations
used in the later screens were relatively low, especially after the last dilution. However, since
all compounds tested at this concentration inhibited the YFP quench in α1β2ε receptors,
it is possible that some inhibited the open, spontaneously active receptor channels before
GABA in NaI solution was injected into the wells. The test compounds were added to 50 µl
NaCl bathing solution before NaI test solution was injected (50.3 to 59.3 nM was the final
concentration of compounds per well).
The preliminary screening tests were performed in singlets and the occurrence of false po-
sitive results among the selected compounds was expected, since they are very common in
single-dose, single-experiment assay setups (Hann & Oprea, 2004). There are many dif-
ferent reasons for false positive results to occur: it could be due to pipetting errors, cross-
contamination or other handling errors, also data handling and analysis. These could have
easily happened despite the great care that was taken due to the large amount of compounds
and subsequent data obtained that were all handled manually. Further reasons are possible
quenching artefacts or auto-fluorescence of compounds, variability of the transfected cells,
measurements on the edge of the plate, reagent differences or other effects triggered by a
compound independently from the GABAA receptor subtypes investigated (Gonzalez & Ma-
her, 2002; Gill et al., 2003; Terstappen, 2005; Inglese et al., 2007a; Sui & Wu, 2007; Janzen
& Popa-Burke, 2009).
Test compounds exhibiting positive effects during the preliminary screening tests were fur-
ther examined to eliminate possible false positive results. Thus, the assays were repeated
using triplicates as well as additional controls, such as cells lacking the GABAA receptors
and, to check for agonist-independent activity, applying the compounds without submaximal
GABA concentrations. Note that the latter control does not function with compounds that
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inhibited GABA-control responses. By this means, several test compounds that previously
inhibited or enhanced GABA-elicited fluorescence quenches could be ruled out for further
testing. Of those, a number of compounds showed a YFP quench on cells lacking the recep-
tors. Hence, it was suggested that the effect seen after applying the compound was caused
via endogenously expressed proteins. The same might be the case where the fluorescence si-
gnal was higher compared to the other controls used in cells lacking receptors. Although it is
not clear, why the fluorescence signal would increase compared to the baseline fluorescence;
it could also be some assay artefact, since the fluorescence signal in no-GABA controls did
not show a comparable increase. Further compounds could be eliminated due to the fact that
the effect seen at first was less prominent or non existent when repeating the assay; the latter
may have happened due to pipetting or data handling errors.
After performing the mutant YFP-based assay, from 800 compounds screened, seven were
identified to be active on α1β2ε receptors and three on α3β2γ2 GABAA receptors. To do a
different type of assay is a frequently applied method to confirm the activity of a test com-
pound (Zheng et al., 2004). Here, the two-electrode voltage-clamp technique was used to
confirm and examine the compound’s activities in more detail. Due to time limitations, not
all of the identified compounds could be examined in oocytes. The first compound investi-
gated was compound TS-3. This compound showed no effects on cells expressing α3β2γ2
GABAA receptors, but inhibited the GABA-evoked fluorescence quench in cells expressing
α1β2ε receptors in the YFP-based assay. However, this effect could not be confirmed when
using the two-electrode voltage-clamp technique and Xenopus oocytes. The problem was
that currents from oocytes expressing α1β2ε receptors were very small, and therefore it was
difficult to distinguish differences between currents elicited by submaximal concentrations
of GABA and those evoked by the compound together with GABA. Additionally, some of
the valves of the perfusion system were stuck and opened manually. It is therefore likely that
the data obtained do not reflect the effect of the test compound but rather unsteadiness of the
perfusion of the compound. The next compound examined in oocytes was compound TS-16,
which increased the YFP quench on both receptor subtypes tested in HEK293 cells using the
YFP-based screening assay. Again, the results obtained for the ε-containing receptor sub-
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type were ambiguous. Interestingly, instead of increasing GABA-evoked currents, at higher
concentrations an “outward” current could be seen in two of four oocytes tested that was not
seen with lower concentrations or GABA alone. This may indicate that, at higher concentra-
tions, the compound blocked the spontaneously open channels. Tests in oocytes expressing
α3β2γ2 receptors confirmed the results of the YFP-based assay; the compound enhanced
GABA-evoked currents in a concentration-dependent manner. Due to the difficulties with
the oocytes expressing the ε-containing receptors, the last investigated compound was com-
pound TS-23, which enhanced the YFP quench in HEK293 cells expressing the α3β2γ2
receptor. The activity of the compound on this receptor subtype could also be confirmed in
oocytes.
In summary, performing two-electrode voltage-clamp experiments in oocytes expressing
α3β2γ2 GABAA receptors could confirm the results obtained from the YFP-based scree-
ning assay in HEK293 cells. To what extend results are comparable is not certain, since the
compounds were only tested at a single concentration using the cell-based screening assay,
except when testing GABA-concentration responses (see Section 4.3.3, Chapter 4). Never-
theless, from the results obtained here, it can be concluded that the screening assay is a
suitable assay format to screen chemical compound libraries against α3β2γ2 receptors. The
EC50 values obtained for the two hit compounds were in the low micromolar range. Pos-
sible future work may lead to generation and screening of compound analogues which may
enhance the potencies of the compounds (see below).
Results obtained for α1β2ε receptors were ambiguous when using the two-electrode voltage-
clamp technique and no subtype-selective compound could be identified yet. This may partly
be a reflection on the cell-based screening assay that exhibited a small signal range and, thus,
low robustness. Nevertheless, it was unexpected that the obtained results could not be confir-
med performing the two-electrode voltage-clamp technique in Xenopus oocytes. It may be
worth trying the patch-clamp method in the future and test the compounds on receptors ex-
pressed in HEK293 cells, rather than oocytes, since the compounds were identified using
these cells. Furthermore, oocytes are less sensitive during pharmacological investigations
compared to mammalian cells (Xu et al., 2001). In the future, the ability to identify hit com-
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pounds could also be improved, if the assays signal range and, thus, quality (Z’-factor) could
be further enhanced. One possibility to improve the assay’s quality could be by manipulating
the ε subunit in a way that the continuous activity could be eliminated without influencing
agonist or modulator binding properties, because amino acid changes would only be ge-
nerated in the pore lining of the channel. One would need to keep in mind that there are
modulators that bind to residues in the channels pore. However, those are not a priority in
the present study mainly seeking test compounds binding elsewhere on the receptor channel
(see Section 1.4, Chapter 1).
Originally, it was planned to verify a number of hit compounds and to generate a second-
generation library, consisting of structural analogues of the compounds exhibiting the stron-
gest effects during the preliminary screening. Afterwards, pharmacological characteristics
of the improved hit compounds could be examined using electrophysiological techniques. In
drug screening tests, the screening of hit analogues generated via parallel synthesis is com-
mon practice, because a compound’s properties towards the target protein can be enhanced
(van Niel et al., 2005; Kim et al., 2008; Wafford et al., 2009). Structure-activity relationships
generated by screening compound analogues would reveal which structural elements are cru-
cial for biological efficacy and would deliver first-generation tools for examining the in vivo
function of ε-subunit-containing receptors. In this study, hit compounds were tested im-
mediately after the preliminary screening in oocytes using the two-electrode voltage-clamp
technique due to time limitations of this project. In the future, due to the fact that it was
possible to screen for compounds modulating GABAA receptor activity using this assay for-
mat, further chemical compounds may be screened and analogues of hit compounds may be
subsequently generated to further evaluate and examine their properties.
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GABAA receptors are targeted by a plethora of different clinically important drugs. Howe-
ver most of them target the receptors non-selectively, hence adverse side effects often occur
(Buffett-Jerrott & Stewart, 2002; Möhler et al., 2002; Bateson, 2004; Agid et al., 2007). Ne-
vertheless, the structural diversity of the receptors offers great prospects for finding subunit
selective modulatory compounds that would target specific receptor subtypes.
Different receptor subunits confer distinct pharmacological and electrophysiological proper-
ties to GABAA receptor subtypes (Sieghart & Sperk, 2002). The ε subunit has only been
investigated in few studies and not much is known about its physiological role in vivo. Pre-
vious studies that investigated pharmacological properties of ε-containing receptors showed
that the subunit confers different properties to the receptor, compared to αβ or αβγ recep-
tors, however, no subunit-selective pharmacological profile could be established (Olsen &
Sieghart, 2009).
6.1 Pharmacological characterisation of the α3β2εGABAA
receptor
The pharmacological properties of α3β2εGABAA receptors were investigated using the two-
electrode voltage-clamp technique. This subunit combination had not been examined before.
Because the β2 subunit is the most widely distributed β subunit in the mammalian brain, it
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is likely that the subunits form functional channels in some areas of the brain. The data
obtained were similar to results obtained in previous recombinant pharmacological studies
investigating the ε subunit in combination with different α and β subunits (Davies et al.,
1997; Whiting et al., 1997; Thompson et al., 1998; Neelands et al., 1999; Maksay et al., 2003;
Ranna et al., 2006). It was shown that the inclusion of the ε subunit into a GABAA receptor
complex changes its pharmacological properties, for example α3β2ε receptors exhibited
high agonist sensitivity compared to α3β2 and α3β2γ2 receptors, but the potency to the
anaesthetic etomidate was less compared to α3β2 receptors. Nevertheless, no ε-selective
compounds are known yet. However, it is possible that there is a specific binding site located
between the α and ε subunits, probably similar to the benzodiazepine binding site (due to
sequence similarities between different subunits) and it was suggested that the ε subunit
represents an important future drug target (Whiting, 1999). It was further shown that the
ε subunit confers unusual properties to α3β2ε receptors, for example constitutive receptor
activity, which was also reported from other recombinant receptor subtypes containing the ε
subunit (Whiting et al., 1997; Neelands et al., 1999; Wagner et al., 2005). It is not known,
whether ε-containing receptors exhibit spontaneous activity in vivo and what implications
this would have on the receptors function or localisation.
Many GABAA receptor subunits exhibit splice versions, however they are usually restricted
to a single splice site, whereas the ε subunit exhibits multiple splice sites (Whiting et al.,
1997; Wilke et al., 1997; Erlitzki et al., 2000; Sinkkonen et al., 2000; Kasparov et al., 2001).
Many of these are expressed in the peripheral tissue, but there are also distinct splice versions
present in the brain and the question arises: why are there so many ε subunit splice variants?
Wilke et al. (1997) suggested that truncated transcripts may be expressed to down-regulate ε
subunit expression or they could have another, as yet unknown, function. The work conduc-
ted here showed that the εT subunit version expressed in brain (described by Kasparov et al.,
2001) is not incorporated into functional receptors when co-expressed with α3 and β2 subu-
nits in Xenopus oocytes. Similar results have also been obtained for other ε subunit splice
variants and the only functional variant known so far is the ε transcript of 3.5 kb found in
brain (Whiting et al., 1997; Davies et al., 2002).
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Due to the fact that not much is known about the ε subunit and no specific pharmacology has
been identified yet, it was decided to search for ε-selective compounds. Previous studies have
screened compound libraries against specific α subunits or δ-subunit-containing receptors
(van Niel et al., 2005; Wafford et al., 2009), but no study has been conducted to search
for ε-subunit-selective modulatory compounds. Such a compound could be an important
pharmacological tool to further study the role of the promiscuous ε subunit and it may also
be a key step towards the development of future drugs targeted to ε-containing receptors,
for example to treat AD. Therefore, the next goal of the study was to set up a cell-based
screening assay to screen the ε-subunit-containing receptor subtype for selective modulatory
compounds.
6.2 Search for and setup of a cell-based screening assay
Electrophysiological recording techniques, such as the two-electrode voltage-clamp tech-
nique, are labour intensive with low throughput, and hence unsuitable for the screening of
compound libraries. Thus, a cell-based screening assay was sought. Several methods exist to
screen GABAA receptors (see Smith & Simpson, 2003; Gilbert et al., 2009b; Verkman & Ga-
lietta, 2009). However, only few were relatively easy to set up and did not require specialised
measuring devices, but could be performed using fluorescence or absorbance plate readers.
Of the three assay formats tested, the last attempted assay approach, applying a mutant YFP,
finally gave the desired results. The mutant YFP-H148Q/I152L acts as an iodide-ion indi-
cator protein and was expressed together with α3β2γ2 GABAA receptors in HEK293 cells.
The cells were plated into a 96-well microtitre plate and exposed to high concentrations
of the agonist GABA. This activated the expressed receptors facilitating iodide influx into
the cells that quenched the YFP, which could be measured using a fluorescence plate rea-
der. Fluorescence quench was prevented when the GABAA receptor blocker picrotoxin was
applied. Kruger et al. (2005) tested the assay format in GlyRs as well as α1β1 GABAA
receptors and obtained a similar fluorescence quench for the GABAA receptor subtype as
was obtained in this study using α3β2γ2 receptors. After it was shown that the assay format
was functional, cells expressing the α3β2ε receptor were tested, but no fluorescence quench
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could be detected. Thereupon, several other receptor subtypes were tested, indicating that
the maximum fluorescence quench could vary widely, depending on the subunit composition
of the expressed receptor. It was proposed that these differences are due to different kine-
tic and gating properties of the receptor subtypes (that are conferred by different subunits).
Furthermore, differences in transfection efficiency also influenced the YFP quench (Gilbert
et al., 2009b). However, it was unclear why no fluorescence quench was detected in cells
expressing the α3β2ε-containing receptor. It was proposed that the constitutive activity of
the receptor subtype could have also influenced the result. In a final attempt it was exa-
mined whether the inclusion of the α1 subunit, instead of the α3 subunit, into the receptor
complex would change the assays outcome, and, surprisingly, a small fluorescence quench
could be detected. Although the YFP quench was less considerable than the one obtained
from α3β2γ2 receptors, the α1β2ε receptor subtype was subsequently used in the screening
assay.
The results of the mutant YFP screening assay setup once again demonstrated that the ε su-
bunit confers different properties to GABAA receptors compared to other receptor subunits.
During the two-electrode voltage-clamp studies it was noticeable that GABA-evoked cur-
rents were smaller in oocytes expressing α3β2ε receptors compared to oocytes expressing
α3β2 or α3β2γ2 receptors. The small signal range obtained in the mutant YFP screening
assay setup raised the question whether there is a relation between the two findings. The
spontaneous activity observed in recombinant ε-containing receptors influences the current
size and probably the signal window of the plate reader assay. However, this is likely not
the only reason. It could be that ε-subunit-containing receptors were less efficiently expres-
sed on the cell surface compared to other GABAA receptors. Gilbert et al. (2009b) showed
that cells expressing fewer receptors and YFP (due to different transfection methods) also
exhibited a smaller % fluorescence quench.
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6.3 Screening of α1β2ε and α3β2γ2 GABAA receptors
After the assay format was optimised and its functionality demonstrated, a chemical com-
pound library was screened against both α1β2ε and α3β2γ2 GABAA receptors expressed in
HEK293 cells. The assay setup to screen the former subtype was not optimal for compound
screening due to a small signal dynamic range. However, it was possible to distinguish the
effect of compounds that inhibited or enhanced the fluorescence quench from the effect evo-
ked by GABA at EC30 concentrations. Screening data were compared with those obtained
from screening α3β2γ2 receptors in order to identify compounds that were selective to the
ε-containing receptor. A similar practice was also used by Wafford et al. (2009) who sought
δ-subunit-selective compounds.
The results obtained from the preliminary screening tests demonstrated that most compounds
that were active on α1β2ε receptors inhibited the receptors activity, whereas it was the op-
posite for cells expressing α3β2γ2 receptors (most active compounds enhanced the fluores-
cence quench). Why most of the compounds inhibited the fluorescence quench is not known.
It could again have something to do with the spontaneous activity of ε-containing receptors.
Next, compounds that showed an effect were further tested using additional controls. By this
means, false positive compounds could be eliminated. Several compounds showed effects
on cells that did not express the GABAA receptor subtypes, but only YFP-H148Q/I152L,
indicating that changes of the fluorescence signal were due to endogenously expressed pro-
teins rather than the GABAA receptors investigated. Endogenously expressed proteins in
HEK293 cells also likely played a role when setting up the iodide-flux assay that was tested
before the mutant YFP-based assay, but failed to give the desired outcome. The data obtained
highlighted the importance of controls.
From the 800 compounds that were screened against the two receptor subtypes, only a few
were identified as hit compounds. In order to verify their activity, the compounds were tested
using the two-electrode voltage-clamp method and Xenopus laevis oocytes expressing the
respective receptor subtypes. Due to time restrictions only few compounds could be tested.
Using oocytes expressing α3β2γ2 receptors confirmed the enhancing effect of compounds
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(32) and (38) that were also seen using the plate reader assay. To what degree the results of
the two methods were comparable beyond that remains unclear, since the YFP-based assay
was only applied using one concentration of the test compounds. Results obtained from
oocytes expressing α1β2ε receptors could not confirm the activity of the two hit compounds
tested. It may be that the assays signal range was too low and the assay indeed was unsuitable
to screen compounds against this receptor subtype. However, currents obtained using the
two-electrode voltage-clamp technique and oocytes expressing α1β2ε receptors were very
small. It is, therefore, likely that a different test using HEK293 cells and the more sensitive
patch-clamp method could produce results that would confirm the effect of the previously
identified hit compounds.
This study as well as the work by Gilbert et al. (2009b) and Kruger et al. (2005) showed that
it is possible to set up a cell-based screening assay and screen chemical compound libraries
using cells transiently expressing mutant YFP-H148Q/I152L and certain GABAA receptor
subtypes. However, the studies also show that there is further room for improvement of the
method in the future. Gilbert et al. (2009b), for example, showed that different transient
transfection methods and transfection efficacies influence the YFP % fluorescence quench
as well as the GABA EC50 values (note that the study was performed using flow cytometry
rather than a fluorescence plate reader). The study by Kruger et al. (2005) and the work
performed here also indicated inconsistencies in conjunction with the GABA EC50 value
obtained using the fluorescence plate reader.
6.4 Future Work
This work demonstrated that the mutant YFP-based assay is suitable to screen chemical
compound libraries. As indicated above, there are still difficulties associated with the method
and no ε-selective compounds could be identified yet. However, the work presents the basis
to further search for ε-subunit-selective modulatory compounds. The improvement of the
assay’s quality and robustness could enhance the chances to identify hit compounds greatly.
One factor that might have affected the small YFP quench was the fact that ε-containing
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receptors exhibit constitutive activity in vitro and the question arose whether a mutation
preventing the receptor from opening spontaneously could improve the assay’s outcome. The
improved assay could be used to screen further chemical compounds against ε-containing
GABAA receptors and hit compounds could be investigated in more detail.
Nevertheless, several promising compounds that showed an effect on ε-containing GABAA
receptors have been identified in this study, which could be continued by verifying the ac-
tivity of those compounds using further tests, for example the patch-clamp method using
HEK293 cells. The next logical step would be to generate structural analogues of hit com-
pounds using parallel synthesis (van Niel et al., 2005; Wafford et al., 2009). This second-
generation library could then be screened again to identify compounds with enhanced bin-
ding affinity and selectivity. Improved compounds could then be examined in more detail
using electrophysiological methods. If the activity of those compounds could be confir-
med, they would present important research tools to further study the ε-subunit-containing
GABAA receptor and help to finally elucidate the subunit’s function in vivo.
6.5 Conclusions
The work conducted showed that α3β2ε GABAA receptors exhibit similar pharmacological
characteristics as other ε-subunit-containing receptor subtypes (Davies et al., 1997; Whiting
et al., 1997; Thompson et al., 1998; Neelands et al., 1999; Maksay et al., 2003; Ranna et al.,
2006). Inclusion of the ε subunit into the α3β2 receptor complex conferred distinct pharma-
cological properties as well as unusual characteristics, such as spontaneous activity, to the
receptor subtype.
A cell-based screening assay was established using the mutant YFP-H148Q/I152L expressed
in HEK293 cells also expressing α1β2ε or α3β2γ2 receptors. It was demonstrated that
the assay format facilitated the screening for compounds that modulate the activity of these
receptor subtypes and several interesting hit compounds could be identified, of which several
have been further investigated using the two-electrode voltage-clamp technique.
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Further work is needed to unequivocally identify ε-subunit-selective compounds. Such com-
pounds are important research tools that would contribute greatly towards the understanding
of the physiological functions of ε-containing GABAA receptor subtypes in the future. In
addition, they are prospective candidates for drug development.
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Vector maps
Figure A.1: Vector map pcDNA3.1 (Invitrogen)
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Figure A.2: Vector map pcDNA3 (Invitrogen)
Figure A.3: Vector map pCMV (from Professor Erwin Sigel)
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Figure A.4: Vector map pBS (Stratagene)
Figure A.5: Vector map pRK5-Clomeleon (from Dr Thomas Kuner)
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Figure B.1: Effect of DMSO on oocytes expressing α3β2, α3β2ε and α3β2γ2 GABAA
receptor subtypes.
Columns represent mean responses of different concentrations of DMSO alone or with GABA (EC20
concentrations) on the receptor subtypes. α3β2: n = 4 for GABA-control response, n = 3 for GABA
+ 0.1 % DMSO, n = 3 for 0.1 % DMSO, n = 3 for GABA + 0.2 % DMSO, n = 3 for 0.2 % DMSO.
α3β2ε: n = 4 for GABA-control response, n = 3 for GABA + 0.1 % DMSO, n = 2 for 0.1 % DMSO,
n = 3 for GABA + 0.2 % DMSO, n = 3 for 0.2 % DMSO. α3β2γ2: n = 9 for GABA-control response,
n = 5 for GABA + 0.1 % DMSO, n = 3 for 0.1 % DMSO, n = 4 for GABA + 0.2 % DMSO, n = 5 for
0.2 % DMSO. Data are means ± SEM; n represents the number of oocytes examined. Currents were
normalised to the maximal response induced by GABA at EC20 concentrations.
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Figure B.2: Fluorescence signal of mutant YFP-H148Q/I152L in response to different
concentrations of DMSO in HEK293 cells also expressing α3β2γ2- (A) or α1β2ε GABAA
receptors .
Fluorescence was measured for 30 seconds after addition of NaI test solution only or together with
100 µM GABA, EC30 GABA or EC30 GABA and 0.1 to 1 % DMSO. Net fluorescence was norma-
lised by setting the averaged baseline fluorescence to 100 % and fluorescence changes (after adding
solutions) were calculated as percentage of the baseline fluorescence.
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Figure B.3: OD405 values from iodide-flux assay in HEK293 cells expressing α3β2γ2
GABAA receptors. Before performing the SK assay, 10 µM GABA or DPBS were incu-
bated for ten seconds to five minutes, respectively.
Readings represent data from SK assay from undiluted cell lysate from assays, which were repeated
three times (first assay = yellow columns, second = green columns, third = blue columns). Values
are means ± SD from six data points each. * indicates p < 0.05, ** = p < 0.01, *** = p < 0.001
comparing GABA-treated cells (A) with their respective DPBS controls (B).
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Figure B.4: OD405 values from iodide-flux assay in HEK293 cells expressing α3β2γ2
GABAA receptors. Before performing the SK assay, 10 µM GABA or DPBS were incu-
bated for ten seconds to five minutes, respectively.
Readings represent data from SK assay from (A) undiluted cell lysate from assays (n = 18). (B) Values
obtained from diluted cell supernatant, 2:3 (n = 6) or (C) 1:5 (n = 6). Values are means ± SEM.
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Figure B.5: GABA concentration-response curve for α1β2ε GABAA receptors (n = 4) ex-
pressed in Xenopus laevis oocytes. The data correspond to means ± SEM; n states the
number of oocytes tested. The EC50 value was 3.553 ± 0.52 µM and the Hill coefficient
0.71. Curves were fitted using a non-linear regression fit with variable slopes as described in
Section 2.3.5.
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Figure B.6: GABA concentration-response curve for α3β2γ2 GABAA receptors (n = 10)
expressed in HEK293 cells. The data correspond to means ± SEM; n states the number of
cells clamped. The EC50 value was 14.65 µM and the Hill coefficient 1.88. Curves were
fitted using a non-linear regression fit with variable slopes as described in Section 2.3.5.
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